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1. Introduction 
 
1.1 Structure-Based Drug Design 
 
Structure-based drug design (SBDD) is an important approach for accelerating the drug-
discovery process.
1,2
 The basic principles rely on designing and optimizing a small molecule in a 
way that it fills optimally the active site of a target protein while disturbing the function of the 
latter and thereby achieving a therapeutic effect. The understanding of the molecular interactions 
in protein-ligand complexes is thus key. Therefore, the three-dimensional structure of a target 
protein is needed, which is usually determined by X-ray crystallography or NMR spectroscopy. If 
no structure of the target exists, a homology model can be calculated derived from closely related 
proteins of the same family. 
SBDD is an iterative process, where after an appropriate target has been selected, a large number 
of library compounds are screened for their biological activity against this target through different 
high-throughput screening (HTS) techniques. Computational approaches are used as a 
complement to HTS techniques.
3
 Once a ligand with suitable affinity is found, the structure of the 
corresponding protein-ligand complex is determined. This information usually serves as a starting 
point for further optimization procedures, such as the synthesis of more appropriate ligands in 
order to optimize the affinity contribution followed by testing the biological activity of the new 
compounds.  
The affinity or the interaction of a ligand with its target known from the three-dimensional 
structure is the prerequisite for considering the ligand for further optimization. The number of 
protein structures deposited in the protein data bank (PDB) has steadily been increasing during 
the last twenty years (Fig. 1.1, status from September 2016).
4
 Nevertheless, there are still many 
other criteria that have to be fulfilled in parallel in order to bring a promising ligand into 
preclinical studies. In latter stages of optimization for instance, the so-called ADME parameters 
(Adsorption, Distribution, Metabolism, and Excretion) are addressed.  
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Fig. 1.1. Structures determined by X-ray crystallography and deposited in the PDB during the last twenty 
years.  
 
1.2 Fragment-Based Drug Discovery 
 
The pharmaceutical industry is currently dealing with unprecedented productivity challenges due 
to the steadily increasing regulatory requirements and the dropping monetary turnover owing to 
patent expirations.
5
 The associated costs with a successful launch of a new lead to the market 
come to approximately $1.8 billion and it takes on an average 1.7 years to pass through each 
stage of development as depicted in Fig. 1.2.
5,6
 Some twenty years ago HTS was the leading 
drug-discovery method, in particular in the pharmaceutical industry.
7
  The main advantage of this 
approach is the possibility of screening thousands of molecules within a short time frame. 
Nevertheless, the expansion of the chemical space with all possible drug-like molecules estimated 
at ~10
63
 represents a huge challenge making even a library with millions of compounds look 
rather poor.
8 
Furthermore, although HTS hits often exhibit appropriate affinity contributions in 
the low µM to the high nM ranges, they have disappointing low ligand efficiency (LE; eq. 1) as 
the number of atoms involved in direct interactions with key pocket residues is rather minor (Fig. 
1.3).
9,10
  
 
                                                     LE = 
−2.303 𝑅𝑇
𝐻𝐴
. 𝑙𝑜𝑔 𝐾𝑑                                                                 [1] 
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Fragment-based drug discovery (FBDD) on the other hand, meanwhile widely used in academia 
and industry, has emerged more and more as a novel paradigm in lead discovery over the past 
two decades, as it represents a great alternative to common HTS techniques.
11–13
 The principles 
of FBDD originate from the early eighties based on the pioneering work of Jencks describing that 
the Gibbs free energy of binding (∆G0) of a larger molecule A-B is the result of the combination 
of the free energies of binding of two or more fragment molecules.
14
 But how are fragments 
actually defined? For this purpose, Congreve et al. at Astex introduced the so-called rule of three 
(RO3)
15
 alluding to criteria similar to the Lipinski’s rule of five (RO5)16. These describe the 
properties of a fragment in the following way: molecular weight (MW) < 300 Da, clogP (o/w) ≤ 
3, number of H-bond donors ≤ 3, number of H-bond acceptors ≤ 3, and number of rotational 
bonds ≤ 3. However, as many screening methods fail to identify fragment binding owing to their 
weak affinity and not least due to solubility issues, researchers tend to use even smaller fragments 
restricting the number of heavy atoms with an upper limit of 17, whereby the lipophilicity is 
likely to be lower while improving the fragment solubility in water.
17,18
  
 
Fig. 1.2. Duration time and costs for each individual stage of development, required for launching a new lead to 
the market. The percentages depicted in the bars indicate the probability of successful passage from one state of 
development to another. The figure is adapted from S. M. Paul et. al. Nat. Rev. Drug Discovery 2010, 9, 203–214.  
 
This technique offers many attractive features compared to HTS techniques. For instance, a much 
smaller number of compounds is usually screened owing to the higher propensity of fragments to 
match the binding site of a target.
19
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Furthermore, although fragments have low MW ~ 150−300 Da they exhibit high LE as a higher 
number of atoms is involved in direct interactions with key pocket residues. Moreover, the low 
MW of the fragments is a huge advantage when it comes to improving the binding affinity and 
selectivity as chemical functionalities can be added to the basic molecular scaffold in iterative 
manner maintaining the range for lead-likeness (Fig. 1.4).
20
 The technique holds great promise as 
there are currently two drugs emerging from FBDD approaches on the market and many more are 
currently in clinical trials (Table 1). The first one (Vemurafenib, Zelboraf 
®
) was approved by the 
US Food and Drug Administration (FDA) as early as 2011 for the treatment of late-stage 
melanoma. The development of Zelboraf 
® 
started as a screening campaign of 20 000 compounds 
for their ability to inhibit a number of kinases.
21
 The additionally performed crystallographic 
analysis with ~1% of the initial compounds revealed the structure of an azaindole bound to the 
Pim1 kinase, the optimization of which led to the structure of Vemurafenib. The second one, 
Venetoclax (Venclexta
®
), was approved by the FDA in April 2016 for the treatment of chronic 
lymphotic leukemia.
22
   
However, as already mentioned above, the methods usually applied to identify fragment binding 
are limited in their capability to achieve high hit rates, often owed to the low solubility of 
fragments in aqueous solutions.
23
 In the following, the basic principles of the applied techniques 
and the properties of the studied systems in this thesis will be presented. 
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Fig. 1.3. Example of bad quality interactions of a HTS hit with its target protein. The figure is 
adapted from D. C. Rees et. al. Nat. Rev. Drug Discovery 2004, 3, 660–672. 
 
Fig. 1.4. Schematic illustration of the relation between MW and affinity of fragment and HTS-hits. The figure is adapted 
from D. C. Rees et. al. Nat. Rev. Drug Discovery 2004, 3, 660–672. 
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Table 1.1. Examples of clinical candidates emerged from fragments with entries on the US National Institutes of 
Health website ClinicalTrials.gov.24  
Compound 
Name 
Developer 
Therapeutic 
area 
Highest phase 
reached 
Ref.
25
 or 
Clinical trial 
identifier 
B cell lymphoma (BCL-2) family 
Venetoclax 
(ABT-199) 
AbbVie Cancer Pre-registration NCT01682616 
Mouse double minute 2 homologe (MDM2)-p53 
Idasanutlin 
(RO5503781) 
Roche Cancer Phase III NCT02545283 
AMG232 Amgen Cancer Phase I/II NCT02110355 
CGM097 Novartis Cancer Phase I NCT01760525 
DS-3032b Daiichi Sankyo Cancer Phase I NCT01877382 
ALRN-6924 Aileron Cancer Phase I NCT02264613 
MK-8242 Merck Cancer Phase I NCT01463696 
JNJ-26854165 Johnson&Johnson Cancer Phase I  NCT00676910 
Leukocyte function-associated molecule 1 (LFA1)-Intracellular adhesion molecule 1 (ICAM1) 
Lifitegrast 
(SAR1118) 
Shire (SARcode 
bioscience) 
Dry eye Pre-registration NCT01743729 
aIIbß3 
Tirofiban Merck Cardiovascular Approved NCT01109134 
a4ß1 
Carotegrast 
methyl 
(AJM300) 
Ajinomoto Ulcerative colitis Phase III Cox et al 2010 
Inhibitor of apoptosis protein (IAP) 
AT-406 (Debio-
1143) 
Ascenta 
Therapeutics/Debiopharm 
Cancer Phase II NCT02022098 
LCL-161 Novartis Cancer Phase II NCT01955434 
Birinapant 
(TL32711) 
Tetralogic Pharma Cancer Phase I/II NCT02587962 
ASTX-660 Astex therapeutics Cancer Phase I/II NCT02503423 
AEG40826 
(HGS1029) 
Aegera and Human 
Genome Sciences 
Cancer Phase I NCT00708006 
CUDC-427 
(GDC-0917) 
Curis (Genentech) Cancer Phase I NCT01908413 
Bromodomain family 
Apabezalone 
(RVX-000222, 
RVX-208) 
Resverlogix Cardiovascular Phase III NCT02586155 
GSK525762 GlaxoSmithKline Cancer Phase I NCT01587703 
CPI-0610 
Constellation 
Pharmaceuticals 
Cancer Phase I NCT02157636 
TEN-010 Tensha Therapeutics Cancer Phase I NCT02308761 
OTX015  Oncoethix (Merck) Cancer Phase I NCT02259114 
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1.3 Experimental Methods used for Identifying Fragment Binding 
 
1.3.1 X-ray Crystallography 
 
X-ray crystallography is a reliable hit-identification method revealing more and more its potential 
as fragment screening technique.
26,27
 It is based on the analysis of the reflection pattern of a 
crystal, in which the atomic arrangement causes a beam of incident electromagnetic radiation (X-
ray) to diffract. For the optimal usage of X-ray crystallography, a robust crystallization system 
with well diffracting crystals is required. For many targets, such as membrane-bound proteins, 
the usage of this approach for screening fragment libraries is presently still rather unsuitable due 
to difficulties of growing sufficient crystals. Nevertheless, X-ray crystallography is key in the 
process of hit-to-lead optimization, thus making its application as primary screening method even 
more attractive as a hit comes directly with a crystal structure. A huge advantage compared to 
other screening techniques is the high compound concentration, which can be applied during 
soaking experiments (~ 100mM) as compound precipitation and thus deposit is not an issue 
unlike for other screening techniques. Even though the high concentration often leads to the 
appearance of bound ligands with otherwise very low affinity, which would fail as hits in any 
other screening technique, the structural information can be very useful with regard to optimal 
extension of a basic molecular scaffold within the protein binding site. Moreover, the method is 
very effective in avoiding false positives since an observed electron density in the crystal 
structure clearly indicates a bound compound. 
 
1.3.1.1 Bragg’s Law 
 
The lattice planes of regularly arranged atoms in a crystal scatter an regular array of spherical 
waves. The reflected beam waves often cancel one another out through destructive interference 
(Fig. 1.5, A) but in a few specific directions they add up only if the Bragg’s law is fulfilled (Fig. 
1.5, B). This is the case when the integer n multiple of the wavelength λ of the incoming beam is 
equal to the path distance 2dsinϴ of the reflected beam (eq. 2).  
 
                                                      2d ∙ sinѲ = n ∙ λ                                                                        [2] 
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Fig. 1.5. Bragg diffraction, according to which the phase shift causes destructive (A) or constructive (B) 
interferences. 
 
The crystal lattice reflects the incoming beam, in a very similar fashion as a mirror, and we obtain 
the diffraction pattern created by the electrons of the atoms (Fig. 1.6, A). The diffraction pattern 
is reciprocal to the crystal lattice. It occurs only when series of parallel crystal planes intersect the 
so-called Ewald sphere, resulting in reflection spots on the detector (Fig. 1.6, B). Every single 
reflection spot includes the sum of the scattering of all atoms within the unit cell.  
During the experiment the information concerning the phases of every diffracted wave is lost. 
The diffraction data provide only the amplitude of the so-called Fourier transform of the electron 
density in the unit cell.  
 
Fig. 1.6. A: Diffraction pattern of an EP crystal. B: Representation of the generation of a diffraction pattern. 
parallel crystal planes 
X-ray  
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1.3.1.2 Crystals and the Unit Cell 
 
A crystal can be described as the three-dimensional regular arrangement of molecules being in a 
low free-energy state. The lattice plane intersections occupied by arrays of atoms form the crystal 
and indicate this regularity (Fig. 1.7, A). The unit cell describes the bulk arrangement of atoms in 
a crystal and it is the smallest repetitive unit within this bulk (Fig. 1.7, B). Three repeating 
vectors ?⃗? , ?⃗? , and ?⃗?  with the angles between them, α, β, and γ define the unit cell. The x-axis of 
the crystal lattice goes along vector ?⃗? , the y-axis along ?⃗? , and the z-axis along ?⃗? . As it can be 
seen it in Fig. 1.7 B, the lattice intersections construct different planes. Depending on the plane 
orientation, either one, two, or all three lattice axes can be intersected by the lattice planes. Such a 
set of parallel lattice planes is determined by three indices, h, k, and l, the so-called Miller 
indices, which are used to label the corresponding reflections and describe the intensity of the 
diffracted beam. If a lattice set of planes is parallel to an axis, this index becomes zero, thus 100 
describes an array of planes cutting the x-axis.  
To calculate the electron density p of any position in space with coordinates x, y, and z, the so-
called structure factors Fhkl are needed. They can be simply described as the sum of the 
diffraction contributions of all individual atoms in the unit cell. Thereby, the structure factor 
amplitude |Fhkl| is proportional to the root of the intensity of the diffracted beam (eq. 3). Hence 
Fhkl describes mathematically the amplitude of the scattered X-ray beam and it can be seen as 
function of the electron density distribution in the unit cell.  
 
Fig. 1.7. A: 2D representation of the unit cell. B: A three-dimensional stack of unit cells 
describing a crystal lattice.  
 
                                                      |Fhkl| = √I(ℎ𝑘𝑙)                                                                         [3] 
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The entirety of all structure factors Fhkl can be translated by a Fourier transformation in an 
electron density distribution p(xyz) in the unit cell (eq. 4), whereby V is the volume of the unit 
cell, x, y, and z are coordinates in the unit cell, and φ is the phase angle.  
 
                                          𝑝(𝑥𝑦𝑧) =  
1
𝑉
∑∑∑|Fℎ𝑘𝑙|𝑒
[−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)+𝑖𝜑(ℎ𝑘𝑙)]
𝑙𝑘ℎ
                             [4]  
However, although the structure factor amplitudes |Fhkl| can be derived from the intensities I(hkl) 
(eq. 3), it is not possible to extract the phase angles φ(hkl) directly from the diffraction pattern. In 
crystallography, this is called the phase problem. 
 
1.3.1.3 Friedel Pairs 
 
As already mentioned in 1.3.1.1, the diffraction pattern of a crystal does not directly illustrate the 
crystal lattice but its reciprocal. Every reciprocal lattice has an inversion center (center of 
symmetry). Thus, every single reflection point on a certain hkl lattice plane produces a reflection 
point on the corresponding -h-k-l lattice plane. The intensities of both reflection spots are equal 
[I(hkl) = I(-h-k-l)], also referred to as Friedel’s law (Fhkl = F-h-k-l). F-h-k-l is the mirror image of Fhkl 
leading to the fact that the Friedel pairs have opposite phases (Fig. 1.8, A). Under specific 
conditions of anomalous scattering the Friedel’s law can be set false (Fhkl ≠ F-h-k-l) while solving 
the phase problem, e.g. by using heavy atoms or a specific X-ray wavelength (Fig. 1.8, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8. Diagram for the structure factors of the reflections Fhkl and F-h-k-l. 
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1.3.1.4 Methods for Solving the Phase Problem 
 
There are different ways to computationally solve the phase problem. The probably fastest one is 
that of the molecular replacement technique (MR). Thereby, the coordinates of a homologous 
protein are used to calculate the structure factor amplitudes Fcalc and the phases φcalc. In general, 
the procedure involves two steps. In the first, the spatial orientation of both molecules relative to 
one another is determined, followed by the second step, in which the translation in the unit cell is 
calculated, needed to overlay the now correctly oriented molecules onto one another. During the 
second step of MR, the so-called R-factor is calculated and used as target function in structure 
refinement. It results as a comparison between the calculated and observed structure factors (eq. 
5). 
                                                    𝑅 =  
∑ |𝐹𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑− 𝐹𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑|
∑ |𝐹𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑|
                                                        [5] 
 
If no homologous protein model is available, the multiple isomorphous replacement (MIR) or 
multiple- and single-wavelength anomalous dispersion methods (MAD and SAD) can be used. 
For the MIR method, a dataset of the apo protein and datasets of at least two crystals with 
different heavy atoms have to be evaluated.
28
 The heavy atoms cause a local shift of the electron 
density distribution. Thus, the dispersive difference between the structure factor amplitudes |Fhkl| 
of the apo and derivative crystals are reduced to the presence of the heavy atom. The heavy 
atoms should not affect the dimensions of the unit cell of the derivative crystal compared to the 
apo crystal in order to make the method useful. The heavy atom component model can be 
calculated with the Patterson method, which is a Fourier transform with intensities as coefficients 
and phase angles equal to zero (eq. 6). The Patterson cell has coordinates u, v, and w, which 
correspond to the x, y, and z coordinates of a real cell. 
  
                                       𝑃(𝑢𝑣𝑤) =  
1
𝑉
∑∑∑|Fℎ𝑘𝑙|
2cos [2𝜋(ℎ𝑢 + 𝑘𝑣 + 𝑙𝑤)]
𝑙𝑘ℎ
                           [6]  
 
In contrast to MIR, in a MAD experiment only one crystal with introduced anomalous scatterer 
e.g. selenomethionine (SeMet) in place of methionine is needed. Data at several wavelengths near 
the absorption edge of the SeMet in the crystal are collected and along with the dispersive 
difference similar to MIR experiments also the anomalous difference is detected.  
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A big advantage of MAD compared to MIR is that non-isomorphism does not occur as all 
datasets are collected from one and the same crystal.  
In a SAD experiment a single appropriate wavelength is used and only the anomalous differences 
are evaluated. For both, MAD and SAD experiments, the presence of a heavy atom in the crystal 
is not necessary but both require the presence of an anomalous scatterer and synchrotron 
radiation to tune the wavelength of the diffraction experiment.  
 
1.3.2 Microscale Thermophoresis (MST) 
 
Microscale thermophoresis is a rather new, immobilization-free method, describing the physical 
phenomenon, by which fluorescence-labeled molecules move in a temperature gradient 
(thermophoresis).
29
 Thermophoresis is measured by monitoring the fluorescence distribution in a 
glass capillary. The temperature gradient is generated by an IR laser impulse and any induced 
diffusion processes are imaged by a CCD camera observing a fluorescence signal of the labeled 
protein molecules.  
While in the initial phase the molecules are homogeneously distributed and a constant initial 
fluorescence (Finitial) of the labeled molecules is measured, a thermophoretic molecular movement 
toward cold regions is observed as soon as the IR-Laser is turned on, becoming evident in a 
fluorescence decrease (Fhot) (Fig. 1.9). The concentration of molecules in the heated region 
decreases until steady-state is reached. At a specific temperature increase ∆T, the molecular 
concentration ratio under this steady-state conditions is described by the Soret coefficient ST 
(eq.7). 
 
                                                                
𝑐ℎ𝑜𝑡
𝑐𝑐𝑜𝑙𝑑
= 𝑒(−𝑆𝑇 .  ∆𝑇)                                                           [7] 
 
When the IR-Laser is switched off, the molecules diffuse back, driven by properties such as 
mass, hydration shell, and charge, which can be used to detect binding. However, in an MST 
experiment a fluorescence signal resulting from the attached label at the protein is used to 
measure the molecular concentration changes, expressed in the normalized fluorescence Fnorm (eq. 
8). In recent studies the intrinsic fluorescence of tryptophan-containing proteins was used to 
monitor their thermophoresis, providing a label-free alternative to the standard approach.
30
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                                                              𝐹𝑛𝑜𝑟𝑚 = 
𝐹ℎ𝑜𝑡
𝐹𝑖𝑛𝑖𝑡𝑖𝑎𝑙
                                                                [8] 
 
 
Fig. 1.9. In the initial state the molecules are homogeneously distributed. They diffuse 
toward colder regions upon heating with an IR laser until steady state is reached. When 
the IR laser is switched off the molecules diffuse back.  
 
In a usual MST experiment, the target of interest is labeled by a fluorescent probe which is 
additionally added to a dilution series of the ligand to be tested. The protein concentration should 
be lower or in the range of the dissociation constant Kd of the ligand of interest. Otherwise the 
inflection point of the binding curve would be shifted and inaccuracy in the determination of the 
Kd would occur.  
Impure samples or aggregates being present in the solution can lead to high signal-to-noise ratios. 
Besides that, the quality of the capillaries is very important for a successful MST experiment. 
Some molecules tend to stick to the capillary surface leading to poor quality data, as only part of 
the molecules is mobile in the temperature gradient. In this case, covalently polymer-coated 
capillaries can be used instead.  
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1.4 Dynamic Combinatorial Chemistry  
 
While the direct crystallographic screening of a fragment library still has a relative low 
throughput potential, the hit identification procedure can be speed up by a method called dynamic 
combinatorial chemistry (DCC).
31,32
 Thereby, a dynamic combinatorial library (DCL) of ligands 
is generated by reactions between building blocks (Fig. 1.10). Under specific conditions the 
bonds between the building blocks are reversible and the system composed by multiple 
components reaches dynamic equilibrium. The product distribution is then dependent on the 
thermodynamic stability of the individual DCL members. The basic idea of this approach is the 
selection of the ligand with the highest affinity upon target protein addition under thermodynamic 
control.  
A major advantage of this method compared to others is that a large number of DCL members is 
desired to speed up the identification of the best binder. The targeted synthesis of a single 
compound and its separation and purification from the large quantity of many side products in a 
conventional synthesis can be avoided, saving time and resources and the screening of multiple 
analogues is inherently performed in the presence of the target protein. 
 
Fig. 1.10. Dynamic combinatorial chemistry. The target can be added either before (A) or 
after the system has reached equilibrium (B). 
 
On the other hand a high number of simultaneously present compounds with similar affinities can 
complicate the analysis since parameters such as compound solubility and chemical reactivity are 
strongly influenced and modulate the available concentrations under the test conditions. This will 
be discussed in chapter 6.  
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1.5 Aspartic Proteases 
 
1.5.1 The Family of Aspartic Proteases 
 
Aspartic proteases are a class of enzymes widespread in vertebrates, fungi, plants, and viruses. 
Their function is the hydrolytic cleavage of peptide substrates using a catalytically activated 
water molecule, which is placed and polarized as a nucleophile between two conserved aspartic 
acid residues. All family members have their optimum at acidic pH conditions and are 
characterized by the conserved position of the catalytic dyad. Remarkably, most of them are 
strongly inhibited by the natural product Pepstatin.
33,34
   
The family of aspartic proteases includes a large number of subfamilies, as summarized in the 
MEROPS database.
35
 Many family members are being intensively pursued as drug targets for 
therapeutic intervention in several diseases such as Alzheimer’s disease (ß-site amyloid precursor 
protein cleaving enzyme 1, BACE1), hypertension (renin), mycosis (secreted aspartic proteases, 
SAP), malaria (plasmepsins), cancer (cathepsin D), and AIDS (human immunodeficiency virus 
type 1 protease (HIV1 protease)). 
In general, the most abundant family members are divided into two subfamilies: pepsin-like (A1) 
and retroviral (A2) aspartic proteases.
36,37
 The members of the A1 subfamily consist of one 
monomer (Fig. 1.11, left hand side). The active site, in the middle of which the catalytic 
aspartates can be found, is rather large and covered by the so-called flap region (Fig. 1.11, blue 
circle). This region is the most flexible part of all aspartic proteases as it has to open so that a 
substrate molecule or an inhibitor can enter the binding pocket and it closes again upon their 
binding. The A2 subfamily members are homodimers, which comprise two identical monomer 
units, each of which donates one aspartate residue for the composition of the catalytic dyad (Fig. 
1.11, right hand side). Retroviral aspartic proteases are active only when both monomer units are 
present. 
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Fig. 1.11. Cartoon presentation of the 3D structures of a pepsin-like (A1, PDB-code: 4LBT) and a retroviral (A2, 
PDB-code: 1SDT) aspartic protease. The flap region is highlighted with a blue circle and the catalytic dyad with a 
blue square. 
 
1.5.2 Functional Mechanism of Aspartic Proteases 
 
As already mentioned all aspartic proteases have two catalytically active aspartic acid residues 
close to one another. Both residues have unusual pKa values, one of ~ 2 and the other of ~ 5.
38
 
Thus, at acidic pH conditions one aspartate residue is protonated and the other one not. An 
important role for the cleavage of the substrate is taken over by the catalytic water molecule, 
which is positioned between the catalytic aspartates (Fig. 1.12). It gets strongly polarized by the 
deprotonated aspartate while the protonated one establishes an H-bond to the substrate’s carbonyl 
group. This enables the nucleophilic attack at the carbonyl carbon atom performed by the 
catalytic water molecule. An intermediate tetrahedral geminal-diol transition state is only short-
lived as it falls apart to the cleavage products, a carboxylic acid and a primary amine. 
 
Fig. 1.12. The catalytic mechanism of aspartic proteases. 
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1.5.3 BACE1 
 
BACE1, also known as membrane-associated aspartic protease 2 (memapsin 2), or aspartyl 
protease 2 (Asp 2), plays an important role in the early stage pathogenesis of Alzheimer’s 
disease. It is a monomeric protein containing 456 amino acids, which cleaves full length ß-
amyloid precursor protein (APP) into a soluble ectodomain fragment (sAPPß) and a C-terminal 
fragment (C99).
39
 The further cleavage of C99 via γ-secretase releases an amyloid-ß protein (Aß) 
which accumulates in the brain and leads to the formation of neuritic plaques, ultimately resulting 
in dementia.
40,41
 As biological studies proved that the Aß amount correlates with the degree of 
dementia in Alzheimer’s disease patients, inhibiting the Aß formation at an early disease stage 
seems a promising therapeutic option.
41
 As BACE1 is marginally expressed in the brain, 
challenges such as crossing the blood-brain barrier come along with the molecular size of 
peptidic inhibitors as well as selectivity features over other aspartic proteases making the research 
in this field very important.
42
 The first developed BACE1 inhibitor is the peptide OM99-2 which 
was designed based upon a transition-state mimetic concept.
43
 While this and many other peptidic 
inhibitors bind to the closed form of the enzyme, second generation compounds emerging from 
fragment-based screening techniques bind to the enzyme’s open form and succeed to penetrate 
the nervous system (CNS). While no BACE1 inhibitor has been approved by the FDA so far, 
some second generation inhibitors have meanwhile reached clinical development stage involving 
AZD3839 from AstraZeneca,
44
 LY2811376 from EliLilly,
45
 (Fig. 1.13) and MK-8931 from 
Merck.
46
  
 
Fig. 1.13. 2D structures of clinical candidates targeting BACE1. The structure of MK-8931 is not known. 
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1.5.4 Renin 
 
Renin is a monomeric aspartic protease with 340 amino acids, which plays an important role in 
the blood pressure regulation. Produced in the kidneys, the enzyme cleaves its natural substrate 
angiotensinogen to the decapeptide angiotensin I. The latter is subsequently cleaved by the 
metalloprotease angiotensin converting enzyme (ACE) to the octapeptide angiotensin II which 
has a strong vasopressive effect on the blood vessels, upregulating the blood pressure.
47
 After the 
successful marketing of ACE-inhibitors, many pharmaceutical companies concentrated on the 
search for selective renin inhibitors. A breakthrough succeeded at Ciba (now Novartis) with 
Aliskiren, the first and only marketed renin inhibitor so far, approved by the FDA in 2007.
48
  
 
1.5.5 Secreted Aspartic Proteases  
 
SAP proteins are secreted by Candida albicans, the main pathogen for candidiasis in humans.
49
 
The risks and consequences of the disease is particularly critical for immunocompromised 
patients, with diseases such as AIDS, cancer, or transplant ones, often leading to higher morbidity 
and mortality rates.
50
 Candida albicans expresses ten different SAPs along with other virulence 
factors.
51
 The best studied so far is the SAP2, a monomer consisting of 342 amino acids.  
There are currently several commercially available topical and systemic agents for the treatment 
of candidiasis.
52
 The gold standard is the intravenous use of amphotericin B given its large range 
of efficiency and low drug resistence.
53
 Nonetheless, the steadily increasing mortality of 
candidiasis patients due to drug resistance makes the development of new antifungal agents 
urgent.
54
  
 
1.5.6 Plasmepsins 
 
Plasmepsins are produced by the protozoan parasite Plasmodium falciparum, which causes, along 
with Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, the most serious form of 
malaria in humans.
55
 After a mosquito bite the parasite is directly transferred into the blood and 
the infection occurs within 10 – 14 days. The plasmepsins digest hemoglobin, which breakdown 
products are used by the parasite for nutrition.  
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For the treatment of uncomplicated malaria an artemisinin-based combination therapy (ACT) is 
recommended by the world health organization (WHO).
56
 The biggest problem in the antimalarial 
therapy is the drug resistance emerging against all antimalarial drugs.
57
  
 
1.5.7 HIV1 Protease 
 
The HIV1 protease belongs to the A2 subfamily. The protease represents a homodimer consisting 
of two monomer units of 99 amino acids each.
58
 It is involved in the pathogenesis of the acquired 
immunodeficiency syndrome (AIDS) which was first described in 1981. According to the United 
Nations Programme on HIV/AIDS (UNAIDS) there are currently 36.7 million people living with 
HIV. The virus causing the disease is transmitted through body fluids encountering damaged 
tissues or mucous membrane or by the direct transfer into the bloodstream. The HIV1 protease is 
required for the viral replication. Thus, the enzyme inhibition reduces the reproduction of the 
virus. The first HIV1 protease inhibitor approved by the FDA in 1995 is Saquinavir followed by 
the market launch of currently eight further inhibitors. Due to the resistance development of the 
HI virus, compliance issues in therapies caused by serious side effects, and the high therapy costs 
make the development of new antiviral drugs urgent.     
 
1.5.8 Endothiapepsin 
 
Endothiapepsin (EP) is a monomer from the A1 subfamily of aspartic proteases, comprising 330 
amino acids. It is produced by the fungus Cryphonectria parasitica which is the main cause of 
chestnut blight.
59
 The fungus is not dangerous to humans.  
EP is used in the industry for the production of cheese due to its lactic coagulation properties.
60
 It 
is commercially available under the name Suparen
®
. However, for research purposes EP should 
be first purified from Suparen
®
. Furthermore, there is no expression system available for the 
protease, which makes mutations within the backbone at present impossible.  
In the field of drug discovery, EP has been used as a model protein for the development of renin 
and BACE1 inhibitors since the early eighties.
61,62
 As EP was the main target investigated in this 
work, the quality of the binding site and key pocket residues will be described in the following. 
EP comprises nine binding pockets in its binding site (Fig. 1.14). The S1’ pocket, surrounded by 
Ile300, Ile302, and Ile304, is the most hydrophobic one.  
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The S2’ pocket is less hydrophobic as it is surrounded by Ile77, Leu133, and Phe194. The 
adjacent S3’ pocket is above the S1’ and S2’ pockets. It exhibits the polar residues Ser78, Tyr79, 
and Gly80 and it thus can be classified as hydrophilic. Hydrophilic is also the S2 pocket, which is 
surrounded by Thr222, Thr223, and Tyr226. The S3 pocket, surrounded by Ile10, Ala16 and 
Ile122 is partly covered by the flap region. It is adjacent to the S1 pocket, which is surrounded by 
Tyr79, Phe116 and Leu125. Both, the S3 and S1 pockets are thus classified as amphiphilic. The 
solvent exposure of the S4 and S5 pockets renders these with hydrophilic character. The S6 
pocket is also exposed to the solvent. However, it is surrounded by the hydrophobic amino acids 
Leu13, Phe280, Ile283 and Phe291. 
 
Fig. 1.14. Surface representation of EP with its binding pockets depicted as spheres. 
 
Although the sequence identity with other aspartic proteases is around 30%, the use of EP in the 
basic research field for determining the interaction pattern of small molecules bound to the target 
is still a common procedure as it allows one to achieve high quality data with up to 1Å resolution, 
which is hardly achievable without spending significant effort for any of the other relevant drug 
targets.
63
 However, structurally identical regions are observed as well as differences, which can 
be used to circumvent putative selectivity issues.  
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For example, by comparing the structure of EP with those of BACE1, renin, cathepsin D, and 
SAP2, conserved regions beyond the catalytic dyad can be observed.
26
 All proteases share a 
tyrosine residue, which resides on the flap region (Fig. 1.15, A). Furthermore, also the position of 
a disulfide bridge (Cys255 and Cys291 in EP) is found conserved in all proteases (Fig. 1.15, B). 
However, in a recent study of EP we found hot spots of binding such as Asp81 neighboring the 
conserved Tyr residue but also Asp119 further away from the catalytic dyad and Phe291 in the 
large S6 pocket. Apparently, all three residues can be found at the same position only in SAP2. 
 
Fig. 1.15. Five aspartic proteases are superimposed (EP in pink (PDB-code: 4LBT), BACE1 in purple (PDB-code: 
5ENM), renin in green (PDB-code: 4RYC), cathepsin D in yellow (PDB-code: 4OC6), and SAP2 in orange (PDB-code: 
1EAG)). A: All proteases are shown as ribbon apart from the catalytic dyad of EP and the overlapping Tyr residues of 
the flap region. B: The conserved disulfide bridges are depicted as sticks and the EP backbone is shown as ribbon. The 
disulfide bond of BACE1 was omitted for more clarity as the bond was reduced in that particular BACE1 structure.       
 
 
 
 
 
 
 
 
1. Introduction 
22 
 
1.6 Preliminary Work and Aims of the Thesis 
 
In the framework of this thesis the identification and characterization of novel efficient binders 
with low molecular weight for the aspartic protease Endothiapepsin (EP) has been performed. For 
this purpose X-ray crystallography was consulted as primary screening method and its hit 
identification potential compared to several biochemical and biophysical screening methods, 
performed in cooperation with industry.  
 
The work was initiated in the past by colleagues from the group of Prof. Klebe, who designed a 
fragment library for general purposes. Initially, all fragment library entries were screened against 
EP via a fluorescence-based assay and obtained hits have been analyzed crystallographically 
using cocktails of two. The biochemical assay resulted in 17% hit rate, while the X-ray analysis 
in only 3%. 
The work in this thesis started at this point. It comprised the following aims: 
1. The setup and performance of a microscale thermophoresis (MST) assay with the in-
house fragment library on EP. In addition, the method’s capability of identifying fragment 
hits was compared to other screening techniques.  
2. Due to the unsatisfactory low overlap of hit lists between the analyzed screening 
techniques, X-ray crystallography was consulted in addition. Thereby, single soaking 
experiments with the in-house library as well as the additional data collection and analysis 
of overall more than 450 datasets were performed. The main aim of the crystallographic 
analysis, used as primary screening technique, was the comparison of the yielded hit rates 
with those of the initially performed assays as well as the determination of binding modes 
and interaction patterns of the fragments with EP. 
3. The analysis and comparison of cocktails with single soaking experiments. It was aimed 
to demonstrate that the use of cocktails to accelerate hit identification often leads to loss 
of hits. 
4. In a separate project, dynamic combinatorial chemistry was investigated as a promising 
alternative for the discovery of potent hits involving the target protein in the hit selection 
step.   
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2.1 Introductory Remarks 
  
The following chapter has been published in ChemMedChem in 2015. The author of the thesis 
developed and performed the MST assay and analysis in collaboration with Nina Schlinck and 
Astrid Sitte (NanoTemper) as well as Franziska Popp and Markus Zeeb (Boehringer Ingelheim). 
Furthermore, Helene Köster performed the biochemical assay, the NMR measurements were 
developed and performed by Robert Meinecke and Markus Zeeb (Boehringer Ingelheim), Maren 
Kuhnert and Wibke E. Diederich contributed the TSA measurements, the ESI-MS analyses were 
performed by Cedric Atmanene, Dominique Roecklin, Valérie Vivat-Hannah, and Jean-Paul 
Renaud (NovAliX), the RDA say was performed by Lars Neumann (Proteros), the assay-data 
correlation and the paper drafting were performed by Johannes Schiebel. 
 
 
 
 
̽ Reprinted with permission from ChemMedChem 2015, 10, 1511‒1521. License number: 3995361210259. 
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2.2 Abstract 
 
Fragment-based lead discovery is gaining momentum in drug development. Typically, a 
hierarchical cascade of several screening techniques is consulted to identify fragment hits which 
are then analyzed by crystallography. Because crystal structures with bound fragments are 
essential for the subsequent hit-to-lead-to-drug optimization, the screening process should 
distinguish reliably between binders and non-binders. We therefore investigated whether different 
screening methods would reveal similar collections of putative binders. First we used a 
biochemical assay to identify fragments that bind to endothiapepsin, a surrogate for disease 
relevant aspartic proteases. In a comprehensive screening approach, we then evaluated our 361-
entry library by using a reporter-displacement assay, saturation-transfer difference NMR, native 
mass spectrometry, thermophoresis, and a thermal shift assay. While the combined results of 
these screening methods retrieve 10 of the 11 crystal structures originally predicted by the 
biochemical assay, the mutual overlap of individual hit lists is surprisingly low, highlighting that 
each technique operates on different biophysical principles and conditions.  
 
2.3 Introduction 
 
Fragment-based lead discovery (FBLD) has matured over the last decade to a reliable and 
efficient method, generating promising leads for subsequent medicinal chemistry optimization.
1,2
 
Stimulated by the low productivity and huge costs of high-throughput screening, compound 
acquisition, management, and handling, FBLD has emerged as a technique that can address a 
large chemical space by using smaller compounds.
3–5
 Nevertheless, even though the initial 
fragment hits are rather weak milli- to micromolar binders, their optimization can be carried out 
quite efficiently, particularly when supported by a structure-based approach.
6,7
 
The field was initiated by the screening of solvent molecules as molecular probes to map protein 
binding sites by crystallography
8
 or by tailored searches for molecular “needles” that bind the hot 
spots of binding pockets.
9
 NMR emerged in the 1990s as the method of choice to detect weak 
binding fragments, to reveal initial structural insight into their binding modes, and to guide initial 
optimization steps.
10
 The major disadvantages of this “SAR by NMR” approach are the need for 
isotope-labeled protein, full assignment of the resonances, and its limitation to rather small 
proteins. Therefore, over time an increasing number of biochemical and biophysical methods 
have been developed and optimized regarding their sensitivity
 
to detect fragment binding.
11,12 
2. One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment 
Hit Lists 
31 
 
Apart from the protein-observed NMR technique that requires isotope labeling, less elaborate 
one-dimensional 1H NMR spectroscopic methods have been developed, such as saturation- 
transfer difference (STD) NMR
13
 and water-LOGSY
14
 experiments. The latter ligand-observed 
NMR methods exploit the transfer of magnetization from protein (or binding site water 
molecules) to a transiently bound fragment. Relaxation-edited NMR experiments evaluate 
differences in the relaxation properties of small and large molecules and use this information for 
fragment discovery. Techniques based on 
19
F NMR resonance detecting the replacement of a 
fluorinated spy ligand can also be applied to detect fragment binding.
15,16 
 
Functional biochemical assays can sometimes be optimized in a way that they still work under 
high-concentration conditions, allowing the detection of inhibition by weak binding fragments.
17
 
The displacement of radioactively labeled probe molecules is an alternative to detect binding.
18
 
This method is very sensitive; however, it requires a labeled reference ligand. Similarly, a 
reporter displacement assay (RDA) can be used.
19,20
 This approach uses a reporter probe 
molecule labeled with an optically sensitive group. Proximity between reporter and protein 
results in the emission of an optical signal, and fragments capable of displacing the reporter 
ligand will cause a loss of signal. 
A popular, simple, and fast assay is based on the fact that the temperature-dependent unfolding of 
a protein is shifted toward higher temperature once a ligand stabilizes a macromolecule. In this 
thermal shift assay (TSA), protein unfolding is monitored using the fluorescence of a dye, which 
is enhanced once hydrophobic portions exposed by the unfolding protein provide a platform on 
which the dye molecules start to assemble.
21–23
 In recent years, native electrospray ionization 
mass spectrometry (ESI-MS) has emerged as a promising label-free technique for medium-
throughput screening of small-molecule libraries against protein targets.
24–26
 In native MS, 
compound binding stoichiometry and relative binding affinity information can be obtained from 
accurate mass measurements and relative signal intensities of the free protein and related protein–
ligand complex, respectively. Alternative methods require the probe molecules to be immobilized 
on a sensor surface, and changes in the optical properties of the surface material are monitored, 
for example, the refractive index close to a thin metal film using an evanescent field.
12,27,28
 These 
surface plasmon resonance (SPR) techniques usually work with an immobilization of the protein 
and detect fragment binding. However, also the reverse concept has been exploited by 
immobilizing ligands as exposed chemical microarrays.
29
 As a medium-throughput method, 
isothermal titration calorimetry (ITC) can also be used to measure the heat signal produced upon 
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complex formation. However, it requires sophisticated titration protocols and large amounts of 
protein material.
11,30,31
 As a rather new technology, microscale thermophoresis (MST) has 
emerged, and its scope has been expanded toward fragment discovery.
32
 The method records the 
motion of fluorescence-labeled molecules in a microscopic temperature gradient. Recent 
developments also exploit the fluorescence of tryptophan to trace molecular motions. Small 
changes in the hydration shell of the observed macromolecule, owing to the accommodation of a 
small molecule fragment, modulate the thermophoretic movement which can be used to detect 
binding. 
A major disadvantage all these approaches have in common is that they do not provide detailed 
information about the binding geometry of the discovered fragment hits. Nonetheless, the 
fundamental consensus that structural information is crucial to an FBLD project to guide the 
subsequent rational potency enhancement in fragment optimization emerged within the medicinal 
chemistry community. At this point, crystal structure analysis is the method of choice.
11,33,34
 
However, as crystallography is still a rather elaborate technique, which requires a robust 
crystallization system producing easily soakable and well-diffracting crystals, it is usually applied 
as a follow-up method only considering a short list of the most promising fragment hits detected 
by the less demanding “pre”-screening approaches (the term prescreening is used in the 
following to highlight that those techniques are usually applied to select fragments for the 
subsequent crystallographic screening).
11
 This kind of stepwise screening cascade is based on the 
important assumption that the coverage of the prescreening methods with respect to possible 
binders is quite exhaustive and reliable. In case they retrieve false positive hits, the follow-up 
crystallographic screening will disclose such inadequacies even though it will then become less 
efficient. The situation becomes more cumbersome if prescreening fails owing to false negatives, 
as they will not be considered in a subsequent crystallographic study and, thus, decrease the 
number of crystal structures that are the basis for subsequent medicinal chemistry efforts. 
We recently presented a newly compiled fragment library,
35
 which had been assembled by 
rational criteria oriented toward, but not strictly adhering to, the rule of three.
36
 This original 
compilation contains 364 entries including three accidentally overlooked duplicates, leading to 
361 non-redundant fragments in the final library. The design of the library and the compounds 
selected for fragment screening is crucial.
37,38
 Apart from aiming at high solubility, we designed 
our library to contain fragments which on average possess a larger portion of Lipinski acceptor 
functionalities. The quality of our library was tested using a biochemical assay on 
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endothiapepsin, an enzyme frequently used as relevant surrogate for the large class of pepsin-like 
aspartic proteases.
35
 This family of enzymes comprises a number of important disease targets 
such as malaria (plasmepsins), fungal infections (secreted aspartic proteinases), Alzheimer’s 
disease (b-secretase), and hypertension (renin). Recently, we demonstrated that this protein is a 
real challenge in drug discovery due to its large binding pocket. In particular, a variety of distinct 
binding modes could be detected for a congeneric inhibitor series that only slightly varied at 
different positions of its parent scaffold.
39
 The crystallographic fragment screening of all 55 hits 
from the biochemical assay led to 11 fragment complexes with endothiapepsin. These different 
fragments cover the binding cleft of the target enzyme quite broadly. Remarkably, consulting the 
rule of three as a putative selection criterion for the library design, we would have only 
discovered four of the eleven hits. The additional seven fragments would have been missed, as 
they all violate the rule of three. 
As mentioned, we followed a cascade approach using crystallography to validate and structurally 
characterize the hits suggested by prescreening with the high-concentration biochemical assay 
based on the cleavage of a fluorescent peptide. The question arises whether an alternative 
prescreening method would have indicated the same or a distinct sample of promising hits to be 
followed up as promising candidates in a subsequent crystallographic study. To the best of our 
knowledge there is no comprehensive study available which tested a full fragment library under 
similar conditions using a series of state-of-the-art fragment screening techniques. We therefore 
decided to consult, apart from the already reported biochemical assay, five other prescreening 
techniques to enumerate our 361-entry library for putative binders. A thermal shift assay (TSA), 
STD-NMR, a reporter-displacement assay (RDA), native nano-ESI mass spectrometry (ESI-MS), 
and microscale thermophoresis (MST) were used to screen our library for promising fragment 
hits. The results of these screening campaigns are compared with the crystallographic hits, which 
were obtained based on the analysis of all fragments significantly inhibiting endothiapepsin in the 
biochemical assay. 
 
2.4 Results and Discussion 
 
In our previously reported fragment screening campaign we focused entirely on the results of a 
biochemical high-concentration prescreening assay. Only fragments inhibiting endothiapepsin to 
at least 40% were subjected to a subsequent crystallographic study to further characterize these 
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most promising hits.
35
 Out of the 55 fragment hits, 11 crystal structures were obtained. This 
success rate of 20% appears already quite convincing. However, it is difficult to assess whether 
we missed important fragments, possibly binding in other sub-pockets, to fully map out the rather 
large binding site of this aspartic protease. Different research groups have suggested the use of 
alternative prescreening approaches in fragment-based drug discovery in order to limit the risk of 
losing false negatives or being misled by too many false positives.
11
 In practice, such assay 
strategies are often considered hierarchically. However, a rationale for which assay to use first is 
not available, and the decision for a particular hierarchy is driven predominantly by the 
availability of an assay and the effort required to perform the screen. Accordingly, in the present 
study we evaluated our library with different screening methods in parallel. This allowed us to 
determine the mutual overlap between the various assay scenarios and to see whether any 
combination or hierarchical protocol of several assays would have proposed a deviating list of 
most promising candidates for a potential follow-up crystallographic study. 
When screening our 361-entry library using the above-mentioned six different prescreening 
techniques, we tried to use the most similar assay conditions possible in light of the different 
requirements for the individual methods (e.g., acidic pH of 4.6; for STD-NMR, the pD was 4.7). 
However, because the applied prescreening assays operate at somewhat distinct fragment 
concentrations (0.1 to 2.5 mM, cf. Table 2.1) and show different sensitivity in detecting weak 
binding, deviating lists of promising hits could be obtained for the crystallographic follow-up 
analysis. In this context, it is also important to bear in mind that the lower threshold or detection 
limit to define binding of a promising fragment hit is usually defined based on empirical concepts 
which are sometimes quite arbitrarily adjusted. In the present study, the assigned hit-definition 
thresholds are based on practical experience gained in the different contributing groups with the 
assay systems and are specified in Table 2.1. The description of the conducted experiments can 
be found in the Experimental Section. 
The detailed assay results for 41 fragments that were identified as hits by at least two 
prescreening methods are listed in Table 2.1. In case we would compile our hit list based on the 
criterion that a fragment has to show up in only one of the assays, the list would have covered in 
total 239 compounds corresponding to 66% of the library. Hits are highlighted in green to 
distinguish them from non-hits. 
Unfortunately, not all compounds could be measured in all assays. Special restrictions and 
applied standards required that in some cases only subsets could be evaluated (Table 2.1). 
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Therefore, we will consider, apart from the total number of hits, particularly the relative hit rates 
normalized by the overall number of compounds subjected to the particular assays. Furthermore, 
three entries were accidentally present twice in the library. This also explains why our library 
contains 361 entries and not 364 fragments as described in our previous report.
35
  
 
Table 2.1. Characteristics and hit rates of the applied screening methods. 
Method c(Fragment)(mM)[a] c(Protein)(μM) Buffer 
DMSO 
(% v/v) 
# of 
compounds 
analyzed (% 
of full 
library) 
Hit 
identification 
# of 
hits 
Hit 
rate 
(%) 
Biochem. 
assay 
1.0 
 
0.004 
0.1M NaAc 
pH=4.6 
1.0 325 (90%) 
>40% 
inhibition 
56[d] 17 
RDA 1.7 0.02 
0.1M NaAc 
pH=4.6 
0.85 358 (99%) 
>30% 
inhibition 
50 14 
STD-NMR 0.3 9.6 
0.05M 
CD3CO2Na 
pD=4.7 
- 206 (57%)[e] 
%STD_AV > 
1.75 and 
%CTL <50 
22 11 
TSA 2.5 2.2 
0.05M Na 
formate 
pH=4.6 
2.7 330 (91%) 
∆Tm ≥ 1.0°C 
= 2.5 σ 
25 8 
ESI-MS[b] 0.1 20 
0.1M NaAc 
pH=4.6 
1.0 342 (95%) 
Categories 
A+, A and 
(B) 
8 
(113) 
2 
(33) 
MST[c] 
0.5 
0.063-0.125 
0.1M NaAc 
pH=4.6 
5.0 
282 (78%)[e] 
∆Fnorm ≥ 6.0 
36 13 
2.5 279 (77%)[e] 75 27 
[a] Fragments for which lower concentrations had to be used due to solubility issues are specified in Table S1. [b] In the course 
of this study the smaller subset, consisting of categories A+ and A (lacking B), is used. [c] All analyses of this study are based on 
the MST experiments at 0.5 mm fragment concentration. [d] This number deviates by one additional hit from the 55 hits in the 
original publication35 because the raw data were re-evaluated for some fragments, and the hit definition cutoff was adapted from 
40% to >40% inhibition. [e] Number of investigated fragments comparably low due to very rigorous fragment quality control 
process (see Experimental Section). 
 
We took this opportunity and analyzed whether the results produced by the prescreening assays 
for these identical compounds were similar. Fortunately, there are no major discrepancies 
between the individual results. The only exception may be that for one duplicate the RDA 
indicated 40 and 22% inhibition, respectively, which would have led to alternative classifications 
based on the chosen 30% hit-definition cutoff.  
All assays result in a crude relative ranking of the compounds’ binding strength, for example, 
expressed in terms of percent effect. In TSA the amount of thermal stability enhancement can be 
used to quantify binding; however, we recently showed that an increase in melting temperature 
highly depends on the adopted binding mode.
39
 As this study was also performed on 
endothiapepsin, we assume that the same effects will hold true for the study of our fragments. 
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Table 2.2 Screening data for all fragments that were indicated as hits by at least two methods. [a] 
Fragment 
Biochemical 
Assay 
RDA NMR ESI-MS TSA MST Solubility
 l
 
ID %inhibition %inhibition %STD_AV %CTL category
f
 ΔTm (°C) 
∆Fnorm 
(at 2.5 mM) 
∆Fnorm 
(at 0.5 mM) 
(µM) 
5 89d 34 2.6 37 WB ≤0.8 -1.3 3.8 1846 
17 97 68 1.9 76 WB 1.9±0.1g -6.4 -18.0 1445 
40 73 46 ≤0.5m NBn WB 0.9±0.2g -6.2 -3.8 NA 
41 49 36 3.0 26 A 1.6±0.3g 2.5 -1.6 >2000 
51 46 56 ≤0.5m NBn B ≤0.8 169.2 62.5 1674 
63 66 37 NA NA B 0.6±0.1g NA -0.6 1860 
64 99 16 ≤0.5m NBn WB 1.9±0.1g -13.8 -18.5 1937 
65 50 31 1.1 29 WB ≤0.8 -5.2 -2.3 1771 
66 NAe 42 NA NA B 1.0±0.1g 8.4 -3.0 1843 
73 42d 31 ≤0.5m NBn WB ≤0.8 3.2 0.6 >2000 
88 47 35 0.9 90 WB NAi -11.5j -6.4 1674 
109 89 26 2.3 32 WB ≤0.8 -1.5j -6.8 1572 
132 <20 -16 ≤0.5m NBn B 1.0±0.1g 6.7 7.5 >2000 
133 28 35 2.8 77 A ≤0.8 -7.1 -2.2 1838 
137 47 30 NA NA B ≤0.8 55.8j -9.6 686 
148 51 18 NA NA NS ≤0.8 -5.2 1.8 1950 
149 100 77 NA NA WB 2.8±0.4g NA NA 1574 
159 60 72 4.0 41 WB 1.9±0.1g -21.2 -13.6 1479 
161 80 -25 NA NA A 1.1±0.1g -13.6 -5.1 1802 
166 <20 44 NA NA B ≤0.8 -34.6 -37.3 1595 
167 24 46 NA NA B ≤0.8 5.3j -34.0 6226 
175 75 23 NA NA WB* 1.0±0.1g NA NA 1626 
177 100b 99 4.8 37 WB 3.4±0.3g,h -16.2 -8.8 1460 
178 100d 81 2.7 96 WB 1.8±0.1g 64.9j -19.2 1916 
183 60 16 1.8 64 WB ≤0.8 471.2j -6.1 >2000 
196 <20 76 1.9 46 WB ≤0.8 -2.5 0.8 1834 
216 45 54 1.9 27 WB 1.8±0.1g 3.9 1.6 1965 
222 52 30 3.1 32 NS ≤0.8 -3.9 1.0 1175 
224 63 87 3.9 38 WB 1.1±0.1g -12.0 -9.2 1806 
236 100 75 2.4 153 WB 1.5±0.2g -2.4 1.2 >2000 
255 84 36 NA NA B 1.9±0.1g -21.3 -19.4 1673 
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Table 2.2 (cont.) Screening data for all fragments that were indicated as hits by at least two methods. [a] 
261 47 48 NA NA WB 0.7±0.1g -3.7 -4.9 1878 
284 87 58 NA NA WB 2.0±0.1g -9.0 -3.6 1789 
290 84 88 6.7 22 A+ 1.2±0.1g -0.7 -1.4 >2000 
291 50 -17 2.7 47 B ≤0.8 -11.5 -7.4 >2000 
301 75 -120 3.0 33 B ≤0.8 3.5 -1.5 1905 
306 93 89 6.7 24 A+ 1.7±0.2g -4.0 -2.0 >2000 
308 53d 35 2.2 42 WB ≤0.8 5.8 57.9j 1483 
333 76 2 ≤0.5m NBn B <-0.8 -15.3 -7.4 >2000 
335 60 25 ≤0.5m NBn WB 1.8±0.0g 2.1 -0.5 1985 
337 38 47 NA NA WB 1.3±0.3g NA NA >2000 
362 43 22 5.5 83 WB ≤0.8 -24.1 -14.7 1348 
[a] In addition to all fragments indicated as hit by at least two techniques, the table contains all 11 fragments that were identified as 
crystallographic hits in a previous study highlighted in the first column in yellow35 (fragment 148, thus, adds to the table). Hits were 
defined on the basis of the cutoffs shown in Table 2.1 and are highlighted in green. Fragments that showed a positive result in only 
one of the two NMR screens or that belong to category B of the ESI-MS assay are indicated in pale green. Fragments with a solubility 
between1.5 and 2.0 mM are also highlighted in pale green, whereas fragments with solubility ≥ 2.0 mM are shown in green. Finally, 
fragments for which no data could be recorded or analyzed properly are highlighted in gray. [b] NA: not available due to the absence 
of significant fragment absorption at wavelengths between 250 and 500 nm. [c] The various ESI-MS categories are defined as 
follows: A+ :most interesting fragments with high binding extent without significant nonspecific adduction, A: interesting fragments 
with a relatively high ratio of specific binding to nonspecific binding, B: potentially interesting fragments with a medium ratio of 
specific binding to nonspecific binding, WB*: fragments with low binding extent but without detection of extensive nonspecific 
adducts, NS: fragments with relatively high binding extent accompanied by high nonspecific adduction(nonspecific binders), WB: 
fragments with low binding extent (weak binders). [d] Fragment displayed self-fluorescence, but could still be measured. [e] 
Determined in duplicate by a second and third TSA screen using a temperature increment of 0.2°C min-1 (performed for all fragments 
indicated as hit in the primary screen). All remaining fragments were only investigated in the initial screen (0.5°C min-1), where they 
were not defined as a hit (∆Tm ≤ 2). [f] Signal-to-noise ratio in STD spectrum too low for integration. [g] NB: non-binder; an exact 
value could not be calculated in case footnote f applies. [h] Not analyzed because of self-fluorescence. [i] Data could not be analyzed 
accurately due to the appearance of the melting curve. [j] These data points were excluded from the analysis because the investigated 
fragments changed the initial fluorescence by > 18 %with respect to the mean initial fluorescence of positive and negative controls on 
the same capillary chip. [k] Measurement at 0.5 mM fragment concentration. [l] Measurement at 1.25 mM fragment concentration. 
 
 
On first glance, it appears more difficult in the case of the thermal shift, ESI-MS and MST assays 
to distinguish active site binders from “unspecific” surface binders (although in the case of 
ESIMS and MST
40
 specific binding can be assessed through competition assays, provided a high-
affinity reference compound is available), while the biochemical assay requires direct binding to 
the active site to be functional (apart from the unlikely event of an allosteric inhibition in case of 
the present aspartyl protease). Moreover, in the case of the STD-NMR and RDA, known active 
site displacement ligands are used to confirm binding to the catalytic site. Here, an appropriate 
selection of the displacement ligand is crucial. In RDA, the large heptapeptidic ligand pepstatinA 
was used as reference ligand, whereas in STD-NMR primary screening hits were validated by 
competitive displacement using ritonavir, a smaller active-site-specific inhibitor with a Ki value 
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of 15 nm for endothiapepsin.
41
 As this inhibitor leaves some sub-pockets in the substrate binding 
cleft of endothiapepsin unoccupied, the ligand might even provide additional interaction sites for 
putative fragments and can recruit further fragment hits not found in the primary NMR screen. 
These facts have to be considered as they may produce non-corresponding results for structural 
reasons.   
In Table 2.1 the total numbers of hits and hit rates resulting from the different assay techniques 
are summarized. Overall, the biochemical and Proteros RDA assays reveal a similar number of 
hits. When considering only the pure binding event in STD-NMR (without confirmation via 
active site displacement, and thus taking the risk of the possibility of unspecific surface binding) 
the number of hits increases from 22 to 71 (based on the 206 studied compounds). In comparison, 
the secondary screen using ritonavir as displacement ligand revealed 30 hits. Because this 
number exceeds the 22 confirmed hits identified in the primary and the ritonavir screen by eight, 
it could well be that the displacement ligand facilitated the discovery of additional hits. Applying 
the more restrictive hit-definition conditions (only categories A and A+), the ESI-MS analysis 
discovers a total of eight strongly binding hits. However, a rather high hit rate of 113 out of 342 
investigated fragments is found when choosing the less stringent hit-definition limit (including 
category B; for details see legend of Table 2.1 and Experimental Section). Using the TSA, 25 hits 
were identified, corresponding to a 7.6% hit rate. The MST assay was run at two concentrations. 
While at the lower fragment concentration (0.5 mM) 36 hits were detected, this number increased 
to 75 fragments at 2.5 mM.  
Even though the overall hit rates of the individual screening methods might still be of similar 
magnitudes (Table 2.1), the mutual overlap between the methods is by no means satisfactory (cf. 
Venn diagrams in Fig. 2.1 and 2.2). Not a single fragment is characterized as hit by all 
prescreening techniques (Fig. 2.1). Even when comparing only the four methods with the largest 
mutual overlaps (biochemical assay, RDA, STD-NMR and TSA; see Table 2.3 as well), the 
number of only seven common hits is rather disappointing (Fig. 2.2). Furthermore, a comparison 
of matching hit list pairs reveals that certain techniques such as the biochemical assay and RDA 
show fairly similar hits, whereas the MST hit set is more distinct from all other screening results 
(Table 2.3). Interestingly, a total of 119 of our fragments were indicated as hits in at least one 
assay when only considering ESI-MS categories A+ and A, the 22 competitive NMR binders and 
the MST results at 0.5 mM fragment concentration (for details see legend of Table 2.1 and 
Experimental Section). Slightly weakening these criteria by including the MST results at 2.5 mM 
2. One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment 
Hit Lists 
39 
 
fragment concentration leads to 153 hits; adding also the results for both NMR screens 
individually results in 182 hits. Finally, including the ESI-MS category B as well leads to 239 
hits. These large overall hit numbers of 119, 153, 182, and 239 fragments correspond to 33, 42, 
50, and 66% of the total library, respectively, again highlighting that the overlap of the different 
hit lists is rather low. In particular, only 41, 21, 10, 6, or none of the 119 prescreening hits are 
indicated as binders by at least two, three, four, five, or all six assay techniques, respectively. 
 
 
Fig. 2.1. Venn diagram for all hit sets of the applied prescreening techniques. As indicated by 
the legend at lower right, the number of overlapping hit sets in a certain region of the diagram 
is indicated by a gradually increasing reddening of the respective field. All hits revealed by the 
biochemical assay, RDA, STD-NMR (competitive binders), ESI-MS (categories A+ and A), 
TSA and MST (at 0.5 mM fragment concentration) are enclosed by red, blue, green, purple, 
orange, and yellow lines, respectively. For instance, the sum of all numbers within the green 
circle gives the overall hit count for STD-NMR (24x0+2x1+3x2+2x3+1x8=22). To get the 
total number of fragments indicated as hits by STD-NMR and RDA (independent of which 
other method might also have found these fragments as hit), one has to sum over the numbers 
included in the upper half of the green circle corresponding to the overlap between the green 
circle and the blue box (11x0+2x1+1x2+2x3=10). The number 3 highlighted by the white 
arrow represents the number of common hits between five different methods (as indicated by 
the shade of light red), namely the biochemical assay, RDA, STD-NMR, ESI-MS, and TSA (but 
not MST, as the object surrounded by the yellow line does not include this number). This 
graphic was produced using the statistical framework R and Inkscape. 
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Fig. 2.2. Venn diagram for those prescreening hit sets with the largest 
mutual overlaps. The number of overlapping hit sets in a certain region of 
the diagram is highlighted by a gradually increasing color intensity. All 
hits of the biochemical assay, RDA, STD-NMR (competitive binders) and 
TSA are enclosed by red, blue, green, and purple lines, respectively. This 
Venn plot was generated by R. 
 
 
Table 2.3. Number and percentage of overlapping hits between pairs of the applied screening 
methods [a] 
Method 
Biochem. 
assay 
RDA 
STD-
NMR[b] 
TSA ESI-MS[c] MST[d] 
Biochem. 
assay 
x 
22 
(39%) 
13 
(23%) 
17 
(30%) 
4 
(7%) 
15 
(27%) 
RDA 
22 
(44%) 
x 
10 
(20%) 
15 
(30%) 
4 
(8%) 
10 
(20%) 
STD-
NMR[b] 
13 
(59%) 
10 
(45%) 
x 
7 
(32%) 
3 
(14%) 
5 
(23%) 
TSA 
17 
(68%) 
15 
(60%) 
7 
(28%) 
x 
4 
(16%) 
8 
(32%) 
ESI-MS[c] 
4 
(50%) 
4 
(50%) 
3 
(38%) 
4 
(50%) 
x 
0 
(0%) 
MST[d] 
15 
(42%) 
10 
(28%) 
5 
(14%) 
8 
(22%) 
0 
(0%) 
x 
[a] The percentage given in parentheses reflects the fraction of all hits identified by a certain 
method that is confirmed as hit by the technique depicted in the respective column; for 
example, 44% of all RDA hits are also found in the biochemical assay. [b] Only the 22 
competitive binders were taken into account. [c] The small subset consisting of categories A+ 
and A (lacking B) was used for this analysis. [d] MST results from the measurements at 0.5 
mM fragment concentration were analyzed. 
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Despite the unsatisfactory consensus of the applied screening methods, the obtained results 
appear rather convincing with respect to the 11 determined crystal structures as, overall, the 
RDA, NMR, MS, TSA, and MST analyses would have suggested 10 of the actually detected 
crystallographic hits. In particular, the RDA, NMR, MS (excluding/including category B), TSA, 
and MST (at 0.5/2.5 mM fragment concentration) assays would have been able to identify 73, 
100, 27/55, 55, and 27/33%, respectively, of the crystallographic hits found owing to the 
evidence from our biochemical assay. For NMR, however, the result must be interpreted based on 
the fact that with this method only seven of the 11 crystallographic binders could be investigated. 
When decreasing the size of the library to the 55 fragments investigated crystallographically and 
taking the resulting X-ray hits obtained after the biochemical assay as a benchmark, a 
crystallographic follow-up screen with the 21- fragment hit list indicated by the RDA would have 
resulted in eight structures. Analogously, the NMR, ESI-MS (excluding category B), thermal 
shift, and MST (at 0.5 mM fragment concentration) assays would have revealed 7, 3, 6, or 3 
structures out of 13, 4, 17, and 15 prescreening hits, respectively. However, conclusions about 
whether some screening methods might be superior to others regarding the prediction of 
crystallographic binders have to be taken very carefully, as our crystallographic hits were only 
found after applying the biochemical prescreening filter, which might, for instance, penalize the 
MST results because they have a comparably low overlap with the biochemical assay hits (Table 
2.3). Possibly applying a different prescreening protocol or combining several of them could have 
detected another set of fragment complex structures. 
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Fig. 2.3. Distribution of measured solubility with respect to the applied screening methods. As reference, the 
fragment screening concentration of each method is highlighted by a vertical line (see Table 2.1 and the 
Experimental Section for details regarding experimental conditions). Each plot compares the solubility kernel 
density estimations of all library fragments that were investigated by a specific screening technique (blue) with 
those indicated as a hit by the same method (pink). All values indicating at least 2 mM solubility were 
summarized in the 2 mM bin. Therefore, the reference line for the TSA, which was conducted at a 2.5 mM 
fragment concentration, was also drawn at 2.0 mM. The depicted plots were generated using the statistical 
framework R. 
 
Moreover, it is very informative to compare the measured fragment solubility of all library entries 
investigated by a certain screening method against the suggested list of hits (for solubility values 
see Table 2.2). The corresponding solubility distributions displayed in Fig. 2.3 clearly highlight 
that most hits display a solubility above ~1 mM, whereas fragments with a solubility <1 mM are 
less likely to be identified as hit. One exception of this observation, however, was the MST assay, 
where also for less soluble compounds binding was equally probable. Nevertheless, our results 
suggest that sufficient solubility is usually an important property of prescreening hits and that it 
would therefore be wise to omit insufficiently or less soluble compounds during the design of 
new fragment libraries. For instance, in our case this has been achieved for the library subset 
investigated by NMR (cf. Fig. 2.3, first row, and third column). The entire library mostly contains 
fragments with a solubility >1 mM (85 %). The fragment concentration used for most of the 
screens remained below this limit (Table 2.1 and Fig. 2.3). Thus, the majority of the fragments 
were fully soluble under the applied assay conditions. Only in the reporter displacement and 
thermal shift assays screening concentrations >1 mM were applied. Nevertheless, these methods 
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also detected fragment hits with solubility below the applied screening concentration. To avoid 
artifacts possibly resulting from compound aggregation, it is advisable to screen at the lowest 
possible concentrations that are still high enough with respect to the sensitivity of a given 
method.  
We also compared the methods that more likely detect specific active site binding (biochemical 
assay, RDA) with those also observing binding events remote from the substrate binding pocket 
(ESI-MS, TSA, MST). In this comparison, the NMR assay played a crucial role, as this method 
is, in principle, capable of discriminating specific active site binding from unspecific binding, 
with the additional effect that the displacement ligand ritonavir may recruit further fragment 
binders. To perform the latter analysis, we divided the NMR hit list into ritonavir- competitive, 
ritonavir-uncompetitive, and ritonavir-induced binders (Fig. 2.4). As anticipated, the functional 
assay hits (biochemical assay, RDA) match better as active site binders with the ritonavir-
competitive binders than with the putative remote binders, whereas the globally sensitive 
methods (ESI-MS, TSA, MST) display a larger overlap with the ritonavir-uncompetitive binders. 
Interestingly, the latter methods only retrieved one of the putative ritonavir-induced binders, 
underlining that the presence of the displacement ligand might indeed be necessary for binding to 
take place in these cases. However, further experiments will be required to confirm that specific 
fragments can actually only bind in the presence of ritonavir. An important question remains: 
why do we detect such a limited overlap among the different fragment screening approaches? 
This observation is shared by other researchers in the field as communicated at meetings; 
however, little results have been thoroughly documented on this fact in the literature, or the 
assays were performed under conditions that are difficult to compare.
42
 The biophysical effects 
exploited by the various methods are quite distinct, which raises the question how much overlap 
actually can be expected from diverse screening techniques. Furthermore, any assay requires the 
choice of a distinct hit-definition threshold necessarily influencing the screening results as well as 
specific conditions to be fulfilled. We tried to keep parameters such as pH, salt conditions, and 
ionic strength similar or at least in a comparable range, but as the influence of these parameters 
on binding is multifactorial along with the differences in the methods’ sensitivity, the overall 
effects on the screening results are extremely difficult to estimate. Moreover, it has to be regarded 
that fragment screening operates at rather high concentrations where micelle formation or 
aggregation of organic compounds, fragment–substrate interactions, interference with 
fluorescence detection (absorption, quenching, auto-fluorescence) or partial protein denaturation 
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can occur and might affect the effective fragment and/or protein concentration differently for 
distinct screening techniques. 
 
 
Fig. 2.4. Comparison of screening methods with respect to their ability to detect active site and unspecific 
binders. The first row contains three Venn diagrams contrasting the merged biochemical assay/RDA hit set 
(green) with those NMR hits (yellow) that were obtained in the primary and secondary (left, competitive binders 
with respect to ritonavir), in the primary but not in the secondary (center, uncompetitive binders with respect to 
ritonavir), and in the secondary but not in the primary screen (right, fragments binding presumably due to the 
presence of ritonavir). In the second row, the same NMR categories are compared with the set union of the ESI-
MS (categories A+ and A), TSA and MST (at 0.5 mM fragment concentration) hits. All Venn diagrams were 
produced using R. 
 
2.5 Conclusions 
 
The last 15 years of fragment-based lead discovery have demonstrated that the approach is only 
really powerful if the actual binding mode of a fragment in the protein binding pocket is known, 
particularly when working with proteins harboring very large pockets. Therefore, a 
crystallographic analysis of fragment binding will be essential in the end. The present study 
shows, admittedly based on the experience with one protease as a reference, that all prescreening 
methods produce different results with minor overlap of putative hits. Usually, crystallography is 
not taken as a primary screening technique as it is considered to be too expensive, elaborate, 
time-consuming and cumbersome. But at the end, the question arises whether the yield detected 
through one of the rapid and well established prescreening methods provides enough hits for a 
follow-up crystallographic study or whether possibly some important, perhaps better suited, or 
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even patent-free fragments are missed. Apart from taking this putative risk, from a drug 
designer’s point of view every structure of a crystallographically confirmed fragment hit provides 
important insight in terms of an experimental active site mapping of the studied target protein. 
Even if such a fragment is finally not taken as the candidate for hit-to-lead optimization, the 
knowledge of its binding mode might help to create new ideas at a later stage of a drug 
development project. This can be of utmost importance to make a drug discovery program finally 
successful. 
 
2.6 Experimental Section 
 
2.6.1 Protein material 
 
Endothiapepsin samples were obtained from Suparen (provided by DSM Food Specialties); the 
buffer was exchanged with 0.1M sodium acetate (pH 4.6) using a Vivaspin 20 with a 10 kDa 
molecular weight cutoff. Protein concentration was determined by absorbance at λ = 280 nm, 
assuming an extinction coefficient of 1.15 for 1 mg∙mL-1 solutions.43  
 
2.6.2 Fragment library 
 
The fragment library was assembled and purchased as previously described.
35
 The originally 
reported compound collection contained three redundant entries, which were independently 
evaluated in most assays providing the opportunity to check for inconsistencies and to assess the 
reproducibility of the assay results. The solubility of all fragments was determined in buffered 
solution as described elsewhere.
35 
 
2.6.3 Biochemical assay 
 
All 361 entries of the library were tested against endothiapepsin in a functional assay using the 
peptide substrate Abz-Thr-Ile-Nle-(p-nitro-Phe)-Gln-Arg-NH2.
35
 Upon substrate cleavage, 
fluorescence increased during the measurement. The assay was performed in a 0.1M sodium 
acetate buffer at pH 4.6 containing 0.01% (v/v) Tween 20. Substrate and the investigated 
screening compound were pre-incubated and the protein was added directly before measurement. 
The final reaction mixture contained 4 nM endothiapepsin, 1.8 µM substrate, 1 mM test 
compound, and 1% (v/v) DMSO. Under these conditions, 18 test compounds were insufficiently 
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soluble and 18 additional compounds had to be studied at a concentration of 500 µM due to 
limited solubility. Finally, 17 fragments had to be excluded from the assay due to self-
fluorescence. Each compound was measured twice, and the percent inhibition given in Table 2.2 
represents the average of both measurements; 56 fragments led to enzyme inhibition of >40%. 
 
2.6.4 Thermal Shift assay 
 
345 sufficiently soluble fragments were subjected to a thermal stability assay following the 
protocol we described previously.
39
 Samples were heated from 20 to 80°C at a rate of 0.5°Cmin
-1
. 
Of the 345 melting curves, 15 could not be analyzed accurately due to their appearance. Potential 
hits (∆Tm > 0.8°C) were re-measured twice at a rate of 0.2°C min
-1
. The 0.1M sodium acetate 
assay buffer at pH 4.6 contained 0.01% (v/v) Tween 20 and a mixture of 2.2 µM endothiapepsin, 
the probe fragment at 2.5 mM (1.25 mM for the less soluble fragments), and 0.2% (v/v) of the 
dye SYPRO Orange to record unfolding (final DMSO concentration: 2.7% (v/v)). Shifts of the 
melting temperature with respect to native endothiapepsin were determined based on the analysis 
of the first derivative of the recorded fluorescence/temperature protocol.  
Thermal shifts of ∆Tm ≥ 1.0°C, which corresponds to the 2.5-fold standard deviation of 15 Tm 
determinations of the apo-enzyme in the presence of DMSO, were assumed significant, leading 
to 25 hits. 
 
2.6.5 Native ESI-MS assay 
  
For ESI-MS experiments, the buffer of endothiapepsin samples was exchanged against 50 mM 
ammonium formate (pH 4.6). The final protein–ligand mixtures contained 100 µM fragment and 
20 µM protein in 50 mM ammonium formate (pH 4.6), 5% (v/v) ethanol and 1% (v/v) DMSO. 
These samples were then analyzed using an automated chip-based nanoelectrospray robot 
(Triversa Nanomate, Advion Biosciences) connected to an electrospray time-of-flight mass 
spectrometer (LCT, Waters) operating with fine-tuned instrument parameters promoting the 
detection of intact noncovalent complexes.
44
 Under these conditions, 342 of the 361 fragments 
could be investigated. Compounds were ranked based on relative complex abundances, applying 
penalties when nonspecific binding was suspected from the detection of 
statistically distributed multi-adduction of the compound to the protein. This resulted in a sixfold 
classification scheme. The two best-ranked compound categories, A+ and A, correspond to 
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compounds with relatively high binding extent with no or low nonspecific adduction, 
respectively. Intermediate categories B (compounds with medium binding extent and some 
nonspecific binding) and WB* (weak binders without nonspecific adduction) encompass 
compounds for which no clear conclusion could be drawn regarding classification as true or false 
positive hits. Finally, less interesting compounds were classified in category NS (compounds 
showing extensive nonspecific adduction) and WB (weak binders showing some nonspecific 
adduction). Two entries were top-ranked (category A+, 0.6% of database referring to 342 
entries), six fragments fell into the second category (category A, 1.8%) and 105 compounds 
(30.7%) were classified as potential binders with medium, slightly nonspecific binding (category 
B). For our comparative analysis we decided to consider the eight top-ranked compounds of the 
first two categories, and the 105 hits from category B were additionally regarded.  
 
2.6.6 Reporter displacement assay 
  
The reporter displacement assay (RDA), developed at Proteros, has been described in detail 
previously.
19,20
 In brief, the reporter displacement assay is based on a reporter ligand that is 
distinctively designed to bind to the site of interest of the chosen target enzyme or receptor. The 
proximity between reporter ligand and protein results in the emission of an optical signal. 
Fragments and compounds that bind to the same binding site displace the reporter ligand to cause 
a signal loss. Quantity and kinetics of signal loss can be monitored. The reporter displacement 
assay is a homogeneous method performed in 384-well plates allowing the measurement of 384 
kinetic traces in parallel. In the present case, pepstatin A, a potent and crystallographically 
confirmed inhibitor of endothiapepsin,
45
 was used as reporter ligand. The 361 fragments were 
tested for their binding to the protease. In the case of competitive binding to the pepstatin A 
binding site, the test fragments displaced the reporter ligand, resulting in loss of the fluorescence 
signal. Due to the nature of the optical signal, interference with the fluorescence properties of the 
fragments can occur. The measurements were performed at a fragment concentration of 1.7 mM 
and a protein concentration of 20 nM (final DMSO concentration: 0.85% (v/v)) in a sodium 
acetate buffer at pH 4.6. Overall, 358 of the 361 fragments could be investigated, and the results 
are reported as percent inhibition of the protein. 
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For 50 fragments, binding led to an inhibition of >30% under the applied assay conditions. To 
quantify the inhibitory potential of the various fragments, the amount of signal loss was 
quantified at different fragment concentrations once the system had reached equilibrium. 
Following this protocol, IC50 values were determined for the 25 strongest binders, which are 
summarized in Table 2.4. 
 
Table 2.4. IC50 values for the 25 top-ranked fragment hits from the RDA. 
Fragment IC50[mM] Fragment IC50[mM] Fragment IC50[mM] 
5 > 1.30 148 > 1.30 261 0.59 
6 0.23 149 0.15 284 0.26 
17 0.10 152 > 1.30 285 > 1.30 
33 1.66 177 0.003 290 0.04 
40 2.09 178 0.23 291 > 1.30 
41 > 1.30 196 0.81 306 0.04 
63 2.28 216 0.09 327 0.10 
75 > 1.30 224 0.02   
78 > 1.30 255 1.16   
 
2.6.7 Microscale thermophoresis (MST) assay  
 
A subset of 295 fragments, mainly selected based on their DMSO solubility (>50 mM), was 
analyzed in an MST assay. Endothiapepsin was labeled with the Monolith NT.115 Protein 
Labeling Kit RED-NHS from NanoTemper Technologies (NanoTemper Technologies, Munich, 
Germany). For labeling, the endothiapepsin stock was diluted in PBS (pH 7.0) to reach a final 
concentration of 20 µM in a total volume of 100 µL. A pH of 7 is required in this particular case 
to prevent endothiapepsin inactivation which occurs at pH values >7. Endothiapepsin solution 
was then mixed with 100 µL PBS (pH 7.0) containing 200 µM NT647-NHS fluorophore and 
incubated at room temperature for 15 min. Free fluorophore was separated from labeled protein 
by size-exclusion chromatography using gravity-flow size-exclusion columns provided in the 
Protein Labeling Kit RED-NHS (NanoTemper Technologies).  
For assay development, potential adsorption of NT647–endothiapepsin to the capillary walls was 
investigated in pre-tests with 60 nM NT647–endothiapepsin in assay buffer (100 mM sodium 
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acetate (pH 4.6), 0.05% (v/v) Tween 20, 5% (v/v) DMSO) in standard treated and premium-
coated MST-grade capillaries (NanoTemper Technologies) using a Monolith NT.115 instrument 
(NanoTemper Technologies). Because the protein did not adsorb to the two capillary types under 
these conditions, all subsequent experiments were performed in standard treated capillaries. The 
interaction of NT647–endothiapepsin with the peptidomimetic inhibitor acetylpepstatin was used 
to identify optimal assay conditions and was used as a positive control throughout the screening. 
Quantitative binding experiments using a 16-fold 1:1 serial dilution of acetylpepstatin showed 
that the optimal binding signal was obtained at an MST power of 80% with quantification of 
thermophoresis after 25 s, yielding a Kd value of ~150 nM and a binding amplitude of 15.9 
counts, while the baseline noise of NT647–endothiapepsin was 3 counts under these conditions. 
The same interaction was measured by MST after 1 h incubation at room temperature, yielding 
similar results, showing that the interaction was stable during this time span. 
For fragment screening, single-point measurements were performed in assay buffer. Two 
different fragment concentrations (0.5 and 2.5 mM) were used to investigate the influence of this 
parameter on the resulting hit list for this rather new technique in the FBLD field. While samples 
containing DMSO without fragments were used as negative controls, acetylpepstatin was present 
at 120 µM in the positive controls. The labeled protein was added to the reaction mixture to yield 
a final concentration of 62.5–125 nM. MST measurements were conducted using the Monolith 
NT.Automated instrument (NanoTemper Technologies) at 80% laser power, 40–50% LED 
power, and 25°C. Fnorm values were derived by dividing the fluorescence intensity after an MST 
laser on-time between 25 and 26 s and the initial fluorescence prior to MST laser activation. 
∆Fnorm values were then obtained by subtracting Fnorm values of the negative controls from Fnorm 
values in the presence of the respective fragments on the same capillary chip. Fragments that 
altered the initial fluorescence by >18% relative to the average initial fluorescence of negative 
and positive controls on the same capillary chip were excluded from the analysis (0.5 mM: 13 
fragments excluded, 2.5 mM: 15). MST data were then exported from the NT Affinity Analysis 
and plotted in Spotfire software (Tibco, Palo Alto, CA, USA) for evaluation of normalized 
fluorescence values (Fnorm) versus initial fluorescence. Runs at 0.5 and 2.5 mM fragment 
concentration were evaluated individually. A fragment was defined as a hit if the |∆Fnorm| 
diverged by >2-fold from the total averaged negative control noise (3 Fnorm counts) to the 
respective negative control on the same capillary chip. This analysis revealed 36 hits at a 
fragment concentration of 0.5 mM and 75 hits at 2.5 mM. 
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2.6.8 STD-NMR assay 
 
For the NMR experiments (Bruker Avance II, 600 MHz with cryogenic probe head) only 
fragments that meet the following three criteria were considered: 1) HPLC–MS purity ≥80%, 2) 
aqueous solubility in the applied buffer of at least 500 µM, and 3) no aggregation (as measured 
by a self STD intensity <2%) at 500 µM. This resulted in the selection of a subset of 206 
fragments for this comparative study. To save data acquisition time, mixtures of two compounds 
were tested. The first set of NMR measurements (binding experiments) was performed in D2O 
buffer solution containing 50 mM CD3CO2D with 100 mM NaCl and 4 mM NaN3, adjusted to 
pD 4.7 (a pH of 4.3 was determined) at 25°C. Sample mixtures contained 310 μM of each 
fragment compound and 9.6 μM endothiapepsin. The total assay volume of 163 μL was filled in 
2.5 mm NMR tubes. To distinguish specific interactions from nonspecific binding outside the 
active site, competitive displacement experiments were performed with all fragment mixtures in 
the presence of 16 μM ritonavir as a potent active site inhibitor.41 Individual fragment signals 
were identified by comparing the screening spectra with the two corresponding reference spectra, 
which were recorded separately in the absence of endothiapepsin or ritonavir. For each binding 
fragment, averaged STD-NMR intensity values were determined by comparing the difference 
with the off-resonance spectrum (Table 2.1, STD_AV>1.75 %). This was done for the binding 
and the corresponding competitive displacement experiment, respectively. Percentage control 
values (CTL [%]) were calculated by dividing the STD intensity values from the binding 
experiment and the competitive displacement experiment (% CTL = 100*(I(competitive 
displacement)/I(binding))). Fragments with an averaged percent CTL of <50% were classified as 
competitive binders. Overall, 22 competitive binders were identified by STD-NMR referring to 
the reduced sample set of 206 compounds. 
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3. Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal 
Structures: Versatile Warheads To Address a Catalytic Dyad 
 
3.1 Introductory Remarks 
 
The following chapter has been published in J. Med. Chem. in 2016. The chapter is a part of a 
major project including the fragment soaking, and data collection of over 450 datasets, discussed 
in the following chapter and in chapter 4. Protein purification, crystallization and all soaking 
experiments were performed by the author of this thesis with additional help from Johan 
Winquist and Ah Young Park. For the data collection and structure refinement, the work of six 
additional colleagues, Johannes Schiebel, Frederik R. Ehrmann, Stefan G. Krimmer, Kan Fu, 
Xiaojie Wang, and Martin Stieler was consulted. The data collection was done at Helmholz-
Zentrum Berlin für Materialien und Energie, BESSY II with the help of Franziska U. 
Huschmann, Manfred S. Weiss, and Uwe Müller. All data collection and refinement statistics can 
be found in the Appendix. 
The author of this thesis carried out the refinement of all datasets collected for fragments F001‒
F070 and performed the data analysis and interpretation for all fragment hits along with drafting 
the paper. 
 
 
̽ Reprinted with permission from J. Med. Chem. 2016, 59, 9743‒9759. Copyright 2016 American Chemical Society. 
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3.2 Abstract 
 
Crystallography is frequently used as follow-up method to validate hits identified by biophysical 
screening cascades. The capacity of crystallography to directly screen fragment libraries is often 
underestimated, due to its supposed low-throughput and need for high-quality crystals. We 
applied crystallographic fragment screening to map the protein-binding site of the aspartic 
protease endothiapepsin by individual soaking experiments. Here, we report on 41 fragments 
binding to the catalytic dyad and adjacent specificity pockets. The analysis identifies already 
known warheads but also reveals hydrazide, pyrazole, or carboxylic acid fragments as novel 
functional groups binding to the dyad. A remarkable swapping of the S1 and S1′ pocket between 
structurally related fragments is explained by either steric demand, required displacement of a 
well-bound water molecule, or changes of trigonal-planar to tetrahedral geometry of an oxygen 
functional group in a side chain. Some warheads simultaneously occupying both S1 and S1′ are 
promising starting points for fragment-growing strategies. 
 
3.3 Introduction 
 
Over the past 10 years fragment-based lead discovery (FBLD) has become popular and is 
increasingly used as first step in the lead discovery process.
1,2
 The fundamental idea of this 
approach is to start with small (MW < 250 Da) but efficiently binding seed fragments, which are 
subsequently grown to lead molecules optimized for a given target protein based on structural 
information obtained from X-ray crystallography.
3
 Usually, at the initial stage of FBLD, 
biophysical methods (“prescreening methods” in the following) such as native mass spectrometry 
(MS), thermal-shift assay (TSA), saturation   transfer difference (STD) NMR, surface plasmon 
resonance (SPR) or microscale thermophoresis (MST) are used to screen a fragment library.
4−7
 
These methods are applied to retrieve the most promising fragment binders from a library.
8,9
 
Although they are expected to be sensitive enough to identify weak binding compounds, none of 
them can unambiguously determine the adopted binding mode of discovered hits. However, 
structural knowledge is an essential prerequisite for subsequent rational hit-to-lead optimization. 
Furthermore, it is rarely considered that prescreening is often equally laborious, expensive, time 
consuming and in fact frequently leads to unsatisfactorily overlapping hit lists.
10
 A serious 
limitation for the applicability of many of the suggested techniques is the compound solubility in 
aqueous buffer, a problem often occurring when high concentrations of weak binding compounds 
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are required for the analysis. An alternative to overcome this bottleneck is the application of X-
ray crystallography as screening method right at the beginning of an FBLD campaign. This 
strategy allows much higher concentrations than are usually applicable in any other technique, 
often accomplished by adding organic solvents such as DMSO to the crystallization buffer.
11−13
 
The capability of crystallographic fragment screening largely remains underexploited, although it 
is one of the most sensitive techniques considered for rational fragment screening.
14,15
 We 
therefore decided to crystallographically screen our entire in-house fragment library in order to 
thoroughly explore the binding site of the aspartic protease endothiapepsin (EP) by elucidating 
different binding geometries. 
Our previously presented library of 361 fragments had been designed using a set of predefined 
criteria, slightly extending the rule-of-three concept for physicochemical properties.
16,17
 The 
chosen protein EP
18
 has been used in the past as a surrogate for aspartic proteases of the A1 
family, e.g., drug targets such as renin (hypertension), plasmepsins (malaria), β-secretase 
(Alzheimer’s disease), or secreted aspartic proteinases (fungal infections).19−21 EP shares folding 
architecture and considerable sequence identity with its related targets and represents a robust 
crystallization system producing well-diffracting crystals. However, in a recent study we 
demonstrated that EP is still a challenging target, as minor structural modifications of a parent 
lead molecule resulted in significant changes in binding modes.
22
 Nonetheless, we believe that EP 
is a relevant model protein for method development in basic drug research, as it provides high 
resolution structural data often not achievable with other aspartic proteases. 
All 361 fragments were soaked individually into premanufactured crystals of the apo protein. 
This is a difference in strategy compared to our previous study,
17
 where we preselected only 
promising fragment candidates according to a biochemical assay and applied cocktails of the 
detected hit compounds. To reach equilibrium for weaker and potentially slow-binding 
fragments, a rather long soaking time of 48 h was used, which was well tolerated by the crystals. 
In total, we identified 71 hits bound to the target protein. As one of these seemed to be 
oligomerized, 70 hits were kept for the subsequent analysis. Of these, 41 hits bound to the 
catalytic dyad, corresponding to a hit rate of 11% (Fig. 3.1). An additional 29 fragment hits were 
found to bind remotely from the catalytic dyad. These are discussed in a companion paper with 
respect to the binding geometry and drug design concepts.
23
 Overall, 86 distinct binding poses 
could be characterized as some fragments occurred multiple times in the binding pocket. 
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According to the proposed enzyme mechanism, the catalytic aspartates (Asp35 and Asp219) have 
varying pKa values due to the influence of their local environment.
24,25
 At the beginning of the 
catalytic cycle, Asp35 is believed to be deprotonated and charged, while Asp219 is 
protonated.
26−28
 Thus, all fragments directly binding to the catalytic dyad require hydrogen-bond 
acceptor and/or donor functionalities to interact with the  aspartates. 
 
 
Fig. 3.1. Results for the crystallographic fragment screening using our 361 fragment library. The 
number of detected hits is given with respect to their binding mode and spatial location on the target 
protein. Several fragment molecules were found with at least one additional copy, resulting in 86 
distinct binding poses (41 + 29 + 16). Of these, only four hits were found outside the substrate-
recognition site. The 41 hits addressing the catalytic dyad were divided into direct and water-mediated 
binders. 
 
Subsequently we describe a detailed comparative analysis of all 41 individual fragment hits.           
We believe that the obtained knowledge of their exact binding mode to the target is essential to 
understand the caused effect, allowing us to make informed design suggestions for potency 
increase and ultimate hit-to-lead optimization. 
 
3.4 Results 
 
The analyzed crystal structures of the 41 fragments have a mean resolution of 1.3 Å and overall 
completeness of 98.5%, highly important criteria for unambiguous fragment assignment in the 
electron density. The data collection yielded high quality characteristics with a mean Rsym of 
5.7%, <I/σ(I)> of 16.6, and Wilson B factor of 10.4 Å2 (c.f. Appendix, Table 8.1).  
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Overall, we were able to produce high-quality data perfectly well suited for subsequent hit-to-
lead optimization and other methodological investigations. 
 
3.4.1 Binding Sites and Overall Physicochemical Properties of Fragment Hits. 
 
Fragment hits were divided into two main categories: (1) catalytic dyad binders, mainly located 
next to the S1 and S1′ pockets and (2) remote binders, which populate the extended binding site 
of EP, distal to the catalytic dyad (cf. chapter 4).
23
 The catalytic dyad binders scatter across the 
active site, occupying the various recognition pockets S1 to S3′ (Fig. 3.2).  
 
 
Fig. 3.2. (A) Superimposition of apo EP (PDB code 4Y5L) with all 41 direct fragment binders, depicted as red 
sticks, showing their spatial distribution across the EP binding site. The recognition pockets S3′ through S3 are 
indicated by yellow and cyan spheres (cf. Experimental Section). (B) Protein surface color-coded by 
hydrophobicity scale. Red intensity of surface patches indicates increasing hydrophobicity according to 
Eisenberg and Schwarz.29 
 
All relevant pockets will be described in the following section. As part of the flap region, the 
polar Ser78, Tyr79, and Gly80 residues are located close to pocket S3′. The S2 pocket is also 
surrounded by polar residues, including Thr222, Thr223, and Tyr226. The S3 pocket, flanked by 
Ile10, Ala16, and Ile122, is partly covered by the flap region, and the S1 pocket, surrounded by 
Tyr79, Phe116, and Leu125, is completely buried under the flap. The flap region furnishes the S3 
and S1 pockets with amphiphilic character. The S2′ pocket is rather hydrophobic, as it is 
surrounded by Ile77, Leu133, and Phe194. Overall, S1′ is the most hydrophobic pocket, being 
largely surrounded by Ile300, Ile302, and Ile304.  
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With respect to the 41 fragments that bind to the catalytic dyad of EP we next analyzed whether 
certain physicochemical properties allow distinguishing X-ray hits from nonbinders. Due to the 
protonation state of its catalytic site, EP has a strong preference to bind positively charged 
fragments at pH 4.6 used in all crystallographic experiments (Fig. 3.3). Considering only those 
101 fragments from our library that are likely positively charged at pH 4.6, our screen would 
have resulted in 47 fragment-bound structures, corresponding to a hit rate of 47%. This 
preference for positively charged fragments is a result of the acidic properties of EP (pI = 4.3 in 
the folded state according to the PDB2PQR (www.poissonboltzmann.org/docs/structures-
ready/)),
30
 which renders its active site negatively charged even at the applied pH of 4.6. Since 
the catalytic Asp35 is assumed to be negatively charged as supported by neutron diffraction 
studies,
31
 it may not come as a surprise that 13 of all 68 aliphatic amines in our library (19%) 
turned out to be catalytic dyad binders in our crystallographic screen. The hit rate is even higher 
for catalytic dyad binders containing aliphatic primary amines (9 of 20 = 45%), whereas it is 
slightly lower for aliphatic secondary amines (3 of 23 = 13%) but equal to zero for 33 tertiary 
amines. Likewise, significant enrichments were found for amidines and guanidines (9 of 23 = 
39%) as well as for aromatic amines (9 of 56 = 16%). The obvious preference of EP for the 
binding of primary over secondary and tertiary amines is likely caused by the limited space 
available next to the deeply buried catalytic dyad, making it difficult to accommodate bulkier 
amines. 
3. Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal Structures: Versatile Warheads To 
Address a Catalytic Dyad 
61 
 
 
Fig. 3.3. Distribution of charges for the 41 X-ray hits binding to the catalytic 
dyad (pink) compared to the 290 nonbinders (blue) estimated at pH 4.6 (cf. 
Experimental Section). Since the p-value is below 0.05 (pt test = 4 × 10−12, 
pMann−Whitney U‑test = 8 × 10−13), the observed difference between binders 
and nonbinders is highly significant. This plot was generated using R.32 
 
In addition to charge, we investigated other physicochemical properties important for fragment 
binding and compared the 41 catalytic dyad hits to all nonbinders (Table 3.1). Notably, there is 
no significant difference between the X-ray hits and nonbinders with regard to their average 
number of rotatable bonds (2.6 vs 2.7) or total polar surface area (TPSA: 51 vs 52 Å2). However, 
the X-ray hits have on average a 30 Da lower molecular weight compared to the nonbinders, 
underlining that fragments with smaller molecular weight or fewer non-hydrogen atoms have a 
higher propensity to bind to the active site, agreeing well with the key concepts of FBLD.
33
 The 
41 catalytic dyad binders also possess on average a higher number of hydrogen-bond donors (2.0) 
than the nonbinders (1.2). The most probable reason for this is the preference of EP to bind 
nitrogen-containing, basic, and thus hydrogen-bond donating molecules. 
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Table 3.1. Comparison of physicochemical properties between the 290 non-binders1 and 41 catalytic dyad binders. 
 
Non-binders Catalytic dyad binders p-value
(a)
 
Range Average Range Average 
Independent 
samples t-test 
Mann-Whitney 
U-test 
No. of non-H 
atoms 
8 - 20 15.0 ± 3.2 8 - 20 13.5 ± 2.9 0.003 0.004 
MW (g/mol) 128.2 - 353.3 222.0 ± 43.1 122.2 - 288.4 192.6 ± 41.0 8 • 10-5 5 • 10-5 
clogP(o/w) -1.25 - 5.39 1.48 ± 0.89 -0.60 - 3.86 1.20 ± 0.85 0.050 0.015 
No. of Lipinski 
donors 
0 - 4 1.2 ± 0.7 0 - 4 2.0 ± 1.0 3 • 10-5 2 • 10-6 
No. of Lipinski 
acceptors 
1 - 7 3.7 ± 1.0 2 - 6 3.4 ± 1.0 0.025 0.025 
No. of rotatable 
bonds
(b)
 
0 - 10 2.7 ± 1.6 0 - 6 2.6 ± 1.4 0.615 0.795 
TPSA (Å
2
) 15.3 - 92.7 52.0 ± 13.3 29.0 - 99.4 51.0 ± 12.4 0.643 0.306 
(a)p-values indicate whether the difference between catalytic dyad binders and non-binders is significant (p < 0.05) 
(b)Definition according to Oprea considering also ring bonds.34 
 
3.4.2 Fragments Binding Directly to the Catalytic Dyad. 
 
Of the 41 X-ray hits, 24 fragments bind directly to the dyad and displace the catalytic water 
molecule W501. They predominantly occupy the S1 and S1′ pockets. We decided to group the 
fragment hits by their chemical composition in order to highlight the multiplicity of interaction 
patterns generated with the carboxylate groups of both aspartates. To allow for a consistent 
comparison of the conservation of hydration sites, we assigned a uniform numbering scheme to 
all hydration sites and observed water molecules. The assigned numbers increase with the 
distance of a considered solvation site with respect to the catalytic W501 as a common reference 
point (cf. Experimental Section). All water molecules are referred to by this number preceded by 
“W”, while individual fragments are referred to by their library identification number preceded 
by “F” (fragment identifier). 
 
Hydrazides. Six hydrazides (F004, F075, F081, F103, F109, and F330) bind to the catalytic 
aspartates via their two hydrazide nitrogen atoms (Fig. 3.4). In F075, the N′-substituted hydrazide 
unit is located between two ring moieties. In five fragments, the hydrazide carbonyl is directly 
attached to a phenyl ring, which is replaced by a benzyl group in F103. The benzene rings are 
substituted either in meta position by a methyl (F004) or a dimethylamino group (F081) or in 
para position by a bromine (F075), a fluorine (F103), or a diethylamino group (F109).  
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Only F330 has a chlorine substituent attached in the ortho position. The in-chain hydrazide F075 
exhibits an additional pyrrole-type ring in the N′ position, which is buried in the S1 pocket. While 
F004, F075, F081, F103, and F330 place their aromatic rings into the S1′ pocket, F109 
unexpectedly adopts a significantly different orientation positioning its benzene ring into the S1 
pocket and its tertiary amine close to Phe116 and Ile122. Since F109 differs from F081 only by a 
sterically more demanding para diethylamino instead of a meta dimethylamino substituent, steric 
crowding might be an explanation for this swapped orientation (cf. Discussion section). While the 
α-nitrogen of F109 forms one 2.8 Å H-bond to Asp35, the terminal nitrogen atom serves as a 
donor addressing both Asp35 and Asp219. In contrast, the other five hydrazides form an H-bond 
of 2.4−2.8 Å between Asp219 and the α-nitrogen as well as bifurcated H-bonds of 2.7−3.1 Å 
between Asp35 and their terminal nitrogen. While F004 and F081 lack additional interactions 
with the enzyme, F075 and F103 accept a 3.0 Å H-bond from Gly80-NH of the flap region via 
their carbonyl oxygen. 
 
Primary Amines. Three fragments (F005, F189, and F274) bind to the catalytic dyad via their 
primary amino groups (Fig. 3.5). Although F005 has an amidine functionality, its binding mode 
is similar to that of primary amines. F005 places the benzo group of its 2H-isoindole moiety into 
the S1 pocket. As suggested by a predicted pKa value beyond 9.0 (cf. Experimental Section), the 
endocyclic nitrogen of F005 is most likely not protonated and thus accepts an H-bond from 
Thr222OH located at the far end of the S2 pocket. The exocyclic amino group donates one H-
bond to each of the aspartates of the catalytic dyad (3.0 and 3.1 Å). In addition, F189 occupies 
the S1 pocket with its pyridine moiety forming a 2.7 Å H-bond between its meta pyridine 
nitrogen and Asp81 of the flap region. F189 adopts two alternative conformations (occ. = 42% 
and 58%) as suggested by the residual difference electron density after placement of the first 
conformer. 
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Fig. 3.4. Binding modes and affinity data of the hydrazides. The fragments are labeled by their library entry number. 
In all cases, the mFo − DFc electron density is shown at 2.5σ, and hydrogen bonds are shown as dotted lines. The 
preferentially occupied pockets are indicated by translucent yellow and blue spheres. While heteroatoms are 
indicated by standard color-coding, the carbon atoms have been colored based on the assigned compound class. For 
all experiments the chiral fragments were used as racemates, but the stereoisomer identified in the crystal structure 
is depicted. Chemical formulas and PDB codes are shown together with the corresponding fragment crystal 
structure. The binding affinity obtained by ITC is given as free energy of binding (ΔG0) in kcal/mol, and Kd values 
are in mM. The ligand efficiency (LE) was calculated as −ΔG0/number of heavy atoms and given in kcal/(mol·atom). 
For very weak binding fragments (Kd > 10 mM), the obtained experimental error was ≥0.5 kcal/mol, thus no exact 
affinity and LE values are listed. 
 
In contrast, F274 positions its para fluorophenyl moiety into the S1′ pocket. The fluorine atom is 
oriented toward Ile300, Ile302, and Ile304, forming a hydrophobic environment. Notably, even 
though the shape and van der Waals radius of fluorine (1.47 Å) closely mimic a hydrogen atom,
35
 
a certain amount of energy must be spent to desolvate the polar fluorine atom in order to 
accommodate the ligand in the target pocket. In the case where the desolvation energy becomes 
too large, the binding process will be unfavorable.  
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The protonated primary amino group of F274 forms three charge-assisted H-bonds with the 
catalytic dyad with appropriate lengths of 2.8−3.2 Å. Furthermore, the hydroxyl group at the S-
stereocenter accepts an H-bond (2.9 Å) from the Gly80NH of the flap region. In addition, two 
DMSO molecules occupy the S2 and S2′ pockets, one of which is neighboring the fragment at a 
distance of 2.6 Å. 
 
 
Fig. 3.5. Binding modes and affinity data of the primary amines. Representation as in Fig. 3.4.  
 
Secondary Amine. Fragment F236 carries three substituents at its central phenyl moiety: a 
methylamino-methylene, an ortho chloro, and a meta nitro group (Fig. 3.6). The phenyl moiety 
occupies the S1 pocket forming a π−π-stacking interaction with Tyr79. The secondary amino 
group donates one charge-assisted H-bond to each of the catalytic aspartates, as suggested by the 
predicted pKa value of 8.4. Additionally, a presumably weak H-bond (3.3 Å) is formed between 
the nitro group and W569, which in turn forms an H-bond (2.8 Å) to the carbonyl oxygen of 
Gly221. 
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Fig. 3.6. Binding mode and affinity data of the secondary amine. Representation as in Fig. 3.4. 
 
Piperidine. Three molecules of F207 bind simultaneously to the EP binding pocket, one of 
which is only partly localized in the electron density (Fig. 3.7). The fragment consists of a polar 
piperidin-3-yl moiety connected via an amide group to a second piperidine moiety. The first of 
the three molecules occupies the S1′ pocket (occ. = 100%) while the other two occupy the S2 
(occ. = 86%) and S6 (occ. = 90%) pockets, respectively. The first molecule forms two H-bonds 
of equal length (2.8 Å), in each case between its protonated piperidin-3-yl and one of the catalytic 
aspartates. In addition, it establishes an H-bond between its amide oxygen and the Gly80NH of 
the flap region. 
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Fig. 3.7. Binding mode and affinity data of the 
piperidine. Representation as in Fig. 3.4. 
 
Guanidine, Amidine, and Isothiourea. All amidine-type fragments form bifurcated H-bonds to 
the catalytic dyad. The singly bound F218 molecule (Fig. 3.8, upper row) contains a terminal 
guanidino group attached to a quinazolin-2-yl moiety, which is oriented toward the flap region. 
Notably, seven amino acids from this region could not be modeled into the electron density 
(Ser78, Tyr79, Gly80, Asp81, Gly82, Ser83, and Ser84), as they would clash with the 
quinazoline moiety if they adopted their usual conformation observed in all other structures. The 
most likely charged guanidino group forms an elaborate chelatetype H-bonding network with the 
catalytic aspartates, in which the nonterminal nitrogen addresses Asp35 indirectly via W512 (2.5 
Å). 
The three amidines F125, F205, and F216 bind directly to the catalytic dyad, most likely in their 
protonated form (Fig. 3.8, upper and bottom row). While only a single molecule of the para 
trifluoromethyl benzamidine F216 is bound in the crystal structure, a second molecule of the 
amidinopiperidine F125 and the thiophenamidine F205 bind simultaneously in the respective 
structures. The amidino groups of the dyad-contacting molecules form three H-bonds to the 
aspartates, with F205 forming an additional H-bond to a nearby glycerol molecule (2.9 Å).  
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The glycerol is absent in the complexes with F125 and F216 where it is replaced by water 
molecules. The benzene rings of this class of fragments occupy the S1′ pocket locating the para 
trifluoromethyl group of F216 in the hydrophobic region formed by Ile300, Ile302, and Ile304. In 
contrast, the additional fragment molecules of F125 and F205 not interacting with the dyad are 
buried in the S1 pocket, forming a single H-bond to Asp81 of the flap region, with F205 forming 
an additional bifurcated H-bond to Ser115. 
The two isothiourea fragments F290 and F306 show a similar binding pattern to the amidine-type 
fragments, as they only differ by the inserted sulfur atom next to the amidino group (Fig. 3.8, 
bottom row). Both F290 and F306 are structurally very similar, varying only in the attachment 
point of the chlorine substituent at the benzyl portion. The para chlorine atom of F290 is oriented 
toward the solvent, while the ortho chlorine atom of F306 forms an edge-on chloro−π interaction 
with Phe194. Both fragments fill the S1′ pocket with their hydrophobic benzyl moiety facing the 
binding region composed of Ile300, Ile302, and Ile304. Remarkably, similar to the amidines, the 
isothiourea fragments form a bifurcated H-bond to Asp35 and an additional H-bond to Asp219. 
 
 
Fig. 3.8. Binding modes and affinity data of the guanidine, amidine, and isothioureas. 
Representation as in Fig. 3.4. 
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Tetrahydroimidazotriazine, Imidazole, Pyridine, and Pyrazole. Fragment F054 contains an 
imidazotriazine heterocycle, which is connected via a single bond to a 3,4-difluorophenyl ring. 
Two fragment molecules are found in the crystal structure (Fig. 3.9, upper row). The first 
molecule occupies the S1′ pocket, whereas the second one is accommodated by the S3 and S4 
pockets. The five-membered ring of the fused heterocycle does not interact with the catalytic 
dyad. Instead, the most likely protonated guanidine-type triazine nitrogen donates an H-bond to 
Asp219 (3.3 Å) and accepts an H-bond from Thr222OH (3.2 Å). The non-guanidine type 
nitrogen forms most likely as an acceptor a weak H-bond (3.1 Å) to W529. Additionally, water-
mediated contacts to Gly80NH (3.2 Å) and Asp81NH (3.1 Å) are formed, both provided from the 
flap region. A sufficient distance between both fragment molecules of more than 5 Å is given so 
that a mutual interaction can be excluded. 
Fragment F338 positions its methylated cyclohexyl moiety into the S2 pocket, while the likely 
protonated imidazole donates an H-bond to Asp35 (2.8 Å) in the S1 pocket (Fig. 3.9, upper row). 
The second aspartate is too far away to interact with this fragment. Furthermore, the imidazole 
ring forms a π−π-stacking interaction with Tyr79 (4.1 Å). The amide carbonyl oxygen of the 
fragment accepts an additional H-bond from Gly80NH, whereas the amide nitrogen interacts with 
Thr223NH mediated by W575. 
A slightly different binding mode is observed for the chiral fragment F162 (Fig. 3.9, upper row), 
of which only the S-enantiomer was identified in the crystal structure. The pyridine ring is buried 
in the S1 pocket, benefiting from a π−π-interaction with Tyr79. Under the applied soaking 
conditions, the pyridine nitrogen (pKa = 4.8) is likely partially protonated in aqueous solution and 
might adopt full protonation in its bound state next to the charged Asp35 (2.7 Å). The remaining 
part of the fragment occupies the S1′ pocket, while the thiophene ring points toward the solvent. 
In addition, the amide carbonyl oxygen of the fragment accepts an H-bond from Gly80NH (2.8 
Å) while the amide nitrogen forms an H-bond to Thr222OH (2.9 Å). 
The pyridine ring of F209, similar to that of F162, interacts with the charged Asp35 at a distance 
of 3 Å (Fig. 3.9, bottom row). Due to the lack of sufficiently defined difference electron density, 
the isoxazole moiety of F209 was not modeled in the crystal structure. 
Fragment F255 donates two direct H-bonds to the catalytic dyad, one from the protonated 
imidazopyridine nitrogen to Asp35 (2.6 Å), the other from the amide nitrogen to Asp219 at a 
distance of 2.7 Å (Fig. 3.9, bottom row).  
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The terminal phenyl ring occupies the S1′ pocket and orients toward the solvent, while the 
imidazopyridine moiety fills the S1 pocket forming a π−π-stacking interaction with Tyr79. 
Furthermore, the carbonyl oxygen accepts an H-bond from Gly80NH of the flap region. 
Two molecules of the pyrazole fragment F114 bind to EP, one directly to the dyad (Fig. 3.9, 
bottom row) and a second completely remote on the EP surface. The terminal pyrrolidine ring of 
the dyad binder occupies the S1 pocket while the substituted pyrazole orients toward the S1′ 
pocket, directly interacting with the catalytic dyad. Additional interactions are formed between 
the nitrile nitrogen and Asp81NH as well as between the exocyclic amino group and Thr222OH. 
  
 
Fig. 3.9. Binding modes and affinity data of the Tetrahydroimidazotriazine, Imidazole, Pyridine, and Pyrazole. 
Representation as in Fig. 3.4. 
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Alcohol. Not only amino groups but also a hydroxyl group binds to the catalytic dyad directly, as 
found for the pyridopyrimidine F231 (Fig. 3.10). The presumably protonated nitrogen is oriented 
toward Thr222 and W550 forming weak H-bonds (3.4 and 3.3 Å). However, the difference 
electron density for one ring carbon atom was insufficiently defined, suggesting the binding of an 
open-chain structure in the crystal structure. This could be due to the formation of a ketone 
tautomer under the applied acidic soaking conditions. Considering the H-bond distances of the 
fragment to the catalytic dyad, we assume that the flexibility of the nonaromatic ring led to the 
ill-defined density around the missing carbon atom. 
 
 
Fig. 3.10. Binding mode and affinity data of the 
alcohol. Representation as in Fig. 3.4. 
  
3.4.3 Fragments Binding to the Catalytic Aspartates Mediated by the Catalytic W501. 
 
Even though the larger portion of fragments (24 of 41) binds directly to the catalytic dyad, we 
also discovered a considerable number of fragments (17 of 41) interacting with the catalytic dyad 
mediated by the catalytic W501. This water molecule takes a versatile role in binding, as it serves 
as either an H-bond donor or acceptor with respect to the accommodated fragment. 
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Primary Amines. In contrast to the above-described fragments that interact directly with the 
catalytic dyad, seven additional fragments (F052, F058, F078, F211, F285, F286, and F066) 
containing also a primary amino group bind only indirectly to the catalytic dyad. Their contact is 
mediated by W501, which is appropriately located within H-bond distance to the fragments 
(2.5−3.0 Å, Fig. 3.11). For all seven fragments, an aromatic ring occupies the S1 pocket forming 
a π−π-stacking interaction with Phe116. This ring is usually a phenyl, but it can also be a 1,3-
dimethylpyrazole (F058) or a pyridine bearing a para furan ring (F066). In addition, the primary 
amino group is attached to the central aromatic rings, usually via an aminomethyl group. In the 
case of F052, a 2-aminoethanone moiety binds to the catalytic dyad. This fragment bears a para-
bromo phenyl ring. 
Fragments F078 and F211 are close analogues, as both have an ethyl or methyl ester 
functionality in the para-position. In the crystal structure of F211 a second, partially occupied 
conformer could be modeled into the residual difference electron density (occ. = 31%). The ethyl 
derivative F078 could only be assigned up to the methylene group due to insufficiently defined 
difference electron density for the terminal ethyl group. The primary amines of all seven 
fragments are likely protonated, donating an H-bond to the carbonyl oxygen of Gly221 and 
W501. In the structures of F058, F078, F211, F286, and F066, the conserved W529 or the 
virtually identical W537 is observed at distances of 2.7−2.8 Å to the fragment’s primary amino 
group. 
Furthermore, the meta carboxamide oxygen of F285 and the para methoxy group of F286 form 
H-bonds to W696 at distances of 2.6 and 3.0 Å, respectively. In addition, F066 (occ. = 70%) 
interacts with the alternatively modeled W618 (occ. = 30%) that is in a chelating position 
between the furan oxygen (1.5 Å) and the pyridine nitrogen (1.7 Å). 
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Fig. 3.11. Binding modes and binding affinity data of the primary amines addressing the catalytic dyad via the 
catalytic W501. Representation as in Fig. 3.4. 
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Pyridine, Pyrrolidine, and Tetrahydrofuran. Four fragments (F063, F267, F272, and F291) 
address the catalytic water by their pyridine moiety (Fig. 3.12). In all cases, the pyridine rings 
occupy the S1 pocket with the pyridine nitrogen located in para (F267 and F291), meta (F063), 
or ortho position (F272). As suggested by their predicted pKa values, these pyridine nitrogen 
atoms are likely deprotonated in aqueous solution at pH 4.6.
36
 Furthermore, two molecules of 
F291 bind simultaneously to EP. One of them interacts with the catalytic dyad while positioning 
its benzodioxyl moiety into the S3 pocket (occ. = 100%). In addition, F063 and F291 form 2.8 Å 
H-bonds to Asp81 via their secondary amino group. F267 performs a similar contact using its 
amide nitrogen (2.7 Å). Only F272 accepts an H-bond from Gly80NH with its amide carbonyl 
oxygen (3.1 Å), as it additionally occupies the S2 pocket with its 1,3,5-trimethylpyrazole ring. 
Moreover, it forms an H-bond between the amide nitrogen and Thr222OH (3.0 Å). The second 
molecule of F291 (occ. = 72%) occupies the S4 and S6 pockets where the aromatic ring system 
performs a π−π-stacking interaction with Phe291. 
Fragments F112 and F260 occupy both the S1 pocket with similar poses (Fig. 3.12). However, 
the pyrrolidine F112 donates an H-bond to W501 (2.8 Å) with its likely protonated endocyclic 
nitrogen atom, whereas F260 accepts an H-bond via its tetrahydrofuran oxygen (2.7 Å). For both 
fragments, only the R-enantiomer is bound. Moreover, the central amide bond of F260 donates an 
H-bond to Thr222OH (2.9 Å) and accepts one from Gly80NH (2.5 Å). For F112, an additional 
H-bond is formed between the tetrahedrally coordinated pyrrolidine nitrogen atom and the 
carbonyl oxygen of Gly221 (2.8 Å). A second molecule of F112 (occ. = 100%) occupies the S4 
and S6 pockets with its benzodioxyl moiety, similar to fragment F291. 
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Fig. 3.12. Binding modes and binding affinity data of the pyridines, pyrrolidine, and tetrahydrofurane addressing the 
catalytic dyad via the catalytic W501. Representation as in Fig. 3.4. 
 
Oxamide. The oxamide fragment F048 interacts with the catalytic dyad via one of its carbonyl 
oxygens, forming a short H-bond to the catalytic W501 (2.2 Å, Fig. 3.13). The second carbonyl 
oxygen points toward Asp81, accepting an H-bond from the backbone NH (2.9 Å). The fragment 
places its pyrrolidine moiety into the S1 pocket, while the para substituted pyridine ring occupies 
the S2 pocket exposing its chlorine substituent to the solvent. An additional interaction is 
observed between the amide nitrogen next to the pyridine ring and Thr222 (3.0 Å). 
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Pyrimidine. Two molecules of F017 bind to EP with full occupancy (Fig. 3.13). In both cases, 
however, the azepane substituent could only be partially assigned to the electron density, 
probably caused by the increased conformational flexibility of a seven-membered ring. The likely 
protonated pyrimidine moiety, which donates a hydrogen bond to the catalytic W501 (2.7 Å), 
occupies the S1 pocket. The pyrimidine ring of the second molecule forms a π−π-stacking 
interaction with Phe291. 
 
Thiazolamine. Two molecules of F171 bind to EP, one interacting with the catalytic W501 (Fig. 
3.13) and the second binding remotely on the protein surface. The aminothiazole of F171, which 
is connected to a methyl imidazole, occupies the S1 pocket where it forms a π−π-stacking 
interaction with Tyr79. The exocyclic nitrogen forms an H-bond to Asp35 and a second one to 
the catalytic W501, whereas the endocyclic nitrogen forms an H-bond to W516 (2.7 Å). The 
methyl imidazole moiety is oriented toward the S3 pocket donating an H-bond from its 
presumably protonated nitrogen to Ser83 (2.7 Å). 
 
Carboxylic Acid. Remarkably, even the carboxylic acid group of F266 forms an H-bond to the 
catalytic W501 (3.3 Å, Fig. 3.13). The fragment is only partially occupied (occ. = 84%) as 
indicated by the mFo − DFc density. The ortho aminopyridine occupies the S1 binding pocket and 
donates an H-bond to Asp81. 
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Fig. 3.13. Binding modes and binding affinity data of the oxamide, pyrimidine, thiazolamine and carboxylic acid 
addressing the catalytic dyad via the catalytic W501. Representation as in Fig. 3.4. 
 
3.5 Discussion 
 
In this study, we collected data sets of 361 different EP crystals soaked in solutions containing 
individual fragments. A total of 41 fragments were found to bind to the catalytic dyad. Twenty-
nine additional remote binders are described in an accompanying paper.
23
 Of the 41 dyad binders, 
24 fragments (59%) bind to the aspartic residues directly, while the interactions of 17 fragments  
(41%) are mediated by the catalytic water molecule W501 (Fig. 3.1). With regard to their binding 
regions, 12 (29%) occupy the S1′, 18 (44%) the S1 binding pockets, five (12%) occupy both 
pockets, and four (10%) are bridging between the S1 and S2 pockets.  
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Of the remaining two fragments (5%), F218 is directed toward the S2′ and S3′ pockets (Fig. 3.8), 
while F291 occupies the S1 and S3 pockets (Fig. 3.12). In the case of fragments binding multiple 
times to EP, we only considered those molecules addressing the catalytic dyad in the current 
analysis. 
The most commonly shared chemical functionality of the described fragment hits is a primary 
amino group. Three fragments (F005, F189, and F274, Fig. 3.5) bind to the catalytic aspartates 
with this group directly, whereas seven fragments (F052, F058, F078, F211, F285, F286, and 
F066, Fig. 3.11) address the dyad mediated by the catalytic W501. The latter group of fragments 
clearly differs from the direct binders by the presence of an amino methyl or, in the case of F052, 
an amino ethanone substituent attached to their central aromatic ring. In contrast, only three 
secondary (F236, F207, and F112) and none of the tertiary amines bind to the catalytic dyad (see 
also Results section). Since the flexible flap region is positioned next to the catalytic aspartates 
partially covering the EP binding site, the space for a fragment to be bound is rather limited. An 
additional restriction is imposed by the spatial proximity of the catalytic aspartates, which 
explains the highest hit rate for primary amines. In the case of the primary amines, we observed 
that structural details such as the presence or absence of a chiral center can have unexpected 
effects on the binding poses of otherwise similar fragments. This is exemplified by the analogs 
F052 and F274 (Fig. 3.14), whose central benzene moieties are substituted by a para bromine or a 
fluorine atom, respectively, but whose binding poses on first sight are determined by the similar 
amino ethanone or amino ethanol side chains. While the S-enantiomer of F274 orients its fluorine 
atom toward the hydrophobic patch formed by Ile300, Ile302, and Ile304 in the S1′ pocket, the 
achiral amino ethanone F052 adopts an oppositely oriented binding pose for this fragment. 
Consequently, the spatially more demanding bromine atom is placed toward the flap region, thus 
converting a direct dyad binder (F274) into one that interacts via the catalytic W501 (F052, Fig. 
3.14, A). Remarkably, the fluorine atoms of the hydrazide F103 and the amidine F216 address 
the same isoleucine-rich pocket as F274 (Fig. 3.14, B). 
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Fig. 3.14. A: The different orientations of primary amines F274 (yellow) and F052 (cyan) are shown. Apart 
from the different halogen atoms in para position of the phenyl rings in both fragments, the absence of a 
chiral center in F052 seems to trigger the conversion from a direct dyad to water-mediated binder. The 
solvent-excluded surface of apo EP is shown (PDB-code: 4Y5L). B: Superimposition of three fluoro-
substituted fragments; hydrazide F103 (magenta), amidine F216 (green) and pimary amine F274 (yellow). 
All fluorine substituents are oriented into a small cavity formed by three isoleucine residues: Ile300, Ile302, 
and Ile304. The coordinates of the catalytic dyad, W501, and the hydrophobic S1’ pocket composed by the 
three isoleucines and indicated by a translucent yellow sphere are shown as found in the crystal structure of 
apo EP (PDB-code: 4Y5L). The surface presentation was omitted for clarity. 
 
On the basis of this observation, we analyzed whether the bromine substituent of F052 is actually 
responsible for the orientation of this fragment. Either steric bulk, unfavorable desolvation 
penalty, or geometric differences of either an achiral amino ethanone or chiral amino ethanol 
substituent can serve as an explanation for the observed differences in binding poses. To 
approach this problem experimentally, we determined the crystal structures of EP in complex 
with the chiral brominated and chlorinated analogs of F274 (PDB codes 5IS4 and 5ISJ, Fig. 3.15, 
A and B) as well as with the achiral fluorinated analog of F052 (PDB code 5ISK, Fig. 3.15, C). 
Notably, despite the larger size of the bromine and chlorine atoms, the analogs of F274 still 
orient as the fluoro-F274, and all three perform an H-bond interaction to Gly80NH via the chiral 
hydroxyl functionality. In contrast, the fluorinated analog of the bromo-F052 occupies the S1 
pocket and performs π−π stacking with Tyr79 of the flap region. This underscores that the 
presence or absence of the chiral center in F274/F052 is the determining factor for the 
surprisingly flipped fragment binding modes. 
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Fig. 3.15. A: Binding mode of the chiral brominated analog of F274 (PDB-codes: 5IS4). B: Binding mode of the 
chiral chlorinated analog of F274 (PDB-codes: 5ISJ). C: Binding mode of the fluorinated analog of the bromo-
F052 (PDB-code: 5ISK). D: Superimposition of F052 (green) and its fluorinated analog (magenta). Representation 
as in Fig. 3.4. 
 
To further investigate the structure−activity relationship of this small series, we determined Kd 
values by isothermal titration calorimetry and calculated ligand efficiencies (LE).
37
 We believe 
that such minute differences cannot be calculated reliably with currently available computational 
methods. As a result, the Kd values of the halogenated fragments F052 (Kd = 3.3 mM) and F274 
(Kd = 3.8 mM) do not differ significantly. It should be noted that the Kd value of F274 was 
determined for the racemic mixture suggesting an even better affinity of the bound S-enantiomer, 
assuming that the R-enantiomer binds with a lower potency to the protein. 
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While all chiral fragments were screened as racemic mixtures, in five cases only one specific 
enantiomer was found to bind (Fig. 3.5, 3.7, 3.9, and 3.12). For F207 both enantiomers were 
found in the crystal structure (Fig. 3.7). While the R-enantiomer addresses the catalytic dyad 
directly, the S-enantiomer occupies the S2 pocket where it is stabilized through van der Waals 
interactions with the flap region. A third molecule could only be partially assigned to the 
mFo−DFc map next to Phe291; however, the fragment moiety containing the chiral center is 
missing in the density, thus making its assignment impossible. Obviously, EP is enantioselective 
with respect to the stereoisomer characterized by the higher binding affinity. This observation 
suggests that crystallographic screening of racemic fragment mixtures may be reasonable despite 
the lower concentration of the individual enantiomers. In addition, our results underscore the 
importance of correct chirality when designing and exploring the structural fragment space by 
computational approaches in drug discovery.
38 
As discussed above, the protonation state of fragments is key to understand their binding 
mechanism and structure−activity relationship, particularly if they bind to a charged epitope such 
as the catalytic center of an aspartic protease. According to pKa predictions in aqueous solution 
using the Web service chemicalize.org,
36
 some fragments, e.g., the pyridines F162 and F209 
(Fig. 3.9), should be partially protonated in solution but will likely adopt full protonation upon 
binding, establishing charge-assisted interactions with the deprotonated catalytic Asp35. In 
contrast, some pyridine fragments that address the catalytic dyad mediated by W501 may do so in 
either protonated or deprotonated state, which is very difficult to determine with the required 
certainty. A prediction regarding the protonation state can easily fail, since pKa values are 
significantly modulated by the local environment. Nevertheless, it is of critical importance to 
correctly tailor the protonation states of titratable functional groups of fragments while growing 
them into follow-up drug candidates. For instance, the charge state is crucial for sufficient 
bioavailability, as membrane passage often requires uncharged molecules. This highlights that at 
a first glance negligible design aspects can be of particular importance to correctly tailor not only 
the affinity but also the physicochemical properties of small molecules. 
While primary amines and pyridines along with many other functional groups have already been 
reported as renin and BACE1 binders,
39−41
 here we report for the first time the interaction of 
hydrazides as putative warheads binding to the catalytic dyad.  
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Comparison of binding modes of the four hydrazides F004, F081, F103, and F330 together with 
F109 reveals that F109 is the only fragment oriented in the opposite direction, likely due to its 
bulkier para diethylamino group (Fig. 3.16). As in the case described further above, the question 
arises of whether steric restrictions imposed by the volume of the S1 and S1′ pockets provide an 
explanation for the deviating orientations or whether other features induce the swapped binding 
modes.  
 
 
Fig. 3.16. Superimposition of the five hydrazides F004, F081, F103, F109, and F330. 
The coordinates of the catalytic dyad and the solvent-excluded EP surface are shown 
as found in the crystal structure of apo EP (PDB-code: 4Y5L). The preferentially 
occupied pockets S1 and S1’ are indicated by the blue and yellow spheres, 
respectively. While four fragments are oriented toward the S1’ pocket, only the more 
potent F109 occupies the S1 pocket. In the other four complex structures, W696 is 
present, whereas upon binding of F109 this water molecule is displaced from the 
complex. 
 
To analyze this in more detail, we performed docking experiments (cf. Experimental Section), 
which revealed that F109, even though it carries the largest substituent in the series, should in 
fact be able to adopt the same binding pose as the other four hydrazides.  
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This disproved our initial steric crowding hypothesis and shifted our considerations in other 
directions. By analyzing the crystal structures more carefully, we found that the conserved W696 
is displaced by the larger F109 in the adopted swapped orientation, while in all other EP-
hydrazide complexes with the reversed orientation this water molecule is present. This suggests 
that the fragments with smaller substituents may not be able to displace W696, leading to lower 
affinity against EP, while attachment of a larger substituent can possibly enhance affinity, most 
likely for entropic reasons.
42 
To validate this hypothesis experimentally, we soaked the slightly 
smaller dimethylamino analogue of F109 (Fig. 3.17) and were able to find the same binding 
mode as for F109. By comparison of the Kd values determined by ITC measurements, F004, 
F081, and F330 were characterized as very weak binders (Kd > 10 mM), F103 with a Kd value of 
4.3 mM as slightly stronger binder, while F109 and the tested dimethylamino analogue are 
significantly more potent, with Kd values of 1.0 mM and 0.6 mM, respectively. (Fig. 3.4 and Fig. 
3.17). Moreover, the previously described biochemical assay showed 89% inhibition for F109 
while none of the remaining terminal hydrazides were detected as inhibitors.
17
 This clearly 
supports our hypothesis and underlines the important influence of water molecules on the binding 
of fragments, especially with respect to the adopted spatial poses. 
 
 
Fig. 3.17. A: Binding mode and affinity data of the hydrazide analogue of F109, directly addressing the 
catalytic dyad. Representation as in Fig. 3.4. B: Overlay of the corresponding crystal structures of F109 and its 
analogue. The binding mode is almost identical. 
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Of particular interest is the in-chain hydrazide F075 (Fig. 3.4), which occupies the S1′ pocket 
with its para bromine-substituted phenyl ring and the S1 pocket with a pyrrole moiety. 
Obviously, addressing both pockets at the same time seems beneficial, as this hydrazide exhibits 
overall the highest affinity against EP (Kd = 0.1 mM). It favorably bridges the catalytic dyad 
allowing optimization into both directions of the binding site. Thus, F075 appears as a highly 
promising candidate with respect to a fragment-growing strategy. 
Another interesting case of swapped binding poses is given for the structurally related amidino 
fragments.
43
 A comparison of the amidino fragments F125, F205, and F216 with the isothioureas 
F290 and F306 clearly shows the same orientation relative to Asp35 (Fig. 3.8). Two of the three 
amidines have affinities in the single digit millimolar range, whereas F216 and the isothioureas 
F290 and F306 exhibit higher potency in the high micromolar range. All five fragments form a 
strong bidentate salt bridge to Asp35, requiring however the presence of a charged amidinium 
group in the ligand (Fig. 3.8). The highly related guanidine derivative F218 addresses the 
catalytic dyad in a swapped orientation, preferring Asp219 for the bidentate salt bridge. This 
binding mode is unique to F218, as the quinazoline moiety would clash with the flap in the 
usually adopted closed conformation. Due to the resulting disorder, the flap residues could not be 
localized in the electron density. Considering the narrow space available above the catalytic dyad 
compared to the steric demand of the bulky quinazoline moiety, the adopted deviating orientation 
of this fragment appears comprehensible. Amidines and guanidines have already been described 
as warheads for the aspartic protease BACE1,
44
 as reported in the field of drug research for 
neurodegenerative diseases.
45
 A phase II/III clinical trial is conducted with the BACE1 inhibitor 
MK-8931, which originated from a cyclic amidine scaffold used as the key pharmacophore.
46
 
Also, acylguanidine-like inhibitors were optimized to single digit nanomolar affinity against 
BACE1.
47−49
 Comparing these literature examples with our EP study, we find that the binding 
mode of the guanidine fragment F218 to EP is similar to those found in BACE1. However, our 
isothiourea fragments F290 and F306 show a swapped orientation compared to isothioureas 
detected by a fragment-based NMR screen on BACE1.
50
 In BACE1, the isothiourea fragments 
address Asp289 (corresponding to Asp219 in EP) while F290 and F306 bind to Asp35 of EP 
(corresponding to Asp93 in BACE1). This indicates changes in the pKa values of the catalytic 
dyad aspartic residues in the different proteases, leading to deviating fragment-pose orientations. 
As a result, this might help to address a possible selectivity issue among different members of the 
aspartic protease family. 
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 Although the use of an amidino-type warhead involves the presence of a charged group in the 
inhibitor, which will likely lead to problems with oral bioavailability, prodrug strategies have 
been successfully employed in the past to overcome these difficulties.
51,52 
 
Dissimilar fragment structures can also adopt similar binding modes. For instance, fragment 
F114 (Fig. 3.9) has a similar interaction pattern as observed for the amidine derivatives (F125, 
F205, F216, F290, and F306), and it matches with those of the hydrazide derivatives (F004, 
F075, F081, F103, F109, and F330), although the molecular scaffold providing the contacts is 
entirely different. This suggests an interesting, not yet reported alternative for bioisosteric 
replacement, highlighting the value of an exhaustive crystallographic active-site mapping.
53
 The 
examples so far clearly demonstrate that positively charged molecules are favored by EP. 
However, in a few cases fragments with typical acceptor functional groups can also address the 
catalytic dyad of the enzyme (Fig. 3.18). For instance, the tetrahydrofuran F260 and the oxamide 
F048 accept a hydrogen bond from the catalytic W501. Quite unexpectedly and reported here for 
the first time as putative warhead for an aspartic protease is F266, which binds to the catalytic 
W501 via its carboxylic acid functional group. Under the applied soaking conditions this group is 
likely deprotonated. The adopted charged state at the binding site, however, next to Asp35 and 
Asp219, is difficult to assess, owing to the crowding of potentially titratable groups. This 
fragment has an occupancy of only 84% in the crystal structure, which is in accordance with its 
weak binding affinity (Kd > 10 mM). Although carboxylic acids are present in several drugs (e.g., 
NSAID aspirin, amoxicillin, or ramipril),
54,55
 they can create problems with regard to crossing 
biological membranes. Nevertheless, for further optimization it is important to recognize that 
both basic and acidic groups can be incorporated into drug candidates. In close proximity such 
groups can compensate each other owing to a zwitterionic state and thus improve bioavailability, 
e.g., as shown for the drug lisinopril.
56
 In addition, particularly for carboxylic acid groups, a large 
variety of prodrug strategies and bioisosters have been reported as successful alternatives.
57,58 
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Fig. 3.18. Superimposition of the three fragments addressing the catalytic W501 
with an acceptor functionality: Carboxylic acid F266 (pink), oxamide F048 (cyan), 
and tetrahydrofurane F260 (dark gray). The coordinates of the catalytic dyad and 
W501 are shown as found in the crystal structure of apo EP (PDB-code: 4Y5L). The 
preferentially occupied pockets S1 and S1’ are indicated by the blue and yellow 
spheres, respectively. 
 
Our fragment study identified structural motifs as warhead groups to address the catalytic dyad in 
addition to those that have been previously discovered and incorporated in more potent aspartic 
protease inhibitors. Still, these fragments provide important information about stereochemistry. 
For instance, crystal structures of EP with the HIV-protease inhibitor saquinavir or the natural 
product pepstatin show that both ligands bind to the catalytic dyad with a hydroxyl group, which 
is also found for the R-configurated fragment F231.
59,60
 Interestingly, the R-enantiomer is clearly 
preferred by EP, highlighted by its higher affinity and in accordance with a previous study 
showing higher ligand potency for the pro-(R) hydroxyl isomer against renin and EP.
61
 The 
structural information also provides a rationale for the synthetic optimization introducing a gem-
diol group, which led to a 10-fold and 90-fold potency increase against renin and EP, 
respectively. A piperidine derivative, binding to the catalytic aspartates as found in F207, has 
been previously reported as a promising peptidomimetic in the renin research field.
62
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Again, the selectivity of EP for the more potent enantiomer is in agreement with a study where 
the R-configurated piperidine derivative showed 40 times higher affinity against renin than the 
respective S-enantiomer. In another crystallographic fragment screening campaign on BACE1 
using cocktails of six fragments, a piperidine moiety was reported to bind to the catalytic dyad.
63
 
However, the fragment orients toward the opposite direction in BACE1 compared to F207 in EP. 
This observation agrees with the abovedescribed swapped orientation found for the isothiourea 
fragments in BACE1 versus EP. 
 
3.6 Conclusions 
 
The present FBLD study identifies a variety of warheads to address the catalytic dyad of the 
aspartic protease EP and gives important suggestions with respect to the preferred occupancy of 
the adjacent specificity pockets S1 and S1′. Some of the observed fragment hits involving 
functional groups such as piperidines, isothioureas, pyridines, and guanidines have already been 
reported as potential dyad binders on other aspartic proteases. In addition, we also discovered 
novel warheads such as hydrazide, carboxylic acid, or pyrazole fragments not yet reported as 
dyad binders for aspartic proteases. These are interesting candidates for bioiosteric replacements, 
for instance, when during the drug development phase charged groups have to be avoided or need 
to be replaced by groups with opposite charge. 
The present study focuses on fragments as warheads to address the catalytic dyad. Due to their 
size, such dyad-binding fragments are in most cases only capable of addressing one of the 
adjacent S1 or S1′ pockets. The source of ideas on how to grow these fragments into larger and 
more potent leadlike candidates is thus limited. A few fragments though, such as F075, F114, 
F162, F255, and F260, bind to the catalytic dyad and simultaneously occupy both the S1 and S1′ 
pockets, providing valuable suggestions on how to expand these into larger molecules. To 
develop such an optimization concept further and even derive initial pharmacophore hypotheses, 
the information about fragment poses binding to remote pockets is essential. This is discussed in 
our companion paper.
23
  
The majority of discovered dyad binders address either the S1 or the S1′ pocket. Only in the case 
of the amidino and guanidine derivatives (Fig. 3.8) forming bidentate H-bonds with the dyad 
steric reasons can explain the swapping of the binding mode.  
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A comparison of the placement of isothiourea groups in BACE1 and EP indicates surprising 
differences as to which of the two aspartates is preferred to form a bidentate salt bridge. In the 
case of the hydrazides (Fig. 3.16), steric bulk cannot explain the swapped orientation of the 
bound fragments. A docking analysis suggested that both orientations should be feasible. We 
therefore followed an experimental approach to prove that the displacement of a fairly well-
bound water molecule is responsible for the selected binding pose. Indeed, another crystal 
structure of a related fragment revealed, in addition to the determination of the dissociation 
constants by ITC, that the swapped orientation is only adopted when the fragments are able to 
displace the crucial water molecule. For primary amines (Fig. 3.14) we also observed a swapping 
in the occupation of the S1 versus the S1′ pocket. Here, the slight geometrical change going from 
a planar carbonyl to a tetrahedral (and thus chiral) hydroxymethylene group influenced the 
interaction pattern established with the residues next to the catalytic dyad strong enough to alter 
the observed binding pose.  
Without a question, the tendency for EP to accommodate basic, mostly positively charged 
fragments was evident. Considering the narrow space for binding close to the catalytic dyad, 
binding of smaller fragments into the binding pocket was preferred over larger molecules, clearly 
emphasized by the strong preference of EP for primary over secondary and tertiary amines. 
Nevertheless, fragments with typical acceptor functional groups addressing the catalytic dyad of 
the protease were also discovered (Fig. 3.18). 
Since many of our findings described here would have been impossible without a detailed crystal 
structure analysis, we strongly advocate consulting crystallography as a primary fragment 
screening technique. It directly provides valuable insights into the adopted binding modes of the 
hits, giving important guidance for the subsequent hit-to-lead optimization. This broad and 
conclusive fragment binding landscape only emerges due to a large number of characterized 
fragments providing initial ideas about protonation states, preferred pocket occupancies next to 
the catalytic dyad, and the putative displacement of active-site water molecules whose removal 
upon ligand binding has a clear contribution to affinity. It is our opinion that these insights are by 
far more important than the discovery of the most potent or most enthalpic binding hits, as the 
affinity of a fragment can be strongly affected by the quality of the local water structure.
64,65
 
During the optimization phase, weak binding fragments can readily be developed into optimal 
starting points for drug development.
66,67
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From a drug designer’s point of view, the wealth of information from a crystallographic 
fragment-screening campaign with a rich yield is clearly beneficial, as the comprehensive 
experimental active-site mapping can suggest novel, unexpected binding motifs usually not 
considered by applying well-established and often no longer scrutinized sets of medicinal-
chemistry rules for particular target classes. 
 
3.7 Experimental Section 
 
3.7.1 Endothiapepsin Crystallization and Fragment Soaking. 
 
EP was purified from Suparen (kindly provided by DSM Food Specialties) by exchanging the 
buffer to 0.1 M sodium acetate at pH 4.6 using a Vivaspin 20 with a molecular weight cutoff at 
10 kDa. Protein crystals were grown as already described using the sitting drop vapor diffusion 
method at 17 °C and equal volumes of mother liquor and protein at a concentration of 150 μM.17 
The reservoir solution consisted of 0.1 M NH4Ac, 0.1 M NaAc, and 24−30% (w/v) PEG 4000 at 
pH of 4.6. Protein crystals were observed after 2 days, while the growth period for diffraction-
quality crystals was on average 2 weeks. Each fragment was dissolved at 1M stock concentration 
in DMSO and soaked for 48 h into the empty protein crystals at a final concentration of 90 mM 
(9% (v/v) DMSO). Furthermore, the soaking drops consisted of 70 mM NH4Ac and 70 mM 
NaAc, 16−20% (w/v) PEG 4000, and 19−23% (v/v) glycerol at pH 4.6. Although we encountered 
solubility problems with some of the fragments during the soaking experiments, it appears 
impossible to calculate the extent to which such fragments were soluble in the crystallization 
buffer. The solid deposit, present in these cases, was not removed and thus could have been 
supportive by constantly readjusting the fragment saturation in solution. 
 
3.7.2 X-ray Diffraction Data Collection. 
 
After 2 days of soaking, the crystals were flash-frozen in liquid nitrogen. The addition of a 
cryoprotectant was not necessary, since the fragment soaking solution served as such. 
Synchrotron radiation was an important prerequisite to obtain highly resolved structures of our 
protein−fragment complexes. The data sets were collected at beamlines 14.1, 14.2, and 14.3 of 
the BESSY synchrotron in Berlin at a temperature of 100 K. Further details about the data 
collection and refinement statistics are listed in the Appendix, Table 8.1. 
3. Active Site Mapping of an Aspartic Protease by Multiple Fragment Crystal Structures: Versatile Warheads To 
Address a Catalytic Dyad 
90 
 
3.7.3 Structure Determination and Refinement. 
 
The diffraction data were indexed, scaled, and merged using XDS and XDSAPP.
68,69
 Occasionally 
HKL2000 was used.
70
 The crystal structures were determined by molecular replacement using the 
program Phaser from the CCP4 program package or via mediated rigid body refinement using 
Phenix.
71−73
 We used the coordinates of a 1.28 Å fragment-bound structure of EP as a reference 
model (PDB code 3PCW). Refinement was done using Phenix, and intermittent model building 
and improvement were performed with Coot.
73,74
 All 41 data sets were refined according to 
predefined criteria. After an initial simulated annealing step, XYZ-coordinates, individual B-
factors, and occupancies were refined with five cycles. The further refinement strategy depended 
on the structural resolution. Isotropic refinement in combination with TLS using eight TLS 
groups (1−62; 63−81; 82−151; 152−190; 191−204; 205−242; 243−258; 259−330) was performed 
at resolutions lower than 1.5 Å, while structures with resolution better than 1.5 Å were refined 
anisotropically. The corresponding refinement strategy was kept if the R-free value was reduced 
significantly (∼0.5%). For ligand building, SMILES codes were first generated with the Web 
server at www.molinspiration.com.
75
 The according restraints were generated with GRADE.
76
 
Water molecules were placed in appropriate difference electron density of at least 3.0 σ, while 
ligands were modeled at 2.5 σ. Hydrogen atoms were added to the model if the given resolution 
was appropriate. Furthermore, if a ligand molecule was refined to an occupancy above 85%, full 
occupancy was assumed. The shown mFo −DFc density maps encompassing each fragment were 
created by removing the fragments from the model. In the case of insufficient different electron 
density for individual fragment atoms, these atoms were omitted from the model (e.g., F231) in 
order to not introduce model bias. After an additional refinement cycle the depicted maps were 
generated with Phenix. In order not to miss any fragment hit, additional processing of the 
crystallographic data has been performed by an automated refinement workflow before 
inspection of the resulting electron density maps.
77
 All structural figures were created with 
Pymol.
78  
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3.7.4 Generation and Distribution of Binding Site Pockets. 
 
The recognition pockets S1 through S3′, depicted as spheres with a radius of 2 Å in all structural 
figures, were defined based on three superimposed EP structures in complex with different 
peptidic inhibitors (PDB codes 2ER6, 4ER4, and 3ER5).
79−81
 Pseudo-atoms characterizing the 
location of each pocket were derived at the center of mass of the three respective P3′ through P3 
peptide side chains. However, the P2 histidine of the ligand in 3ER5 was omitted for the 
placement of the sphere representing the S2 pocket position, since this residue clearly pointed 
toward the S1′ pocket. 
 
3.7.5 Water Renumbering Procedure. 
 
Unified water numbers were assigned based on a clustering
73,82 
of all possible water positions 
identified via Phenix for all refined EP-structures of this project. Moreover, water numbers were 
consistently increased with increasing distance to the catalytic W501. 
 
3.7.6 Computational Property Predictions. 
 
All 361 fragments were prepared, and their physicochemical properties were calculated within 
KNIME (KNIME.COM AG).
83
 Hydrogens were added to yield the neutral form, and 3D 
coordinates were generated using CORINA (Molecular Networks GmbH), version 3.491.
84
 
Subsequently, all solution-state physicochemical properties shown in Table 3.2 were calculated 
using MOE (Chemical Computing Group Inc.), version 2014.09.
85
 While fragment charges at pH 
4.6 were assigned by Marvin (ChemAxon LCC),
86
 aqueous pKa values were predicted with the 
Web service chemicalize.org.
36
 The FILTER program (OpenEye Scientific Software Inc.), 
version 2.5.1.4,
87
 was used to flag all fragments for the presence or absence of aliphatic amine, 
primary amine, secondary amine, tertiary amine as well as primary and alkylated aniline 
functional groups, whereas amidine and/or guanidine functional groups were flagged by the 
presence of fconv
88
 atom type N.gu1, N.gu2, N.mi1, or N.mi2. The resulting properties were then 
statistically analyzed and compared between X-ray binders and nonbinders using the R package, 
version 3.1.2.
89 
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3.7.7 Docking Experiments. 
 
Docking of F109 to the binding pocket of EP (PDB code 3T6I) was done with the program SEED 
(Solvation Energy for Exhaustive Docking).
90
 SEED exhaustively samples fragment poses and 
calculates interaction energies using the generalized Born approximation describing solvent 
effects by continuum electrostatics to account for the effects of bulk water. Hydrogens were 
placed and their positions minimized with CHARMM using the CHARMm22 force field.
91 
 
3.7.8 Isothermal Titration Calorimetry (ITC) Measurements. 
 
To determine the thermodynamic signature of the weak binding fragments, displacement 
titrations were carried out using the nanomolar, strongly enthalpic EP inhibitor SAP114 (PDB 
code 4LAP). SAP114 was titrated into a solution containing 0.1 M NaAc, 0.25−3.0 mM of the 
respective fragment, and 3% (v/v) DMSO. As a reference, 0.5 mM SAP114 was titrated into the 
same solution excluding the fragment.
37
 For fragments with Kd values above 10 mM the obtained 
experimental error in ΔG0 was ≥ 0.5 kcal mol−1. Thus, exact affinity values for these ligands are 
not provided while defining them as extremely weak binders (Kd > 10 mM). 
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4. Experimental Active-Site Mapping by Fragments – Hot Spots Remote from 
the Catalytic Center of Endothiapepsin 
 
4.1 Introductory Remarks  
 
The following chapter has been published in J. Med. Chem. in 2016. The project included the 
soaking and data collection of over 450 datasets, discussed in the following chapter and in 
chapter 3. Protein purification, crystallization, and all soaking experiments were performed by the 
author of this thesis with additional help from Johan Winquist and Ah Young Park. For the data 
collection and structure refinement, the work of six additional colleagues, Johannes Schiebel, 
Stefan G. Krimmer, Martin Stieler, Kan Fu, Xiaojie Wang, and Frederik R. Ehrmann was 
consulted. The data collection was done at Helmholz-Zentrum Berlin für Materialien und 
Energie, BESSY II with the help of Franziska U. Huschmann, Manfred S. Weiss, and Uwe 
Müller. All data collection and refinement statistics can be found in the Appendix. 
The author of this thesis carried out the refinement of all datasets collected for fragments F001‒
F070 and performed the data analysis and interpretation for all fragment hits along with drafting 
the paper. 
 
 
̽ Reprinted with permission from J. Med. Chem. 2016, 59, 7561‒7575. Copyright 2016 American Chemical Society. 
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4.2 Abstract 
 
Successful optimization of a given lead scaffold requires thorough binding-site mapping of the 
target protein particular in regions remote from the catalytic center where high conservation 
across protein families is given. We screened a 361-entry fragment library for binding to the 
aspartic protease endothiapepsin by crystallography. This enzyme is frequently used as surrogate 
for the design of renin and ß-secretase inhibitors. A hit rate of 20% was achieved providing 71 
crystal structures. Here, we discuss 45 binding poses of fragments accommodated in pockets 
remote from the catalytic dyad. Three major hot-spots are discovered in remote binding areas: 
Asp81, Asp119, and Phe291. Compared to the dyad binders, bulkier fragments occupy these 
regions. Many of the discovered fragments suggest an optimization concept on how to grow them 
into larger ligands occupying adjacent binding pockets that will possibly endow them with the 
desired selectivity for one given member of a protein family. 
 
4.3 Introduction 
 
As enzymes play a key role in the pathogenesis of different diseases, their inhibition is a 
frequently followed concept for therapeutic intervention.
1
 Potent enzyme inhibitors are usually 
designed starting with a small-molecule lead that mimics the binding of the natural substrate in 
the enzyme’s binding site. However, preferred hot spots of binding for such small molecules have 
first to be determined and thoroughly analyzed, particularly as this information is of utmost 
importance to facilitate a subsequent optimization to convert an initial binding hit into a 
promising lead and finally a drug. Apart from this hot-spot mapping, small-molecules can 
disclose important aspects of protein function that correlate with induced conformational changes 
of one or more residues.
2,3
 Some screening techniques allow to discriminate between active-site 
and remote binders. For instance, biochemical assays usually require binding to the catalytic 
center to produce an assay read-out. In assays such as RDA (reporter displacement assay) and 
STD-NMR (saturation transfer difference NMR) specific displacement ligands are frequently 
used to confirm binding to specific parts of a binding pocket.
4–7
 Other techniques such as MST 
(microscale thermophoresis) or the thermal shift assay (TSA) can hardly distinguish binders that 
address the catalytic center from remote pocket binders.
8,9
 Thus, many biophysical screening 
techniques (named in the following “prescreening techniques”) are limited in predicting small-
molecule’s binding sites.  
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We therefore performed an elaborate fragment screening to map the extended binding site of the 
aspartic protease endothiapepsin (EP). In the past, EP has been successfully used as a surrogate 
for the development of renin and β-secretase inhibitors. Sequence and fold similarity to 
homologous pepsin-like aspartic proteases along with robust crystallization properties make EP a 
perfect platform for an exhaustive crystallographic analysis.
10–12
  
Out of a well-designed 361-entry fragment library, the overwhelmingly large number of 71 hits 
was detected. In contrast to our previous study on EP, where the hits of a fluorescence-based 
biochemical assay were soaked in cocktails to the protein, the intention of this study was to 
directly screen each fragment in an individual soaking experiment.
13
 Of the 71 hits, 70 crystal 
structures were deposited in the protein databank (PDB) as one fragment requires additional 
analysis due to a reaction, which likely occurred prior to protein binding. Remarkably, for 14 of 
the identified fragment hits up to three molecules bind to different pockets of the protein. 
Considering these fragment copies, in total 86 individual binding poses were determined. Here, 
we thoroughly analyze 29 fragments binding remote from the catalytic dyad, giving rise to 45 
individual binding poses including remotely bound molecules of direct binders. These fragments 
address hot spots of binding in regions remote from the catalytic center, addressed also by known 
larger high-affinity EP ligands, demonstrating the importance and utility of fragments for an 
optimization strategy. In the following Results section, we describe the individual fragment 
binding poses, interaction patterns including solvent molecules, and order/disorder phenomena in 
the structures. A comparative analysis also with respect to fragment expansion and lead 
development follows in the Discussion section.  
 
4.4 Results 
 
To screen the entire library of 361 fragments by crystallography, we performed soaking 
experiments with individual fragments and EP crystals. The procedure was highly successful as 
86 single binding poses of fragments were detected. Of these, 45 molecules were identified 
addressing remote parts of the EP binding site. Only four fragments bind to the EP surface 
outside of the substrate-binding site, of which two address the catalytic dyad with a second copy 
(Fig. 4.1). For the presented study, 39 datasets have been analyzed. These datasets convince 
through a mean resolution of 1.4 Å, overall completeness of 98.2 %, mean Rsym of 7.9 %, and 
<I/σ(I)> of 16.9.  
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The high data quality is highly important to correctly assign fragments in the electron density. 
The majority of the remote binders (41 out of 45 = 91%) are distributed along the extended EP 
binding site, four assembled in an area on the protein surface. We split the large binding site into 
nine pockets, indicated by spheres and labeled according to the Schechter and Berger 
nomenclature (Fig. 4.1).
14
 The most hydrophobic site is the S1’ pocket, surrounded by Ile300, 
Ile302, and Ile304. The S2’ pocket is also hydrophobic as it is enclosed by Ile77, Leu133, and 
Phe194. The S3’ pocket is rather hydrophilic exhibiting Ser78, Tyr79, and Gly80 as the polar 
residues, which are part of the adjacent flap region. Furthermore, the S2 pocket exhibits 
hydrophilic character as it is enclosed by Thr222, Thr223, and Tyr226. The flap region covers 
part of the S3 pocket, encompassed by Ile10, Ala16 and Ile122. It merges with the S1 pocket, 
which is enclosed by Tyr79, Phe116 and Leu125. Accordingly, the S3 and S1 pockets are 
furnished with amphiphilic character. The S4 and S5 pockets are rather hydrophilic as they are 
largely exposed to the solvent. Similarly, the S6 pocket is also solvent-exposed but enclosed by 
hydrophobic amino acids including Leu13, Phe280, Ile283 and Phe291.  
The spatial fragment distribution reveals some preferences for certain regions of the binding site. 
Such sites, besides the catalytic center, are close to Asp119 or Asp81, the latter is part of the flap 
region. Notably, however, the largest number of fragments is located close to Phe291 (Fig. 4.1). 
To provide some evidence for preferential binding at particular sites, a thorough understanding of 
the given structural features and individual attributes of the adopted binding modes of the 
identified fragment hits is required. Only then, the assembled knowledge can be translated into 
concepts for a subsequent hit-to-lead optimization. In the following, we will describe the 
observed binding poses in terms of addressed hot spots and binding pockets.  
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Fig. 4.1. EP solvent-excluded surface representation with all defined binding pockets indicated by spheres. 
(PDB-code: 4Y5L). The determined hot spots of binding (Asp81, Asp119, and Phe291) are shown as green 
sticks; residues more rarely addressed by fragments are depicted in light green. The flap region is indicated 
by a yellow line. The four fragments bound on the right-hand side to the EP surface (F056, F114, F171, and 
F227), remote from the catalytic dyad, and the additional four fragments, addressing the S1’ and S2’ pockets 
(F031, F131, F261, and F268) are shown as beige sticks. The remaining 37 fragment molecules, bound 
remote from the catalytic dyad were omitted for clarity. 
 
4.4.1 Fragments addressing Asp81 and the S1 pocket 
 
Asp81 resides, well exposed, on the flexible flap region pointing into the binding site of the apo 
protein. This enables the formation of H-bonds to bound fragments. Thirteen fragments (F014, 
F125, F158, F041, F323, F206, F240, F073, F205, F207, F224, F328, and F261) address 
Asp81, eleven of which mainly occupy the adjacent S1 binding pocket.  
F014 donates a hydrogen bond to the carboxylate oxygen of Asp81 via its methylated thiourea 
NH group (3.4 Å) and places its ortho and para halogenated phenyl ring further remote into the 
S3 pocket (Fig. 4.2, a).  
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The electron density around the methyl group is ill-defined, suggesting multiple orientations of 
the latter group. Additionally, F014 is fixed by Thr223OH, which accepts a hydrogen bond from 
the second thiourea nitrogen (2.7 Å).  
F125 (occ. = 92%), similarly to F014, donates an even longer H-bond (3.5 Å) via its terminal 
amidinopiperidine NH group to the carboxylate oxygen of Asp81 (Fig. 4.2, b). This hydrogen 
bond deviates by 24° (N-H
…
O) from ideal geometry due to a slight shift of the aspartate residue 
compared to its position in the apo protein. This shift allows binding of the fragment´s six-
membered ring next to the flap region. Furthermore, a fully occupied DMSO molecule is 
localized in van der Waals distance to F125 between the S2 and S3 pockets. A second fragment 
molecule (occ. = 100%) addresses the catalytic Asp35.
15
  
F158 likewise occupies two distinct binding sites (Fig. 4.2, c). The first fragment molecule (occ. 
= 78%) occupies the S1’ pocket with its isoxazole moiety, whereas its methylated piperidine 
moiety is accommodated in the S1 pocket forming an 2.7 Å H-bond between piperidine NH and 
carboxylate oxygen of Asp81. The piperidine is only partially visible in the electron density. 
Moreover, the fragment’s carbonyl oxygen accepts a hydrogen bond from the backbone NH of 
Asp81 (3.0 Å), while the fragment’s amide donates an H-bond to Thr222OH (2.7 Å). The 
isopropyl group of the second fragment molecule occupies the S2 pocket, while its remaining part 
could only be modeled up to the carbonyl oxygen due to an ill-defined electron density.   
 
Fig. 4.2. Fragments, addressing Asp81. In all cases, the mFo−DFc electron density around the fragment is shown at 
2.5σ, while hydrogen bonds are depicted as dotted lines. Heteroatoms are indicated by the usual color coding, and the 
carbon atoms of the basic fragment scaffold are colored in yellow. For all experiments, the fragments were used as 
racemates. The chemical formulas of the bound stereoisomers are displayed in the upper left corner of each image. In 
addition, the fragment number is shown in the upper right corner and the corresponding PDB code is indicated in the 
lower right corner. Binding pockets are highlighted as black circles. 
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F041, chemotypically similar to F158, likewise occupies the S1 pocket with its unsubstituted 
piperidine moiety and addresses Asp81 and Thr222 identically (Fig. 4.2, d). In contrast to F158, 
only one copy of F041 is bound, and its piperidine ring is fully visible in the electron density. 
This might be due to a slightly improved resolution (1.12 vs. 1.24 Å) of the crystal with F158 or 
better ordering. The piperonyl moiety of F041 occupies the S1’ pocket. 
F323, similar to F041, contains a piperonyl moiety, which orients differently as it occupies the 
S1 instead of the S1’ pocket (Fig. 4.2, e). For this fragment, five carbon atoms could not be 
assigned owing to an ill-defined electron density. Of these unassigned atoms, two carbon atoms 
belong to the fused piperidine moiety and three are attached methyl groups. A rather short H-
bond distance of 2.5 Å is measured from the fragment’s endocyclic NH to the carboxylate 
oxygen of Asp81, whereas the same NH group contacts Ser83OH with a rather long distance of 
3.3 Å.  
F206 and F240 both donate H-bonds from their primary amino groups to the carboxylate oxygen 
of Asp81 (Fig 4.2, f and g). The amino group of F206 is presumably protonated and donates 
additional H-bonds to Ser115OH (2.8 Å) and an entrapped buffer acetate (ACT, 2.8 Å). The latter 
in turn, mediates a further H-bond to the carboxylate oxygen of Asp119, which adopts two 
alternative conformations. Remarkably, either the acetate or Asp119 must be protonated to 
establish the observed hydrogen-bonding network, depending on the locally induced pKa. 
F240 establishes, apart from an H-bond to Asp81 (2.7 Å), hydrogen bonds to Ser115OH (2.8 Å), 
W696 (2.8 Å), and W691 (3.5 Å) via its protonated secondary amino group (Fig. 4.2, g). 
Furthermore, a glycerol molecule (GOL), which replaces the catalytic W501 and an 
oligoethyleneglycole (PEG) molecule are found in van der Waals distance to F240. The 
fragment’s imidazole moiety forms a π-stacking with Tyr79 in the flap region.  
The fragments F073 and F205 also donate an H-bond to the carboxylate oxygen of Asp81 and 
accept one from Ser115OH via their amidino groups (Fig. 4.2, h and i). Moreover, the NH of 
F073 accepts an H-bond from Ser83OH (3.1 Å), whereas F205 donates an additional one of 2.7 
Å via its NH group to W696, which mediates the contact to Asp119 (2.9 Å). Furthermore, H-
bond contacts between the same NH group, Ser115CO and the second rotamer of Ser115OH, 
refined to 34% occupancy, are established (3.2 Å and 3.1 Å, resp.).  
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F205 adopts three binding poses. In two with slightly different orientations, the fragment 
occupies the S1 pocket (occ. = 45%/55%) and in a third, the molecule interacts directly with the 
catalytic dyad. 
 
Fig. 4.2. (cont.) Fragments, addressing Asp81. Representation as in the first Fig. 4.2. 
 
F207 occupies three distinct binding sites (Fig. 4.3, a). One fragment molecule binds to the 
catalytic dyad, a second is found next to Phe291 in the S6 pocket, and a third (occ. = 86%) is 
located adjacent to Asp81 placing its piperidine-3-yl moiety into the S2 pocket. The latter 
molecule merely binds via van der Waals contacts to the flap region. 
F224, F328, and F261 occupy multiple distinct binding sites (Fig. 4.3, b-d). While F224 
addresses the carboxylate oxygen of Asp81 and Ser115OH with one of its copies, the second 
copy donates an H-bond to the carboxylate oxygen of Asp119. F328 and F261 simultaneously 
form H-bonds to the carboxylate oxygens of Asp81 and Asp119. Thus, the structural features and 
binding positions of these three fragments will be described in the following. 
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4.4.2 Fragments addressing Asp119 and the S3 and S5 pockets. 
 
Asp119 marks an additional hot spot addressed by eight fragments (F224, F328, F261, F051, 
F321, F035, F054, and F278), involving adjacent amino acids such as Ser115 and Gly118 into 
contacts (Fig, 4.3, b-i). Asp119 is localized near the S5 pocket and mostly adopts an alternative 
conformation compared to the apo protein to enable an H-bond with bound fragments. 
F224 shows two fully occupied molecules, positioned in mutual van der Waals contact to each 
other (Fig. 4.3, b). The first addresses the carboxylate oxygen of Asp81 and Ser115OH via its 
secondary amine (2.8 Å and 2.9 Å, resp.). It occupies the S1 pocket with its methylated pyrrole 
moiety, which performs a π-stacking with Tyr79 of the flap region. The second molecule 
addresses the carboxylate oxygen of Asp119 via its indole nitrogen (3.0 Å) positioned in the S3 
pocket, where Asp119 adopts an alternative conformation with respect to the apo protein to 
enable this H-bond. The methylated pyrrole ring orients toward the S6 pocket. Interestingly, the 
central secondary amino group is surrounded by an oligoethyleneglycole (1PE) molecule; this 
cryoprotectant is frequently entrapped and found at this position (S4 and S6 pockets). However, 
here it wraps around the fragment in a fashion similar to host-guest interaction found with crown 
ethers.  
F328 occupies two distinct binding sites (Fig. 4.3, c). The first molecule addresses 
simultaneously the carboxylate oxygens of Asp119 and Asp81 in the S3 and S5 pockets, whereas 
the second molecule stacks onto Phe291 in the S6 pocket. Asp81 accepts an H-bond from the 
terminal tertiary amino group of the first molecule, which occupies the S1 pocket (2.7 Å), 
whereas Asp119 accepts an H-bond from the exocyclic imino nitrogen of the same molecule in 
the S5 pocket (3.4 Å). Furthermore, the imino nitrogen accepts H-bonds from two neighboring 
water molecules (W606 and W718). Both fragments are fully occupied and orient with edge-to-
face geometry to one another. 
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Fig. 4.3. Fragments, addressing Asp119. Representation as in Fig. 4.2. 
 
F261 occupies three distinct binding sites (Fig. 4.3, d). One fully occupied molecule is found in 
the S3/S5 pockets performing a parallel π-π stacking with a second fragment molecule (occ. = 
83%), which is only partially visible in the electron density. The first, fully visible fragment 
molecule addresses the carboxylate oxygen of Asp119 (3.0 Å) via the 4-N atom of its 
quinazolinone moiety. To establish this contact, Asp119 adopts an alternative conformation 
compared to the apo state, and either the fragment or Asp119 have to be protonated. Asp81 
instead accepts a hydrogen bond from the fragment’s amide-like NH group (3.1 Å). 
Simultaneously, the most likely protonated tertiary in-chain amino nitrogen, located between the 
S1 and S3 pockets, is recruited for a contact to Asp81 (2.9 Å), while the cyclopropyl moiety 
orients toward the S1 pocket. The third fragment molecule (occ. = 86%, omitted in the figure for 
clarity) places its quinazolinone moiety into the S1’ pocket while the cyclopropyl group points 
toward the solvent. The fragment’s binding pose could not be fully resolved due to ill-defined 
electron density.   
F051 occupies the S3 pocket (Fig. 4.3, e). It interacts directly with Asp119 through its pyridine-
type nitrogen atom (2.7 Å) suggesting a protonated state either on the aspartate or on the pyridine 
ring. Furthermore, F051 donates a hydrogen bond with its benzimidazolone moiety to the 
backbone carbonyl group of Gly221 (3.0 Å) and accepts one from Thr223NH and W629 (3.1 and 
2.8 Å, resp.). Furthermore, the pyridine ring interacts with an edge-to-face geometry with 
Phe116. In addition, GOL is found in van der Waals distance to the fragment, additionally 
stabilizing its position.   
 
4. Experimental Active-Site Mapping by Fragments – Hot Spots Remote from the Catalytic Center of 
Endothiapepsin 
113 
 
F321 occupies the S1 pocket with its piperonyl moiety (Fig. 4.3, f). The fragment donates an H-
bond via its protonated secondary amino group to the carboxylate oxygen of Asp119 (2.9 Å), 
which adopts an alternative conformation compared to the apo protein. A rather short H-bond of 
2.5 Å to W655 is formed, which mediates a further interaction to Ser115OH (3.3 Å). In addition, 
the fragment’s piperonyl oxygens accept H-bonds from W511 and W569 in distances of 3.3 Å 
and 3.2 Å, respectively. 
 
Fig. 4.3. (cont.) Fragments, addressing Asp119. Representation as in Fig. 4.2. 
 
F035 occupies two distinct binding sites in the crystal structure (Fig. 4.3, g). One molecule faces 
Phe291 in the S6 pocket while the second one places its morpholino moiety into the S3 pocket. 
The latter molecule addresses Asp119 with its tertiary and primary amino groups, which are 
supposedly both protonated (2.8 Å and 2.9 Å). Ser115 and Glu118 are also involved in hydrogen 
bonding to the primary amino group. To establish this contact, Glu118 has to adopt a second 
conformation compared to the apo structure. Both fragment molecules are fully occupied. 
F054, similar to F035, occupies two distinct binding sites (Fig. 4.3, h). The first molecule 
interacts directly with the catalytic dyad, while the second one occupies the S3 and S4 pockets 
donating an H-bond to the carboxylate oxygen of Asp119 via its tetrahydroimidazo triazine 
moiety (2.9 Å). Additional H-bonds are formed between the tetrahydroimidazo triazine nitrogen 
of the six-membered ring and W753, which mediates an additional contact to Asp119.  
As unique example, F278 (occ. = 83%) addresses the carboxylate oxygen of Asp119 via a 
carboxamide oxygen (2.7 Å) (Fig. 4.3, i). The phenyl-cyclopropyl moiety is surrounded by 
Phe116 and Leu125 in the S1 pocket while the hydroxyl-piperidine substituent occupies the S3 
pocket, where also a DMSO molecule from the soaking buffer is entrapped and stabilizes the 
fragment through van der Waals interactions.  
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Fig. 4.3. (cont.) Fragments, addressing Asp119. Representation as in Fig. 4.2. 
 
4.4.3 Fragments addressing Phe291 and the S6 pocket. 
 
Phe291 serves as prominent interaction partner in the S6 pocket. In total, sixteen fragments 
(F164, F034, F311, F181, F337, F017, F328, F333, F203, F042, F305, F273, F112, F291, 
F035, and F207) address this amino acid (Fig. 4.4). Interestingly, in the crystal structure of the 
apo protein an oligoethyleneglycol (PEG) molecule is found at this position.  
F164 faces Phe291 with its pyridine ring (Fig. 4.4, a). The fragment’s nitrile substituent and the 
conformationally flexible morpholinopropyl portion could not be placed due to insufficiently 
defined electron density.  
F034 (occ. = 85%) stacks on top of Phe291 with its quinolone-2-one moiety (Fig. 4.4, b). The 
endocyclic carboxamide group forms H-bonds to W761, while the cyclopropyl moiety points 
toward the solvent.  
In contrast, the cyclopropyl ring of F311 occupies the space between the S4 and S6 pockets (Fig. 
4.4, c). The fragment (occ. = 74%) performs a parallel-displaced π-π stacking with Phe291 using 
its methoxyphenyl moiety, which is attached in R-configuration to a thiazolidin-4-one ring.  
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Fig. 4.4. Fragments, addressing Phe291. Representation as in Fig. 4.2. 
 
F181 and F337 exhibit similar topology and binding modes (Fig. 4.4, d and e). F181 (occ. = 
72%) is substituted by a dimethylpiperidine ring while F337 (occ. = 100%) bears an azepane 
ring, attached in S-configuration. Although the azepane ring is conformationally more flexible, 
the density defining the dimethylpiperidine of F181 is less-well characterized, in agreement with 
the reduced occupancy of F181. Both fragments form a parallel-displaced π-π stacking with 
Phe291 using their aromatic triazine moieties. Furthermore, Phe280, Pro282 and W1115 are 
involved in hydrogen bonding via the fragment’s exocyclic primary amino functions.  
F017 (occ. = 100%) has also a partially visible azepane ring (Fig. 4.4, f). The fragment occupies 
two distinct binding sites in the crystal structure with one molecule bound to the catalytic W501. 
The pyrimidine ring of the second molecule stacks on Phe291 in the S6 pocket.  
F328, similar to F017, occupies two distinct binding sites (Fig. 4.3, c and 4.4, g). The partially 
visible molecule performs via its heterocycle π-π stacking with Phe291 in the S6 pocket. The 
spatial orientation of the dimethyl aminopropyl substituent remains unresolved in the crystal 
structure, likely due to scatter over multiple orientations. Additionally, the exocyclic imino 
nitrogen donates an H-bond to W880 (2.9 Å), which mediates the contact to the carboxylate 
oxygen of Asp15 (2.8 Å).  
Remarkably, F333 (occ. = 50%) stacks with its heterocycle on top of Phe291 (Fig. 4.4, h). 
However, Phe291 adopts a different and so far unique rotamer orientation (occ. = 50%), which is 
then faced by the fragment. Presumably, the fragment’s n-propyl and isopropylsulfanyl 
substituents reinforce this alternative orientation of Phe291, as at least one substituent would 
clash with the protein if the usual rotamer of Phe291 would be populated.  
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F203 (occ. = 64%) has an aromatic pyrazole ring, which is not directly involved in a π-π stacking 
with Phe291 (Fig. 4.4, i). Instead, the fragment’s isopropyl substituent, attached to the sulfonyl 
spacer, faces Phe291. Furthermore, the primary amino group attached to the pyrazole ring 
donates an H-bond to the carbonyl oxygen atoms of Pro282 (2.8 Å) and Ile283 (3.3 Å), and 
accepts one from W1115 (3.4 Å). This example highlights that aromatic ligand portions can be 
mimicked by an isopropyl group as bioisosteric replacement. 
 
Fig. 4.4. (cont.) Fragments, addressing Phe291. Representation as in Fig. 4.2. 
 
F042 represents a particularly interesting case (Fig. 4.4, j). The fragment stacks on top of Phe291 
although the cycloheptatrien ring of F042 is per se non-aromatic. Presumably, it becomes 
aromatic upon protonation of the imine nitrogen as then the seven-membered ring formally 
corresponds to a six-π-electron system.  
F305, a borinic acid derivative, also stacks on top of Phe291 (Fig. 4.4, k). However, the π-π 
stacking with Phe291 seems to be performed via the neighboring thiophene ring.  
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F273 stacks parallel displaced to Phe291 in the S6 pocket (Fig. 4.4, l). F273 exhibits a 
dihydroisoquinoline moiety with broken aromaticity at the chiral center, bearing an N,N-
dimethylacetamide substituent. A single H-bond is established to W744 via the fragment’s 
carbonyl oxygen at a distance of 2.6 Å.  
F112 and F291 share similar scaffolds and occupy two distinct binding sites in the respective 
crystal structures with a second fragment molecule bound to the catalytic dyad (Fig. 4.4, m and 
n). Both fragments exhibit benzodioxine moieties stacking onto Phe291 and interacting 
additionally with the carbonylate oxygen of Asp15 via their pyrrolidine or in-chain amino groups.  
F035 occupies two and F207 even three distinct binding sites (Fig. 4.4, o and p and Fig. 4.3, a). 
The fragment molecules stack on top of Phe291, either via their morpholino (F035) or piperidino 
(F207) groups, showing that even aromatic-aliphatic interactions are possible at the Phe291 hot 
spot. 
 
Fig. 4.4. (cont.) Fragments, addressing Phe291. Representation as in Fig. 4.2. 
 
4.4.4 Fragments binding to the S1’ and S2’ pocket and outside the substrate binding pocket. 
 
F031 occupies the S1’ pocket with its phenyl moiety establishing H-bonds with its exocyclic 
amino group to W515 (2.8 Å) and Thr222OH (3.4 Å) (Fig. 4.5, a). The ethyl ester portion is fully 
solvent exposed and not defined in the electron density. F268 and F131 occupy the S1’ pocket 
using their tetrahydrofurane or trifluoroethyl substituents, respectively (Fig. 4.5, b and c).  
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Both fragments show a central amide bond, which bridges via H-bonds to Gly80NH and 
Gly37CO. Notably, the central amide bond in F131 is placed with reversed orientation between 
Gly80 and Gly37 compared to F268. In addition, both fragments occupy the S2’ pocket with the 
methylated cyclohexyl and isoxazole rings, respectively.  
F261 occupies three distinct binding sites (Fig. 4.3, d and Fig. 4.5, d1 and d2). Two molecules 
occupy the S3 and S5 pockets, while the third one (occ. = 86%) occupies the S1’ pocket with its 
quinazolinone moiety simultaneously exposing its cyclopropyl substituent to the solvent. This 
substituent is only partially detectable in the electron density.  
F114 and F171 bind with one molecule to the catalytic dyad and a second is placed distal on the 
protein surface (Fig. 4.5, e and f). F114 donates an H-bond to Tyr251OH with one of its pyrazolo 
nitrogen atoms (2.9 Å) and accepts an additional one from W1739 (2.7 Å) via the same nitrogen. 
The latter water molecule mediates a hydrogen bond to Ser233OH (2.8 Å) and the neighboring 
nitrogen involves W1398 into an H-bond (2.8 Å). Furthermore, the exocyclic primary amino 
group donates an H-bond to Ser4OH from a symmetry-related protein molecule in the crystal 
packing. F171 forms H-bonds via its exocyclic aminothiazole nitrogen atom, first, to Leu259CO 
(2.9 Å) and in addition, water-mediated, to Asp276CO (2.8 Å and 2.5 Å). The adjacent 
Leu259NH addresses the endocyclic aminothiazole nitrogen of F171 (2.9 Å). Furthermore, the 
most likely protonated nitrogen atom of the imidazole ring donates an H-bond to W2212 (2.8 Å). 
The latter water molecule mediates further H-bonds with the carbonyl oxygens of Ala257 (2.7 Å) 
and Cys255 (2.9 Å). 
Two fragments with an acid function bind on the EP surface: F056, a m-chloro mandelic acid, 
and F227, a p-bromomethylene benzoic acid (Fig. 4.5, g and h). F056 exhibits two water-
mediated hydrogen bonds to Ser256OH and Ser289OH, and additionally addresses Ser288OH in 
a direct contact. F227 is the only fragment that interacts covalently with EP namely via a 
nucleophilic substitution reaction with Asp279. As the fragment-binding site is close to the 
disulfide bridge Cys255-Cys290, possibly the disulfide bridge supports the orientation of the 
benzoic acid in a way to facilitate the nucleophilic attack of the aspartate’s carboxylate oxygen on 
the fragment’s benzyl carbon atom to displace the reactive bromine atom. This example 
underlines that benzyl halides are quite reactive agents, which can easily attach covalently to 
polar residues on the surface of proteins. 
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Fig. 4.5. Fragments bound remote to the catalytic dyad. Representation as in Fig. 4.2. 
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4.5 Discussion 
 
The binding site of EP is quite large (Fig. 4.1) and partly hydrophobic. Hence, it appears very 
difficult to predict which fragments will bind at which position in this binding site. Although the 
many aspartic acid residues found in particular in the substrate-recognition site of EP allow the 
assumption that positively charged fragments would predominantly occupy the binding site, the 
experimental determination of binding poses are key and can hardly be overrated for any 
fragment-to-lead optimization procedure. This also becomes apparent from recent studies 
described in literature. For instance, an X-ray crystallographic screening with more than a 
hundred fragments on 24 different targets was performed by Astex, and, on average, 2.2 binding 
sites per target were discovered. The study has a particular emphasis on secondary binding sites. 
A study with similar focus has been performed by Bauman et al., in which an intensive fragment 
screen on the HIV-1 reverse transcriptase is presented.
16,17
 There, halogenated fragments were 
used to identify hot-spots of binding profiting from the halogens’ anomalous scattering signal to 
detect the bound fragments. The latter group presented in 2013 an X-ray fragment screen against 
the same target using cocktail experiments, where seven novel protein binding sites were 
discovered.
18
  
Our analysis is based on single soaking experiments with the model protein EP and seeks for the 
physicochemical properties that distinguish binders from non-binders and, in particular, remote 
from direct dyad binders, and whether the preferred fragment binding position can be explained 
by means of these molecular properties. First, the 29 remote binders show, compared to the non-
binders, slightly higher mean clogP (o/w) value (1.7 vs. 1.5), and a slightly larger number of 
Lipinski hydrogen-bond donor atoms (1.4 vs. 1.2, Table 4.1). The difference becomes more 
significant when comparing the mean number of rotational bonds (3.3 vs. 2.7). The latter value 
indicates that molecules with higher flexibility can more easily adopt the required binding 
position in the EP binding site. Notably, while the 29 remote binders do not deviate significantly 
from the non-binders with respect to their mean molecular weight, the remote binders have, on 
average, a 32 g/mol higher molecular weight than the catalytic dyad binders (Table 4.2).
15
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Table 4.1 Comparison of physicochemical properties between the non-binders and 29 remote binders. 
 
Non-binders Remote binders p-value
(a)
 
Range Average Range Average 
Independent 
samples t-test 
Mann-Whitney 
U-test 
No. of non-H 
atoms 
8 - 20 15.0 ± 3.2 9 - 20 15.6 ± 3.3 0.343 0.292 
MW (g/mol) 128.2 - 353.3 222.0 ± 43.1 125.2 - 279.6 225.3 ± 40.8 0.680 0.509 
clogP(o/w) -1.25 - 5.39 1.48 ± 0.89 -0.15 - 3.58 1.73 ± 0.99 0.203 0.127 
No. of Lipinski 
donors 
0 - 4 1.2 ± 0.7 0 - 3 1.4 ± 0.8 0.299 0.195 
No. of Lipinski 
acceptors 
1 - 7 3.7 ± 1.0 2 - 6 3.6 ± 1.2 0.500 0.307 
No. of rotatable 
bonds
(b)
 
0 - 10 2.7 ± 1.6 0 - 8 3.3 ± 1.9 0.110 0.070 
TPSA (Å
2
) 15.3 - 92.7 52.0 ± 13.3 24.4 - 88.8 47.3 ± 15.4 0.119 0.078 
(a)p-values indicate whether the difference between remote binders and direct binders is significant (p < 0.05); please note 
that for the Mann-Whitney U-test a normal approximation was used  
(b)Definition according to Oprea considering also ring bonds.38 
 
Table 4.2 Comparison of physicochemical properties between the 41 dyad binders and 29 remote binders.15 
 
Catalytic dyad binders Remote binders p-value
(a)
 
Range Average Range Average 
Independent 
samples t-test 
Mann-Whitney 
U-test 
No. of non-H 
atoms 
8 - 20 13.5 ± 2.9 9 - 20 15.6 ± 3.3 0.008 0.009 
MW (g/mol) 122.2 - 288.4 192.6 ± 41.0 125.2 - 279.6 225.3 ± 40.8 0.002 0.001 
clogP(o/w) -0.60 - 3.86 1.20 ± 0.85 -0.15 - 3.58 1.73 ± 0.99 0.022 0.019 
No. of Lipinski 
donors 
0 - 4 2.0 ± 1.0 0 - 3 1.4 ± 0.8 0.008 0.019 
No. of Lipinski 
acceptors 
2 - 6 3.4 ± 1.0 2 - 6 3.6 ± 1.2 0.412 0.617 
No. of rotatable 
bonds
(b)
 
0 - 6 2.6 ± 1.4 0 - 8 3.3 ± 1.9 0.089 0.095 
TPSA (Å
2
) 29.0 - 99.4 51.0 ± 12.4 24.4 - 88.8 47.3 ± 15.4 0.280 0.283 
(a)p-values indicate whether the difference between remote binders and direct binders is significant (p < 0.05); please note 
that for the Mann-Whitney U-test a normal approximation was used  
(b)Definition according to Oprea considering also ring bonds.38 
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In addition, the remote binders show higher mean clogP (o/w) value (1.7 vs. 1.2), and a higher 
number of rotational bonds (3.3 vs. 2.6) compared to the catalytic dyad binders. Furthermore, 
considering all of our 361 fragment-library entries, 68 fragments have an amino function (19%). 
Only two out of all 20 primary aliphatic amines, present in the library, are detected in the EP 
binding site remote from the catalytic dyad. This ratio gradually increases for secondary (4 out of 
23 = 17%) and tertiary aliphatic amines (8 out of 33 = 24%). Along with the information given in 
Table 4.2, it becomes obvious that fragments with sterically more demanding substituents prefer 
remote binding sites. As the space above the catalytic dyad is quite limited, only fragments with 
rather small substituents find a way to occupy the area next to the catalytic aspartates, while the 
larger fragments simply require more space for binding. For example, a number of bulkier 
fragments bind to the broad S6 pocket, where, in most cases, fragments with aromatic portions 
stack on top of the hydrophobic residue Phe291 (Fig. 4.4). In total, sixteen molecules are 
accommodated in this region (35% of all remote binders). The moieties performing π-stacking 
with the phenyl ring of Phe291 cover a broad range of diverse chemistry, ranging from aromatic 
portions (F311, F112, F291) to heteroaromatic rings (F164, F034, F181, F337, F017, F328, and 
F333), thiophene as a phenyl bioisoster (F305) to open-chain aliphatic portions (F203), cyclic 
aliphatic fragments (F273, F035, F207) to non-aromatic ring systems, achieving aromaticity 
upon protonation (F042). For example, F042 and F017 (Fig. 4.4, f and j) both exhibit a seven-
membered non-aromatic ring, namely an azepane and cycloheptatrien, respectively. Nevertheless, 
at pH 4.6 the imine nitrogen of F042 is protonated and turns the seven-membered ring into an 
aromatic tropylium cation, which then performs cation-π stacking interactions with Phe291. At 
the same time, F017 addresses Phe291 with its aromatic pyrimidine ring and orients the azepane 
ring in opposite direction, away from Phe291. Moreover, the attached substituents at the ring 
used for stacking can take influence on the placement of the fragment molecule and the adopted 
conformation necessary for the π-stacking interaction.19 For instance, F112 and F291 face 
Phe291 with their benzodioxine moieties (Fig. 4.4, m and n). Additional H-bonds between the 
carboxylate oxygen of Asp15 and the fragment’s pyrrolidine or in-chain nitrogen atoms, 
respectively, provoke a slight parallel displacement of the benzodioxine moieties to undergo the 
π-π stacking with Phe291. Remarkable is also the binding of F333, which induces through mutual 
aromatic stacking, an alternative conformation of Phe291, which exposes its hydrophobic face 
toward the bound fragment (Fig. 4.4, h).  
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Moreover, our analysis supports the theory that non-aromatic cyclic polyenes can build favorable 
non-covalent interactions with aromatic residues of the protein chain as also previously suggested 
by computational and experimental methods (Fig. 4.4, i).
20,21
 Interestingly, an 
oligoethyleneglycol (PEG) molecule binds either in crystal structures of the apo or complexed 
EP, occupying the S6 pocket next to Phe291, where many hydrophobic fragments bind. In most 
of the crystal structures with a bound fragment at this position, the PEG molecule is displaced. As 
a curiosity, one molecule of F224 penetrates in the semicyclic conformer of the oligomeric PEG 
molecule and forms within the S6 pocket a kind of host-guest complex. Crown ethers, the fully 
cyclized analogues of our oligomeric PEG species, are known to host positively charged ions 
such as potassium in their center. In analogy, the positively charged secondary ammonium ion of 
F224 adopts the pivotal position for a rotaxan-type complexation. At the same time, the fragment 
establishes edge-to-face π-interactions with Phe291. In previous studies, this fragment was 
detected as hit by five different screening methods and a Kd value of 400 μM was measured via 
displacement ITC titration.
4,22
   
Apart from standard π-π interactions also aliphatic substituents can experience hydrophobic 
contacts to Phe291. For instance, F203 represents an interesting example as it orients its 
isopropyl rest toward Phe291 performing C-H/π interactions (shortest distance = 3.6 Å). 
Supposedly, as beneficial effect to enhance this interaction, the adjacent acidic sulfonyl group 
transfers its electron-withdrawing properties onto the isopropyl group, which additionally 
acidifies the isopropyl substituent rendering its terminal methyl group with a more positive partial 
charge.
23
  
Our study also indicates cation-π interactions, e.g., for F035 (Fig. 4.4, o), which places its most 
likely positively charged morpholino moiety close to the π-electron cloud of Phe291 in about 6 Å 
distance.
24
 Remarkably, a similar geometry is found for F207, placing its piperidino moiety on 
top of Phe291 (Fig. 4.4, p). Here, however, the nitrogen is involved in an amide functionality and 
remains therefore uncharged. The six-membered ring in this complex is closer to the center of the 
stacked Phe291 (4.4 Å).  
The second largest portion of our fragments binds to Asp81 of the flap region. Twelve of the 
studied fragments occupy the region under the flap (27% of all remote binders). The flap operates 
as a kind of lid, intermediately opening the binding cleft to give access for substrate binding.  
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We define this region by the following amino acids: Ser78, Tyr79, Gly80, Asp81, Gly82, Ser83, 
and Ser84. The high flexibility of the flap is noticeable by the enhanced average B-factors 
assigned to this region compared to those of the protein main chain atoms in the different crystal 
structures (Table 4.3). Fragments such as F240 and F224 donate strong H-bonds to Asp81 (2.7 Å 
and 2.8 Å, respectively) and are additionally stabilized by H-bonds to Ser115. These interactions 
lower the flap’s residual flexibility and result in a lower flap-to-main protein B-factor ratio (1.3 
and 1.1, respectively). On the other hand, in the crystal structure of F014 only a weak H-bond 
between the fragment and Asp81 (3.4 Å) is observed, or no interaction at all is established with 
the flap for F035. Accordingly, higher B-factor ratios result for these complexes (2.1 and 2.9, 
respectively). This reflects the overall reduced crystal packing order with F014 and F035, and the 
flexible flap region most likely disturbs this packing. Moreover, while for F224 an affinity value 
in the three-digit micromolar range could be measured, significantly lower Kd values were found 
for F014 and F035 (5 mM and 3.2 mM, resp.). However, F240 was determined as very weak 
binder with a Kd value greater than 10 mM.
22
  This underlines the importance of structural 
information in order to purposefully grow a basic molecular scaffold using fragment data to 
optimally fill a certain region of the substrate’s binding site without relying solely on affinity 
values.  
Table 4.3. Comparison of the mean B-values of the flap region with those from the protein chain.  
 
[a] Asp119 is not a part of the flap, but most of the fragments reach this residue and influence its flexibility. 
[b] The ratio was calculated by dividing the flap’s B-factor by the average EP’s B-factor including the flap region. 
 
Amino acid addressed Fragment # average B-factor of the flap region average B-factor of EP ratio flap/EP
[b]
F240 18.2 13.9 1.3
F158 17.4 12.2 1.4
F206 15.7 10.8 1.5
F041 18.6 12.5 1.5
F073 19.0 12.3 1.5
F323 22.8 13.5 1.7
F205 18.9 10.0 1.9
F125 26.5 12.8 2.1
F014 38.8 18.6 2.1
F224 13.6 12.2 1.1
F261 19.3 13.8 1.4
F328 20.4 13.3 1.5
F278 21.9 13.6 1.6
F054 20.6 12.0 1.7
F039 32.9 19.1 1.7
F051 23.6 11.8 2.0
F035 52.7 17.9 2.9
Asp81
Asp119
[a]
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Considering all twelve fragments bound to Asp81, it becomes obvious that they all share a 
positively charged nitrogen atom in common, enabling the formation of a direct H-bond to the 
aspartate. Ten of the twelve fragments additionally occupy the S1 pocket, while F014 places its 
sterically more demanding halogenated phenyl ring into the further remote S3 and S5 pockets. 
Moreover, also one molecule of the triply populated F207 is in close vicinity to Asp81, but it 
does not interact directly with this residue, as the distance is too large. In consequence, it prefers 
to occupy the S2 pocket.  
Interestingly, the two fragments F224 and F240, which reduce the mobility of the flap at most, 
adopt related binding poses, presumably because of their similar topology (methylpyrrole and 
methylimidazole, resp.) (Fig. 4.6). F240 and one copy of F224, both fill the S1 pocket and 
interact with the same residues. In both crystal structures, GOL and PEG bind in van der Waals 
distances to the fragments, and the additives further stabilize the position of the fragments. 
Interestingly, the GOL molecules in the binding site of both crystal structures bind between the 
catalytic aspartates, obviously displacing the catalytic water molecule found in the apo crystal 
structure at this position.  
 
Fig. 4.6. Superimposition of F224 (cyan) and F240 (pink). 
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Other chemical groups that are shared by some of the fragments do not bind, however, in the 
same region of the large EP binding site. While F323 and F321 orient their piperonyl substituents 
identically, F041 places this group with totally different orientation into the S1’ pocket (Fig. 4.7). 
In the latter case, the piperidino substituent likely determines the binding pose and is 
accommodated in the S1 pocket to establish a 2.9 Å H-bond to Asp81. This example highlights 
the challenge to selectively target a binding site as big as that of EP. 
The third hot spot in the EP binding site to which eight fragment hits are bound (18% of all 
remote binders) is Asp119 (Fig. 4.3). All eight fragments occupy the S3 pocket. Three are found 
with only one molecule in the respective crystal structures (F051, F321, and F278), whereas five 
occupy two distinct binding sites (F224, F328, F261, F035, and F054). Of all eight fragments, 
six donate an H-bond via their protonated nitrogen atoms to Asp119, while F278 faces the 
residue via its carboxamide oxygen in 2.7 Å distance. This would require Asp119 to be 
protonated (Fig. 4.3, i). In the crystal structure of F051, the fragment’s pyridine ring addresses 
Asp119 in a similar fashion (Fig. 4.3, e). Using the webserver tool chemicalize.org,
25
 the 
protonation state of the pyridine ring in solution is predicted as largely deprotonated at the 
applied soaking conditions. Thus, also in this case Asp119 would have to be protonated to 
establish the observed hydrogen bond. Even though neutron diffraction studies observe Asp119 to 
be deprotonated,
26,27
 many studies have shown that the local environment can strongly influence 
the pKa value of ionizable groups. Hence, the protonation state of Asp119 remains to be 
elucidated and might change in each individual case.
28,29
    
 
Fig. 4.7. Piperonyl moieties occupying different binding pockets. 
Yellow: F323, green: F321, cyan: F041. 
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The eight remaining fragment molecules bind less specifically to the EP surface (18% of all 
remote binders, Fig. 4.5). Of these, four (F031, F268, F131, and F261) occupy the S1’ pocket 
whereas the remaining four (F114, F171, F056, and F227) bind on the EP surface, outside of the 
substrate binding site. While two of the surface binders occupy also an additional position in the 
substrate binding site (F114 and F171), F056 and F227 appear only once in the respective crystal 
structures. F227 is the only fragment among the wealth of fragment hits that forms a covalent 
attachment via Asp279 to EP near a disulfide bridge. Predictions of the pKa value suggest F056 
and F227 to be deprotonated at their acid functions, thus making plausible why binding sites 
remote from the rather negatively charged EP substrate-binding site appear comprehensible. 
Furthermore, F261 attracts attention as it was considered a hit by the HCS and RDA prescreening 
methods from our previous study, and the subsequently performed ITC measurements further 
characterized this fragment as surprisingly efficient surface binder with a Kd value of 0.6 mM and 
an LE = 0.23 (kcal mol
-1
 atom 
-1
).
4,22
    
The analyzed fragments and their binding poses are an excellent source of information for 
putative optimization strategies.  
EP was and is still a relevant surrogate to investigate putative binding modes of potent 
peptidomimetic renin and ß-secretase inhibitors, long before the crystal structures of the latter 
enzymes became available. It is important, however, to consider deviations between the model 
and actual proteins. We thus compared the structures of EP and five additional therapeutically 
relevant pepsin-like aspartic proteases (renin, ß-secretase (BACE-1), secreted aspartic protease 
(SAP2), cathepsin D, and plasmepsin II).
30
 Overall, the essential regions around the catalytic 
dyad are well conserved in all six structures. Furthermore, a tyrosine residue (Tyr79) in the flap 
region is commonly shared by all six proteases. One of the EP’s hot spots Asp81 is only present 
in SAP2, whereas cathepsin D and plasmepsin II exhibit a serine at the same place. In renin, a 
serine is found at the preceding position 80. Moreover, Asp119 is shared by renin, cathepsin D, 
and plasmepsin II.  
In a recent study on EP inhibitors, synthesized by the Gewald reaction, we could demonstrate, 
that small variations at the parent scaffold resulted in quite distinct inhibitor binding poses, not 
least owing to the large size of the EP binding site (Fig. 4.8, A).
31
 Considering these ligands, 
expansion of their basic molecular scaffold toward the above-mentioned hot-spot residue Asp119 
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might improve binding. The phenyl or indolyl substituents, presently attached to their parent 
scaffold and accommodated in the S1 pocket, could potentially be substituted with a 
cyclopentanamine, as suggested by the binding pose of F321 (Fig. 4.8, B). Striving for an 
additional hydrogen bond to be established with Asp119, a potential affinity enhancement can be 
expected. Phe291 however, hot spot in EP, does not occur in any of the other mentioned 
proteases at the same position. Instead, an aspartate residue is found at the same position in renin. 
Though, such a difference can be used to sustain purposefully designed ligands with a desired 
selectivity advantage for the target protein. If we analyze for instance, the binding pose of three 
early-stage renin inhibitors, which had been co-crystallized with EP and deposited in the protein 
databank, we see that they form weak hydrophobic CH-π contacts with the EP hot spot residue 
Phe291 using either a tert-butyl (PDB-codes: 2ER9, 2ER7), or iso-propyl group (PDB-code: 
2ER0) (Fig. 4.9, A).
32–34
 Furthermore, they place a proline residue into the S4 pocket. 
Accordingly, the P4 and P6 substituents remain spatially separated. For improved EP binding, 
our fragment study would suggest to merge the P4 and P6 substituents in the S4 and S6 pockets, 
simultaneously optimizing the interactions with the hot spot at Phe291.  
Several fragments, e.g. F034, F181, F273, F291, F311, F328, and F337 suggest such binding. 
These fragments extend across the S4 and S6 pockets and involve Phe291 in a favorable contact 
(Fig. 4.9, B).  
 
Fig. 4.8. A: Superposition of seven inhibitors, synthesized by the Gewald reaction, is shown by using graded 
blue colors for the ligands (PDB-codes: 3T7Q, 4L6B, 3PSY, 3WZ6, 3WZ7, 3T7X, and 3WZ8).39 B: The 
inhibitors shown in A are superimposed with the crystal structure of our EP-F321 complex (magenta). 
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A similar concept is suggested to merge the occupants of the hydrophobic S1 and S3 pockets, 
which are filled by a P1-cyclohexylalanyl and a P3-phenylalanyl side chain in the crystal 
structures of many early-stage renin inhibitors.
33,35
 With such a strategy, a breakthrough in the 
renin project was made at Ciba (now Novartis), which resulted in the marketed renin inhibitor 
Aliskiren.
36,37
 Similarly, our detected fragments F278, F321, F328, and F291 suggest such a 
promising bridging from the S1 into the S3 pockets (Fig. 4.9, B). The latter fragment F291 would 
even be able to address the catalytic W501 via its pyridine-type nitrogen atom.  
 
Fig. 4.9. A: Superposition of three peptidomimetic renin inhibitors co-crystallized with EP. Binding pockets are 
indicated by cyan transparent spheres and heteroatoms are colored according to the usual color-coding. PDB-
codes: 2ER9 (cyan), 2ER7 (green), and 2ER0 (yellow).32–34 B: Superposition of the peptidomimetic inhibitors and 
the fragments found in the respective EP complexes. F278, F291, F321, and F328 expand over the S1 and S3 
pockets, whereas S4 and S6 are simultaneously occupied by F034, F181, F273, F291, F311, F328, and F337. 
For reasons of clarity, all fragment molecules are colored in magenta, with the usual color-coding for 
heteroatoms. 
 
Furthermore, in many peptidomimetic renin inhibitors an amide group is found between the S1’ 
and S2’ pockets. A similar pattern is detected for F268 and F131 at that position (Fig. 4.5, b and 
c). These fragments bridge between the two pockets addressing Gly37 and Gly80 with their 
amide groups. While Gly80 is only found in SAP2 and cathepsin D at the same position, the 
position of Gly37 is conserved throughout all discussed pepsin-like protein structures, suggesting 
the amide-bond motif as a very promising pattern for optimization.  
These examples show that the plethora of fragments observed in this study can propose structural 
motifs actually found in larger ligands. They also suggest the fusion of occupants in adjacent 
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binding pockets emerged from the fragment’s binding positions with respect to that of the natural 
substrate. The collected information is meant to serve as a template, based on which proposals for 
optimization strategies can be acquired.   
4.6 Conclusions 
 
The present study uncovered an impressive high number of binding modes by use of 29 
fragments disclosing 45 distinct binding poses in regions remote from the catalytic center of the 
aspartic protease EP. The broad chemical diversity of the discovered fragment hits enables a 
meaningful mapping of the available chemical space. Fragments addressing the catalytic dyad 
have higher relevance as starting points for the de novo design of a lead structure. However, the 
remote binders constitute a valuable source of information on how to develop feasible lead-
optimization strategies particularly with respect to selectivity. The large number of detected 
fragments indicates that only a small number of hot spots apart from the catalytic dyad is given. 
Most likely, a putative ligand scaffold has to address these spots successfully in order to achieve 
optimal binding with a limited number of iteration steps. However, these hot spots may differ in 
their positions in structures of other pepsin-like aspartic proteases. Thus, only global aspects can 
be gained from such analysis. With respect to physicochemical properties, we observe that larger 
fragments preferentially occupy remote parts of the substrate-binding site (Table 4.1 and 4.2). 
Furthermore, fragments with amino groups are preferred by aspartic proteases, considering that 
many members of this enzyme family operate in acidic conditions. Moreover, only two of the 20 
primary aliphatic amines from our fragment library bind remotely, whereas this number increases 
gradually for secondary and tertiary amines, indicating once again that sterically more demanding 
fragments prefer remote binding sites.  
Additionally, we detected fragments bridging between adjacent pockets, e.g., F278, F321, F328, 
and F291 between the S1 and S3 pockets, or F034, F181, F273, F291, F311, F328, and F337, 
found to virtually crosslink S4 and S6. Such fragments can provide valuable ideas on how to 
modify and reduce the size of a peptidomimetic inhibitor during optimization campaigns. We 
thus believe that the large selection of remote binding fragments combined with an appropriate 
optimization strategy will significantly support the discovery of new attractive scaffolds but also 
the optimization of existing ones. 
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4.7 Experimental Section 
 
Protein crystallization, soaking experiments, data collection, processing, and structure 
determination, graphical representation of the pockets in the binding site of EP as well as the 
computational predictions of fragment properties have already been described in chapter 3.7. 
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5. Comparison of Cocktail versus Single Soaking Experiments: Pitfalls to be 
emphasized 
 
5.1 Introductory remarks 
 
The set up and data collection of cocktail experiments A and C and the single soaking experiment 
with F333 at 50 mM were prepared by Johannes Schiebel. The set up and data collection of 
cocktails B and D were performed by Helene Köster.  
The author of this thesis performed the structure refinement of all experiments provided by 
Johannes Schiebel and carried out the comparison of the data with the corresponding single 
fragment soaks described in chapters 3 and 4. 
 
5.2 Introduction 
 
X-ray crystallography is gaining in importance as primary screening method in FBDD since 
recent progress in academia and industry. 
1–3
 Synchrotron radiation, robotic crystal mounting and 
sample changing, advancement in detector technologies, and automated refinement pipelines 
have been introduced to increase the method’s applicability as an efficient high-throughput 
technique.
1,4,5
 In this context the method outperforms other techniques as it can handle higher 
fragment concentrations that other methods cannot. Furthermore, eventual ligand precipitation 
can be neglected as soon as the deposit is removed from the crystal surface immediately before 
freezing. Advantage of this procedure is that the fragment is exposed to a saturated solution and 
changes in concentration by absorption of the fragment into the crystal are easily compensated by 
increasing solvation. 
A popular procedure is the design and application of cocktail experiments involving up to eight 
compounds in a mixture in order to accelerate the hit identification procedure.
6–9
 The technique 
allows for the fast reduction of the number of non-binders while estimating bound fragments 
based on the electron density. However, the higher the number of compounds in a mixture, the 
higher the influence on parameters such as solubility and the thereof resulting reduced fragment 
occupancy, chemical reactivity, and crystal damage. Furthermore, compounds often prefer one 
and the same region for binding resulting in rather diffuse electron density, which is difficult to 
interpret or which requires subsequent analysis, decelerating the process of hit identification.  
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In such a case, single soaking experiments are subsequently carried out to determine the bound 
compound with absolute certainty. First of all, to assign the electron density unambiguously to 
one of the cocktail members, the structural diversity of all compounds included in a mixture must 
be well selected. Second, such a repetitive single soaking protocol is only applied if the initial 
cocktail soaking indicated any successful binding of a cocktail member. 
The purpose of this chapter is to set out major differences between structures of singly soaked 
fragments and cocktails exposing these fragments as an example to the aspartic protease 
endothiapepsin (EP). The following examples will demonstrate how similar binding motifs 
compete for same binding sites and how the quality of electron densities is significantly 
influenced by the presence of two or more fragments in a mixture.  
5.3 Results and Discussion 
 
In the first experiment three fragments (F63, F267, and F291) with pyridine moieties were 
simultaneously soaked at a concentration of 90 mM each (cocktail A). The produced data of 
cocktail A are of high quality with statistics slightly better than the mean of the data sets collected 
for singly soaked fragments (Table 5.1).
10
 In the single soaking experiments all three fragments 
addressed the catalytic water W501 and oriented toward the S1 pocket with their pyridine rings 
(Fig. 5.1, A‒C). However, in the cocktail experiment varying binding sites for F63 and for one 
molecule of F291 were observed (Fig. 5.1, D‒D2). However, despite the simultaneous fragment 
soaking into EP, the difference electron density in the cocktail structure is well defined. This 
allowed the assignment of all fragments together with the doubly populated F291.  
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Table 5.1 Data collection and refinement statistics cocktail A and single soaking experiments. 
Fragment number 
Cocktail A:  
F63, F267, F291 
F63 F267 F291 
PDB code 5MB0 4Y57 4Y5C 4Y45 
Data collection and 
processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline BESSY BL14.1 BESSY BL14.1  BESSY BL14.1   BESSY BL14.1  
Detector PILATUS 6M MX-225 CCD PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a        
     a, b, c (Å) 45.4, 73.1, 52.5 45.6, 73.3, 53.1 45.3, 73.1, 52.8 45.3, 73.0, 52.8 
     α, β, γ (°) 90.0, 109.6, 90.0 90.0, 109.9, 90.0 90.0, 109.4, 90.0 90.0, 109.6, 90.0 
Resolution range (Å)  42.8-1.15 (1.22-1.15) 42.8-1.49 (1.58-1.49) 42.7-1.19 (1.26-1.19) 42.7-1.06 (1.12-1.06) 
Wilson B factor (Å2)   9.5 10.9 11.2 9.7 
No. of unique reflections  113549 (17691) 53579 (8621) 103484 (16282) 144991 (22289) 
Multiplicity  3.6 (3.2) 4.2 (4.2) 3.5 (3.3) 3.6 (3.3) 
Rsym (%)  7.4 (46.6) 7.5 (49.4) 3.7 (49.4) 3.8 (46.5) 
Completeness (%)  98.8 (95.2) 99.8 (99.6) 99.1 (96.8) 98.8 (94.1) 
<I/σ(I)>  9.5 (2.8) 13.5 (2.9) 17.9 (2.2) 16.7 (2.4) 
Refinement        
Resolution range  42.8 - 1.15 41.2 - 1.49 39.5 - 1.19 42.7 - 1.06 
No. of reflections used for 
refinement (work (free))  
113540 (5677) 50900 (2679) 98309 (5175) 137741 (7250) 
Rcryst (%) 15.2 11.7 11.5 12.0 
Rfree (%)  17.0 15.3 14.1 13.6 
No. of refined residues  330 330 330 330 
No. of fragment atoms 59 15 16 31 
No. of other ligand atoms 30 20 22 18 
No. of water molecules  387 326 277 288 
RMSD, bond length (Å)  0.006 0.008 0.006 0.006 
RMSD, bond angles (˚)  0.9 1.2 1.2 1.2 
Ramachandran plot (%) b       
     Most favoured  94.2 93.5 93.5 92.8 
     Additionally allowed  5.8 6.5 6.5 7.2 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c       
     All protein atoms  11.2 11.8 13.2 11.5 
     Main chain  10.3 10.9 12.0 10.5 
     Side chain  12.1 12.6 14.4 12.4 
     Fragment atoms 13.4 13.2 34.7 16.1 
     Other ligand atoms d 21.6 24.6 26.5 16.2 
     Waters  28.7 27.2 27.6 24.9 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Fig. 5.1. Crystal structures of the singly soaked fragments F63, F267, and F291 (A-C) versus 
fragment binding from cocktail A (D, D1, and D2). For all heteroatoms, the standard color-coding 
has been used, while the carbon atoms have been colored based on the assigned fragment. The mFo-
DFc meshes around the fragments are shown at 3σ.  
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However, as not all pyridine moieties of the three fragments can simultaneously occupy the S1 
pocket next to the catalytic W501 as observed in the single soaks, a competition must have 
occurred, leading to the spatial displacement of F63 addressing now Asp119 with its secondary 
amine. F267 was found to bind as expected in full agreement to the single soak. Also, one 
molecule of F291 addressing Phe291 through π-π stacking is observed as in the single soak. 
However, the second molecule of F291 could only be partly assigned to the electron density with 
its benzodioxanyl instead of its pyridine moiety in the S1 pocket.  
In another cocktail experiment (cocktail B), a set of two fragments (F224 and F236) was 
prepared at 50 mM (Table 5.2). Also here, based on the structural information obtained from the 
single soaking experiments, fragments with an aliphatic secondary amine as warhead within the 
set were chosen from the library. In the single soaking experiments these fragments occupy 
different binding pockets supposedly as no direct competition as given in the cocktail has been 
experienced (Fig. 5.2, A and B). Although both fragments use their secondary amino group for an 
H-bond interaction, F224 places one of the bound copies under the flap region addressing Asp81 
and the second molecule in van der Waals distance to the first one where its secondary amino 
group is virtually wrapped by an oligoethylene glycol picked up from the buffer. In contrast, 
F236 uses its secondary amino group for a direct interaction with the catalytic dyad. An overlay 
of the initial fragment binding poses with the mFo‒DFc map at 3σ from cocktail B clearly 
demonstrates that the original binding modes are no longer preserved by both fragments (Fig. 5.2, 
C). Moreover, the resulting density allows only the placement of F236 under the flap region, 
forming a 2.8 Ǻ H-bond to Asp81 via its secondary amino group, where one of the molecules of 
F224 in the single soaking experiment was found (Fig. 5.2, C). The residual electron density in 
the cocktail experiment at 3σ suggests that the binding mode found for F236 (Fig. 5.2, B) in the 
single soak is no longer adopted, instead the fragment is moved next to Asp81. However, the 
fragment’s mean B-value of 37.6 Ǻ2 at a structural resolution of 1.30 Ǻ indicates the mobility of 
the fragment molecule and the probability of varying fragment atomic positions in different unit 
cells (Table 5.2). Remarkably, hardly any electron density next to the catalytic dyad or between 
Asp81 and Asp119 suggest the population of F224 (Fig. 5.2, D).  
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Fig. 5.2. Crystal structures of the singly soaked fragments F224 and F236 (A and B) versus cocktail B (C), where only 
one fragment was modeled into the electron density. In D the original fragment binding modes are superimposed with 
the electron density, resulted from the cocktail experiment. For all heteroatoms, the standard color-coding has been 
used, while the carbon atoms have been colored based on the assigned fragment.  
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Table 5.2 Data collection and refinement statistics cocktail B and single soaking experiments. 
Fragment number 
Cocktail B:  
F224 and F236 
F224 F236 
PDB code 5MB7 4YD3 4YD5 
Data collection and 
processing       
Wavelength (Å)   0.91841 0.91841 0.91841 
Beamline  BESSY BL14.2   BESSY BL14.1  BESSY BL14.1 
Detector MX-225 CCD PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 
Unit-cell parameters a      
     a, b, c (Å) 45.4, 72.9, 52.7 45.3, 73.2, 52.7 45.3, 73.0, 52.7 
     α, β, γ (°) 90.0, 109.5, 90.0 90.0, 109.7, 90.0 90.0, 109.3, 90.0 
Resolution range (Å)  30.0-1.30 (1.32-1.30) 42.7-1.25 (1.32-1.25) 42.8-1.21 (1.28-1.21) 
Wilson B factor (Å2)   10.9 9.8 9.8 
No. of unique reflections  78870 (3975) 86779 (13216) 96832 (14290) 
Multiplicity  3.2 (3.1) 3.4 (3.3) 3.6 (2.8) 
Rsym (%)  5.2 (52.0) 3.9 (33.1) 5.2 (22.4) 
Completeness (%)  99.9 (99.3) 96.5 (91.0) 98.1 (89.8) 
<I/σ(I)>  22.3 (2.0) 18.9 (3.3) 13.7 (3.6) 
Refinement      
Resolution range  18.9 - 1.30 42.7 - 1.25 42.8 - 1.21 
No. of reflections used for 
refinement (work (free))  
78840 (3850) 82440 (4339) 91990 (4842) 
Rcryst (%) 13.5 11.1 11.9 
Rfree (%)  15.8 13.2 13.6 
No. of refined residues  330 330 330 
No. of fragment atoms 13 34 13 
No. of other ligand atoms 6 59 34 
No. of water molecules  337 293 226 
RMSD, bond length (Å)  0.006 0.006 0.006 
RMSD, bond angles (˚)  0.9 1.2 1.2 
Ramachandran plot (%) b      
     Most favoured  93.5 94.2 94.2 
     Additionally allowed  6.5 5.8 5.8 
     Generously allowed  0 0 0 
     Disallowed 0 0 0 
Mean B-values (Å2) c      
     All protein atoms  12.5 11.4 11.6 
     Main chain  11.5 10.4 10.6 
     Side chain  13.4 12.3 12.5 
     Fragment atoms 37.6 15.6 18.6 
     Other ligand atoms d 17.5 23.6 23.6 
     Waters  27.2 27.0 25.5 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by 
PROCHECK; c Calculated by MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 
1PE, and acetate. Columns are sorted according to the order the fragments are mentioned in 
the text. 
The examples so far clearly demonstrate that the presence of two or more competing fragment 
binders can strongly influence the binding poses observed for separately studied fragments in 
single soaking experiments. Moreover, the examples highlight the importance of structural 
diversity when compiling cocktail experiments.  
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Otherwise same or very similar structural motifs would compete for one and the same binding 
site, often leading to diffuse and inexplicable electron density.  
Thus, an additional cocktail experiment (cocktail C) was performed using a set of two fragments 
at 90 mM each. This time their structural diversity was regarded (Table 5.3). Thereby, the 
hydrazide F103 and the thiazolamine F171 were simultaneously soaked into EP. In the 
previously performed single soaking experiments F171 occurred twice in the crystal as one 
molecule was found on the protein surface while the second one addressed Asp35 and the 
catalytic W501 with its exocyclic amino group (Fig. 5.3, A). In contrast, F103 displaced the 
catalytic W501 while directly interacting with both of the catalytic aspartates (Fig. 5.3, B).  
In cocktail C only the remotely bound molecule of F171 could be clearly assigned to the electron 
density (Fig. 5.3, C).  
 
Fig. 5.3. Crystal structures of the singly 
soaked fragments F171 and F103 (A and B) 
versus cocktail C (C). In cocktail C only the 
remotely bound molecule of F171 was 
modeled into the electron density. The 
original fragment binding poses next to the 
catalytic aspartates are superimposed with 
the difference electron density, which 
resulted from cocktail C.  For all 
heteroatoms, the standard color-coding has 
been used, while the carbon atoms have been 
colored based on the assigned fragment. The 
mFo-DFc meshes are shown at 2.5σ. 
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Table 5.3 Data collection and refinement statistics cocktail C and single soaking experiments. 
Fragment number 
Cocktail C:  
F171 and F103 
F171 F103 
PDB code 5MB5 4Y3X 4Y3M 
Data collection and 
processing 
  
    
Wavelength (Å)   0.91841 0.91841 0.91841 
Beamline  BESSY BL14.1   BESSY BL14.1  BESSY BL14.2 
Detector PILATUS 6M PILATUS 6M MX-225 CCD 
Space group P21 P21 P212121 
Unit-cell parameters a       
     a, b, c (Å) 45.4, 72.9, 52.6 45.3, 73.0, 52.7 45.2, 72.5, 104.1 
     α, β, γ (°) 90.0, 109.7, 90.0 90.0, 109.7, 90.0 90.0, 90.0, 90.0 
Resolution range (Å)  42.7-0.98 (1.04-0.98) 42.7-1.25 (1.33-1.25) 45.2-1.55 (1.64-1.55) 
Wilson B factor (Å2)   8.4 8.8 11.1 
No. of unique reflections  179855 (27996) 87058 (13331) 50445 (8029) 
Multiplicity  3.8 (3.5) 3.8 (3.6) 8.0 (8.1) 
Rsym (%)  6.6 (45.0) 5.9 (40.0) 6.7 (42.0) 
Completeness (%)  97.4 (94.0) 97.5 (92.7) 99.9 (99.7) 
<I/σ(I)>  10.2 (2.2) 13.9 (3.0) 23.1 (5.1) 
Refinement       
Resolution range  36.5 – 0.98 42.7 - 1.25 42.3 - 1.55 
No. of reflections used for 
refinement (work (free))  
179793 (8989) 82705 (4353) 47922 (2523) 
Rcryst (%) 14.7 12.0 14.5 
Rfree (%)  16.2 14.2 16.6 
No. of refined residues  330 330 330 
No. of fragment atoms 13 26 12 
No. of other ligand atoms 30 32 43 
No. of water molecules  408 296 294 
RMSD, bond length (Å)  0.005 0.015 0.008 
RMSD, bond angles (˚)  0.9 1.6 1.2 
Ramachandran plot (%) b      
     Most favoured  93.5 93.5 93.1 
     Additionally allowed  6.5 6.5 6.9 
     Generously allowed  0 0 0 
     Disallowed 0 0 0 
Mean B-values (Å2) c      
     All protein atoms  9.6 9.9 12.4 
     Main chain  8.8 9.1 11.4 
     Side chain  10.3 10.7 13.4 
     Fragment atoms 10.1 13.0 20.5 
     Other ligand atoms d 19.8 20.7 35.6 
     Waters  27.2 24.4 25.1 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by 
PROCHECK; c Calculated by MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 
1PE, and acetate. Columns are sorted according to the order the fragments are mentioned in 
the text. 
Furthermore, F103 can hardly be assigned to the electron density with the required confidence 
(Fig. 5.3, C). Although the resolution of the cocktail structure C with 0.98 Ǻ clearly exceeds that 
of the single soaking experiments (1.25 and 1.55 Ǻ) the electron density in the active site of 
cocktail C is significantly more diffuse and disconnected compared to the density of the single 
soaks.   
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We finally decided to remove the active site copy of F171, initially modeled into the density after 
subsequent refinement cycles, as a high level of negative and positive difference electron density 
remained after reducing and refining the fragment’s occupancy.  
In this experiment with an electron density from an optimally diffracting crystal, the refinement 
indicates a bound fragment in the active site but likely with strongly reduced occupancy. F103 
would have definitely failed to be discovered as hit without performing the study with 
individually soaked crystals, while the assignment of F171 to the electron density strongly 
depends on how rigorously the individual crystallographer sets the criteria to interpret the 
residual electron density. Nevertheless, the single soaking experiment for F171 would have 
provided an unambiguous answer. The cocktail experiment would have again greatly decelerated 
the hit identification process. 
A similar experience has been made in our group in a previous study on EP, in which the in-
house fragment library was first screened via a biochemical assay resulting in 55 hits, which were 
subsequently analyzed via X-ray crystallography using cocktails of two fragments at 50mM 
each.
9
 Thereby, only structurally diverse fragments have been combined. In one of the cocktails, 
the benzothiopyranone F308 and the pyrimidinone F333 with an attached isopropanylthiolether 
were simultaneously soaked into apo EP crystals (cocktail D, Fig. 5.4, A). Although both 
fragments were identified as hits in the initially performed biochemical assay none of them could 
be found in the electron density of the studied cocktail D. Only a very fragmented density could 
be seen next to Phe291, not suited to unambiguously assign a fragment binder (Fig. 5.4, B). 
However, the subsequently performed single soaking experiments with F333 at 50 mM (Fig. 5.4, 
C) and 90 mM (Fig. 5.4, D) clearly confirmed the fragment’s binding next to Phe291.11 In the 
single soaking experiment at a lower concentration, F333 could be clearly assigned to the 
electron density, whereas the electron density of cocktail D next to Phe291 is hardly significant 
(Fig. 5.4, B). Also in this case, when the two fragments would have been selected randomly for a 
cocktail experiment and no complementary information regarding their potency would have been 
available both would have remained undetected as hits. 
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Fig. 5.4. Crystal structures of the singly bound fragment F333 at concentrations of 50 mM (C) and 90 
mM (D) versus cocktail D (B). The two dimensional structures of fragments F333 and F308, used for the 
cocktail experiment, are presented in the upper left hand side of the figure (A). For all heteroatoms, the 
standard color-coding has been used, while the carbon atoms have been colored based on the assigned 
fragment. 
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Table 5.4 Data collection and refinement statistics cocktail D and single soaking experiments. 
Fragment number 
Cocktail D:  
F308 and F333 
F333_50mM F333_90mM 
PDB code 5MB6 5MB3 5DR3 
Data collection and 
processing       
Wavelength (Å)   0.91841 0.91841 0.89500 
Beamline BESSY BL14.2 BESSY BL14.1  BESSY BL14.3  
Detector MX-225 CCD PILATUS 6M Mar CCD 165 
Space group P21 P21 P21 
Unit-cell parameters a    
     a, b, c (Å) 45.4, 73.5, 53.2 45.4, 73.0, 52.7 45.3, 73.0, 52.8 
     α, β, γ (°) 90.0, 110.5, 90.0 90.0, 109.5, 90.0 90.0, 109.5, 90.0 
Resolution range (Å)  30.0-1.20 (1.22-1.20) 42.8-1.05 (1.11-1.05) 42.7-1.24 (1.31-1.24) 
Wilson B factor (Å2)   8.3 9.1 9.6 
No. of unique reflections  95743 (3095) 146432 (22858) 91107 (14458) 
Multiplicity  2.8 (1.8) 3.8 (3.7) 4.2 (4.1) 
Rsym (%)  5.4 (23.8) 5.0 (47.8) 4.4 (43.3) 
Completeness (%)  94.2 (61.2) 97.0 (93.9) 99.2 (97.8) 
<I/σ(I)>  21.7 (3.8) 13.0 (2.4) 20.3 (3.3) 
Refinement    
Resolution range  27.9 – 1.20 36.5 - 1.05 20.9 - 1.24 
No. of reflections used for 
refinement (work (free))  
95693 (4629) 146410 (7319) 86551 (4556) 
Rcryst (%) 13.3 13.3 11.2 
Rfree (%)  14.9 15.1 13.3 
No. of refined residues  330 330 330 
No. of fragment atoms ‒ 17 14 
No. of other ligand atoms 11 28 28 
No. of water molecules  464 407 341 
RMSD, bond length (Å)  0.006 0.005 0.006 
RMSD, bond angles (˚)  0.9 0.9 1.2 
Ramachandran plot (%) b    
     Most favoured  94.2 93.5 93.5 
     Additionally allowed  5.8 6.5 6.5 
     Generously allowed  0 0 0 
     Disallowed 0 0 0 
Mean B-values (Å2) c    
     All protein atoms  9.6 10.9 12.0 
     Main chain  8.7 10.1 11.0 
     Side chain  10.4 11.7 12.9 
     Fragment atoms ‒ 16.0 17.5 
     Other ligand atoms d 12.6 26.7 29.1 
     Waters  26.9 29.3 26.6 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by 
PROCHECK; c Calculated by MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 
1PE, and acetate. Columns are sorted according to the order the fragments are mentioned in 
the text. 
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5.4 Conclusions 
 
In drug discovery, the information about the three dimensional structure of a fragment bound to 
its target is mandatory as it is prerequisite for any rational design in a hit-to-lead optimization 
campaign. X-ray crystallography can be used as a primary screening technique due to recent 
improvements in this field and the broad accessibility of synchrotron radiation. However, we 
believe that the application of cocktail experiments to maximize the method’s throughput can 
easily lead to drop outs owing to false negative hit rates. Moreover, diffuse electron density 
results from reduced fragment occupancy provoked by lower fragment concentrations in the 
crystal and the mutual competition of fragments for same binding sites. Such densities often 
require additional analysis and, as a result, the hit identification process is decelerated.  
Many of the fragments, which failed to be identified as hits in the cocktail experiments (F224, 
F103, one molecule of F171, and F333) appeared as clearly bound to EP using individual soaks. 
These results indicate that the individual fragment concentration in a cocktail is significantly 
lower than expected. Moreover, same warheads competing for the same binding sites result in 
either remote fragment binding (cocktail A, F63) or complete fragment displacement (cocktail B, 
F224). Furthermore, the kinetics of fragment penetration into crystals can take an important 
impact on the fragment population across a crystal. This population is not necessarily uniform 
across the entire specimen. In addition, the simultaneous presence of more than one fragment in a 
binding site might create novel contacts among the fragments influencing in a kind of synergistic 
effect the potency and the adopted binding pose of fragments. It is difficult to estimate how such 
observations can be exploited in fragment-to-lead optimization. 
Since the complexity of fragment screening and binding pose characterization is clearly 
augmented by cocktail experiments, we strongly endorse the application of single soaking 
experiments instead of cocktails when consulting X-ray crystallography. To our opinion this is 
the only way to significantly reduce the false negative rates while optimizing the yield of well-
defined electron densities to elucidate the three-dimensional structure of a fragment, bound to its 
target. 
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5.5 Experimental Section 
 
The protein crystallization procedure has been described in chapter 3.7.1. Also, the 
implementation of cocktail experiments B (F224 and F236 at 50 mM each) and D (F308 and 
F333 at 50 mM each) has been previously descrived.
9
 In short, the beforehand prepared crystals 
were soaked for 1-2 days in the reservoir buffer containing 0.1 M NH4Ac, 0.1 M NaAc, and 26% 
(w/v) PEG 4000, to which 25% GOL and the two corresponding fragments at 50 mM each were 
added. After 48 h the crystals were frozen in liquid nitrogen. The diffraction data were collected 
at beamline 14.2 of the BESSY synchrotron in Berlin at 100 K and processed with HKL2000.
12
 
The structures were determined as described previously.
9
 
The single soaking experiment with F333 at a concentration of 50 mM was performed in 70 mM 
NH4Ac, 70 mM NaAc, 16-20% (w/v) PEG 4000, and 23% GOL. The crystal was soaked for 48 h 
before freezing in liquid nitrogen. 
Cocktail experiment A included three fragments (F63, F267, and F291) at 90 mM each. These 
were soaked for 24 h in a mixture of 65 mM NH4Ac, 65 mM NaAc, 14-18% (w/v) PEG 4000, 
and 8% GOL. Cocktail experiment C (F171 and F103 at 90 mM each) was prepared analogous to 
cocktail A with the only difference that 17% instead of 8% GOL were used.  
Diffraction data for cocktails A and C and for the single soaking experiment with F333 at 50 mM 
were collected at BESSY beamline 14.1 and processed with XDS.
13
 For the initial refinement of 
these datasets an automated refinement pipeline was applied.
1
 For the molecular replacement step 
of the pipeline, the coordinates of the apo EP structure (PDB-code: 4Y5L) were used. In addition, 
the intermittent model building was performed with Coot as fragments and solvent molecules 
were modeled into a difference electron density of at least 2.5 σ.14  
As very high structural resolutions are given, the structures were refined anisotropically, leading 
to significant improvement of the Rfree values. If the level of difference electron density at 
appropriate ligand occupancy was significantly reduced after subsequent refinement cycles with 
Phenix, the ligand was retained.
15
 In the final refinement cycle hydrogen atoms were added to the 
models and ADP weight were optimized. The mFo-DFc difference electron densities shown in the 
structural figures were generated with Phenix. All structural figures were made with Pymol.
16 
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6. Structure-based Drug Design and Optimization of Inhibitors for 
Endothiapepsin by Exploiting Dynamic Combinatorial Chemistry 
 
 
6.1 Introductory Remarks  
 
The following work was done in cooperation with the group of Prof. Anna Hirsch from the 
University of Groningen, Netherlands, and coworkers from the National Hellenic Research 
Foundation in Athens, Greece, and the Stratingh Institute for Chemistry in Groningen, 
Netherlands. The work resulted in three shared publications: two were published in Angewandte 
Chemie in 2014 (DOI: 10.1002/anie.201309682) and 2016 (DOI: 10.1002/anie.201603074), and 
the third one was published in Internatinal Journal of Molecular Science in 2015 (DOI: 
10.3390/ijms160819184).   
The author of this thesis contributed the X-ray analysis of EP with bound ligands and the 
interpretation of the binding modes of those ligands to the publications. In this chapter the main 
content of the papers will be summarized whereby the main focus will be set on the structural 
information. 
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6.2 Introduction 
 
Dynamic combinatorial chemistry (DCC) is a technique used for the molecular amplification of 
the members of a compound library assisted by the presence of a target protein. 
1–3
 The principle 
is based on the reversible and continuous interchange of the library members (building blocks) 
under thermodynamic control and in case of the studied system under acidic pH conditions. Such 
a dynamic combinatorial library (DCL) is therefore able to respond to molecular recognition by 
the target protein, which then can induce a shift of equilibrium, favoring the predominant 
formation of the selected species.  
In the first project, we applied the technique to identify the best binder(s) from a DCL composed 
of five aldehydes and five hydrazides, reacting under a simple condensation reaction to 
acylhydrazones (Fig. 6.1).
4
 First, different acylhydrazones were designed using the software 
MOLOC
5
 and docked via FlexX
6
, whereby two alternative binding poses were modeled, with and 
without binding through the catalytic water molecule. An additional primary amino group was 
introduced to serve as a putative anchor to bind to the target protein EP (see Chapter 3, 
warheads). Based on the docking analysis, a series of acylhydrazones were selected, which 
retrosynthetically led to the five hydrazides and five aldehydes shown in Fig. 6.1. Hydrazides H1 
to H4 were subsequently synthetized from their enantiomerically pure methyl esters, while H5 
and all five aldehydes were commercially available.  
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Fig. 6.1. Dynamic combinatorial library with identified acylhydrazones. 
For the condensation reaction, five sub-libraries were built, consisting of five hydrazides and one 
aldehyde each. Those sub-libraries were pre-equilibrated and upon addition of EP, eight protein-
bound acylhydrazones were identified via 
1
H-STD-NMR (Fig. 6.1).
7
 The latter identified 
acylhydrazones were subsequently synthetized individually from their parent building blocks and 
their biological activity was tested in a fluorescence-based enzyme-kinetic assay (Table 6.1).  
Table 6.1. Affinity data of the detected acylhydrazones. 
Inhibitors IC50 (µM) Ki (µM) ∆G
0
 (kJ∙mol-1)[a] LE (kJ∙mol-1∙atom-1) 
(S)-H4-A4 12.8 ± 0.4 6 ± 0.2 –30 0.27 
(R)-H3-A5 14.5 ± 0.5 7 ± 0.2 –30 0.29 
(S)-H1-A1 150 ± 17 71 ± 8 –24 0.27 
(S)-H2-A1 177 ± 13 83 ± 6 –23 0.23 
(R)-H3-A4 206 ± 19 97 ± 9 –23 0.25 
(R)-H3-A1 352 ± 13 166 ± 6 –22 0.22 
(S)-H1-A3 365 ± 95 172 ± 45 –22 0.30 
H5-A1 insoluble – – – 
[a] The Gibbs free energy of binding was derived from the experimentally determined IC50 values. 
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To confirm the binding modes of the initially predicted binding poses, the acylhydrazones with 
the highest affinity, (S)-H4-A4 and (R)-H3-A5, were subsequently soaked into apo EP crystals 
and their binding modes were determined (e.g. 6.3 Results and Discussion). 
We applied the method in a second round of design along with fragment linking strategy to 
improve the affinity and ligand efficiency of the acylhydrazones presented in the first project.
8
 
For this purpose the mesityl moiety of (S)-H4-A4 was virtually linked with the naphthyl moiety 
of (R)-H3-A5, whereby series of bis-acylhydrazones were designed. Retrosynthesis of the latter 
led to a bis-aldehyde (Fig. 6.2, bis-A1) and nine hydrazides (Fig. 6.2, 2-10). The bis-aldehyde 
and hydrazides 8 to 10 were purchased, while the remaining hydrazides (2-7) were synthetized 
from their corresponding methyl esters. The analysis was facilitated while combining the building 
blocks into two sub-libraries, each consisting of the bis-aldehyde and four or five hydrazides. In 
addition, a mixture of the bis-aldehyde with all nine hydrazides was made. All built bis-
acylhydrazones were identified via LC-MS. However, upon EP addition to the pre-equilibrated 
sub-libraries, the amplification of six bis-acylhydrazones shown in Fig. 6.2 was observed. In 
addition, the bis-acylhydrazones bis-1 and bis-4 (Fig. 6.2) were synthetized from their 
corresponding building blocks and their biochemical activity was determined in a fluorescence-
based assay (Table 6.2). 
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Fig. 6.2. Dynamic combinatorial library of bis-aldehyde and nine hydrazides linked together to bis-acylhydrazones. 
 
Table 6.2. Affinity data of the detected bis-acylhydrazones in contrast to the acylhydrazones from the first experiment. 
Inhibitors IC50 (µM) Ki (µM) ∆G
0
 (kJ∙mol-1)[a] LE (kJ∙mol-1∙atom-1) 
(S)-H4-A4 12.8 ± 0.4 6 ± 0.2 –30 0.27 
(R)-H3-A5 14.5 ± 0.5 7 ± 0.2 –30 0.29 
bis-1 0.054 ± 0.0005 0.0254 ± 0.0002 –49 0.29 
bis-4 2.1 ± 0.1 0.98 ± 0.05 –34 0.25 
[a] The Gibbs free energy of binding was derived from the experimentally determined IC50 values. 
 
Remarkably, the bis-acylhydrazone bis-1 exhibited 240-fold improvement of potency compared 
to the previously identified acylhydrazones while keeping the ligand efficiency constant. We thus 
choose this ligand to validate the predicted binding mode and performed X-ray soaking analysis 
(e.g. 6.3 Results and Discussion). 
 
6. Structure-based Drug Design and Optimization of Inhibitors for Endothiapepsin by Exploiting Dynamic 
Combinatorial Chemistry 
156 
 
6.3 Results and Discussion 
 
The acylhydrazones (S)-H4-A4 and (R)-H3-A5 bind each with two molecules to the active site of 
EP (Fig. 6.3). As can be seen from Fig. 6.3, A, the acylhydrazone (S)-H4-A4 places its 
hydrophobic indolyl moiety into the S1 pocket, while establishing an H-bond interaction with 
Asp81 from the above located flap. Interestingly, it has already been reported that indol 
substituents prefer this binding region.
9
 Furthermore, the mesityl moiety occupies the S2 binding 
pocket so that the ligand bridges between the S1 and S2 pockets with its acylhydrazone linker 
and the primary amino group is directly bound to the catalytic dyad. In contrast, the contact 
between the second promising (R)-H3-A5 and the catalytic aspartates is mediated by the catalytic 
water molecule (Fig. 6.3, B). This ligand also occupies the S1 pocket with its hydrophobic phenyl 
moiety, but the inverted stereochemistry at the introduced chiral center does not allow the same 
binding mode as discovered for (S)-H4-A4 to be adopted. Instead, the primary amino group is 
oriented away from the catalytic dyad as the acylhydrazone linker represents now the only 
possibility for an interaction with the dyad.   
 
Fig. 6.3. Binding modes of the EP-acylhydrazone-complexes (S)-H4-A4 (A) and (R)-H3-A5 (B). The mFo-DFc 
density around the ligands is shown at 3σ. 
 
We also analyzed whether the acylhydrazone molecules, found in addition to the dyad binders in 
the crystal structures, were only observed due to the high ligand concentration applied during the 
soaking experiments (20 mM, e.g. Experimental Section). For this purpose, we performed 
additional soaking experiments with (S)-H4-A4 as we soaked the ligand once with five times 
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higher (100 mM, Fig. 6.4, A) and once with ten times lower concentrations (2 mM, Fig. 6.4, B). 
Remarkably, with the lower applied concentration only the molecule directly bound to the 
catalytic dyad could be assigned to the electron density, while the concentration increase to 100 
mM led to the appearance of two additional molecules. However, due to the lack of additional 
interactions with EP we suppose that the appearance of those molecules is purely concentration 
induced. 
 
Fig.6.4. A: (S)-H4-A4 at 100 mM concentration; B: (S)-H4-A4 at 2 mM concentration. The mFo-DFc 
density around the ligands is shown at 3σ. 
 
We also determined the crystal structure of the highly potent bis-acylhydrazone bis-1 bound to 
EP (Fig. 6.5, A). Interestingly enough, only part of the ligand could be assigned to the electron 
density. The visible part, which corresponds to (S)-H4-A4, used for the linking reaction, retained 
its original binding mode as observed before for the parent ligand. As a matter of fact, the second 
part of the bis-acylhydrazone could not be assigned to the electron density.  
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Fig. 6.5. A: Binding mode of the EP-bis-acylhydrazone-complex. B: Superimposition of all three analyzed 
ligands. The mFo-DFc density around the ligand in A is shown at 3σ. 
 
6.4 Conclusions 
 
The application of dynamic combinatorial chemistry as method to generate compound libraries 
through self-assembly reactions has been successfully demonstrated in the above-described 
projects. The applicability of the method is highly interesting as by use of a few well-selected 
building blocks, hydrazides and aldehydes, a large number of potential high-affinity acyl- or bis-
acylhydrazones are generated, covering a wide range of compounds as options to bind to the 
target protein requiring only a small amount of experimental effort. Furthermore, the method was 
successfully combined with de novo SBDD to identify the acylhydrazones with the highest 
affinity to EP. Moreover, the determined binding modes of the most promising acylhydrazones 
revealed alternative binding modes at the catalytic dyad in agreement with our fragment 
screening study (see chapters 3 and 4). The alternative binding modes were provoked by the 
inverted stereochemistry at the introduced chiral center, which led to the occupancy of different 
binding pockets. In a subsequent design step, the structural information has been further used to 
combine DCC with fragment linking, whereby the occupancy conservation of the already 
addressed pockets was intended. By this a bis-acylhydrazone could be obtained with a 240-fold 
improved potency compared to the parent single acylhydrazones. 
Finally, the construction of specific receptors able to recognize particular molecules is a task that 
has been accomplished by biological systems over millions of years of evolution, and which is 
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hardly achievable via a straightforward synthetic concept. To reproduce evolution in a kind of 
test-tube approach, DCC appears ideally suitable as it can be applied to a wide range of target 
proteins and it has a great potential to rapidly identify potent hit molecules through natural 
selection by the target of interest. 
 
6.5 Experimental Section 
 
The synthesis of the hydrazides H1-H4 and hydrazides 2-7 along with the experimental 
procedures for the inhibitory assays, the modeling and docking studies, the STD-NMR spectra, 
and the UPLC chromatograms can be found in the associated papers (see 6.1 Introductory 
Remarks).  
The data collection and refinement statistics of the acylhydrazone (S)-H4-A4 at the different 
concentrations along with the bis-acylhydrazone bis-1 are listed in Table 8.2 in the Appendix. 
The EP crystallization procedure has already been described in chapter 3.7.1. For the soaking 
experiments, ligands (S)-H4-A4 at 2 mM (PDB-code: 4LHH), 20 mM (PDB-code: 4KUP), and 
100 mM (PDB-code: 4LBT), (R)-H3-A5 at 20 mM (PDB-code: 3T7P), and bis-1 at 90 mM 
(PDB-code: 5HCT) were soaked for 48 h in a mixture of 75 mM NH4Ac, 75 mM NaAc, 20% 
(w/v) PEG 4000, and 25% GOL before freezing in liquid nitrogen.  
Datasets 4LHH, 4KUP, 4LBT, and 3T7P were collected at BESSY beamline 14.2 in Berlin and 
additionally processed with HKL2000.
10 
Only dataset 5HCT was collected at BESSY beamline 
14.1 and processed with XDS.
11 
For all structures a simulated annealing was initially performed, 
followed by refinement of the XYZ-coordinates, individual B-factors, and occupancies performed 
with Phenix.
12
 Structures with resolution better than 1.5 Ǻ were refined anisotropically, with all 
other structures an isotropic refinement was performed. Model building was done with Coot.
13
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7. Summary  
 
The present work focuses on the evaluation and comparison of different fragment-based 
approaches, for which purpose the model system Endothiapepsin (EP) has been used. The 
enzyme belongs to the large family of aspartic proteases. Many representatives are involved in 
the pathogenesis of serious diseases such as malaria, Alzheimer’s disease, AIDS, hypertension, 
and fungal infections. Due to the rapid resistance development of those targets against 
commercially available drugs, the compliance issues due to side effects, and the high therapy 
costs, the development of novel drugs is highly important.  
We dealt with fragments as these are optimally suitable for optimization strategies due to their 
low-molecular weight and high ligand efficiency. For this purpose, we used a 361-entry in-house 
fragment library compiled based on physico-chemical properties similar to the rule-of-three. In 
cooperation with partners from industry we applied six different techniques to screen the 
fragment library: saturation-transfer difference NMR (STD-NMR), thermal shift assay (TSA), 
reporter-displacement assay (RDA), microscale thermophoresis (MST), fluorescence-based 
biochemical assay (HCS), and native mass spectrometry (MS). However, due to method’s 
diversity and their individual sensitivities for detecting weak binders, varying fragment 
concentrations at applied assay conditions, as similar as possible, were used (chapter 2, Table 
2.1). For each assay a threshold was set based on the assay systems used and on the practical 
experience given in each of the individual contributing groups. This might have influenced the 
screening results. Moreover, as not all fragments could be measured, mainly due to solubility 
issues, the relative hit rates normalized by the total number of fragments used in the individual 
assays were also considered. Altogether, the RDA and biochemical assay showed comparable 
number of hits (50 versus 56). However, the number of hits is drastically lower for the TSA and 
MS assays (25 and 8, respectively), although the total number of fragments used for each of the 
four assays was very similar (325, 358, 330, and 342, respectively). Alarmingly, the overlap 
between the hits produced by all six methods was very low. While only 41 out of all 361 
fragment library entries could be identified by at least two methods, only 3 were identified by 
five methods, and not a single fragment was identified as hit by all six methods taken together 
(chapter 2, Fig. 2.1).  
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We thus decided to perform X-ray crystallography with individual fragments separately soaked 
into beforehand prepared apo EP crystals. For this purpose very high fragment concentrations of 
90 mM, hardly applicable in any of the other screening techniques, were used. Intriguingly, we 
were able to identify 71 fragment hits as bound to EP, corresponding to a 20% hit rate. 
Perturbingly, only 30% of the 71 hits were predicted by only one of the beforehand applied 
screening techniques, clearly emphasizing that any screening strategy comprising at least two 
prescreening methods would have been able to identify only 19 (27%) of the 71 crystallographic 
hits.  This implicates that we would have failed to identify 73% of the crystallographically 
detected fragment hits. As the fragment hits were spread throughout the entire EP binding cleft 
with few examples found on the protein surface, we divided the hits into two groups: catalytic 
dyad binders and remote binders. 
Chapter 3 deals with the catalytic dyad binders. Therein we describe a variety of warheads, which 
address the catalytic aspartates either directly or via the catalytic water molecule W501, while 
occupying the S1 and S1’ binding pockets. Amazingly, we were able to discover novel warheads, 
which have not been reported as potential dyad binders to any other relevant aspartic protease 
yet.  One of these is the group of hydrazides, four of which occupy the S1’ pocket, while one 
(F109) is oriented oppositely, accommodated in the S1 pocket. After additionally performed 
docking analysis, soaking experiments of a similar fragment, and ITC measurements to 
investigate this behavior, we found that the displacement of a single conserved water molecule 
was responsible for the swapped orientation of F109 and the related affinity enhancement. 
Furthermore, we found fragments, which occupied both pockets simultaneously (F075, F114, 
F162, F255, and F260), offering an optimal platform for further optimization strategies into 
adjacent pockets on each side of the catalytic aspartates.  
The very useful information regarding preferred spots of binding remote from the catalytic dyad 
is described in detail in chapter 4. The so called hot spots represent key pocket residues, which 
have to be addressed in an optimization procedure in order to achieve optimal ligand binding. For 
example, many large and hydrophobic fragments addressed the hot spot residue Phe291 in the S6 
binding pocket. Moreover, the moieties performing the contact with this hot spot exhibited 
diverse chemistry, allowing a conclusive mapping of a broader part of the very large chemical 
space. Nevertheless, the position of Phe291 can vary within the different members of the pepsin-
like aspartic protease family. For instance, in renin an aspartate is found at the same place, which 
7. Summary 
163 
 
would require a Lipinski donor instead of a hydrophobic substituent. Such differences, however, 
can be very well used with regard to selectivity issues. Furthermore, we discovered fragments, 
which occupy simultaneously the adjacent S1 and S3 and the S4 and S6 binding pockets, 
suggesting valuable ideas on how to merge these pockets while reducing the size of 
peptidomimetic inhibitors.  
The high-throughput potential of X-ray crystallography (chapters 3 and 4) compared to the other 
six prescreening techniques presented in chapter 2 is still very low. Because of this, a lot of effort 
has been invested in academia and industry to extend the method’s applicability as a primary 
screening technique. Whenever used as such, practitioners exposed protein crystals to a mixture 
of compounds to accelerate the hit identification step. However, we cannot recommend the use of 
cocktail experiments with clear conscience as we believe that parameters such as compound 
solubility, chemical reactivity, competitive binding poses, and crystal damage, often resulting in 
reduced ligand occupancy, diffuse electron density, or deviating fragment binding poses are 
provoked by the presence of multiple compounds in a mixture. These issues are exemplified in 
chapter 5 where we directly compared the difference electron density in the binding pocket of EP 
between singly soaked fragments and cocktails prepared from those. For example, many of the 
fragments used in a mixture of two failed to be identified as hits, whereas clear density indicating 
these fragments could be observed in single soaking experiments. Moreover, the clear assignment 
of a fragment to diffuse electron density usually requires additional experiments, which confirm 
the binding pose. When considering the elaborate steps, even more time has to be spent, which 
extremely slows down the hit identification procedure. 
The only plausible reason to use several compounds in a mixture is when a reaction between 
those is aimed. This is an approach named dynamic combinatorial chemistry (DCC) and 
described in chapter 6. The compounds, hydrazides and aldehydes, chosen for the mixtures react 
with one another involving a dehydration step to merge to larger acylhydrazones. The formation 
of the strongest binders among others, acylhydrazones (S)-H4-A4 and (R)-H3-A5, was induced 
by natural selection as the target protein EP extracts by potent binding such compounds from the 
equilibrium mixture. Moreover, in a follow-up optimization project, which started based on the 
binding modes of the two acylhydrazones, the combination of a bis-aldehyde with hydrazides 
resulted in the natural selection of a bis-acylhydrazone by EP, with an 240-fold improved potency 
compared to the initial acylhydrazones, resulting in a two-digit nanomolar lead. 
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7. Zusammenfassung 
 
Die vorgelegte Arbeit beruht auf der Auswertung und dem Vergleich verschiedener, 
fragmentbasierter Verfahren, für welche Zwecke das Modellprotein Endothiapepsin (EP) 
verwendet wurde. Das Enzym gehört zu der großen Familie der Aspartylproteasen. Viele 
Vertreter dieser Familie sind in die Pathogenese schwerer Krankheiten wie Malaria, Alzheimer, 
AIDS, Bluthochdruck, und Pilzinfektionen involviert. Aufgrund der raschen 
Resistenzentwicklung dieser Enzyme gegen kommerziell verfügbare Medikamente, der 
mangelnden Patientencompliance aufgrund von unerwünschten Nebenwirkungen und hoher 
Therapiekosten, ist die Entwicklung neuartiger Medikamente besonders wichtig. 
Fragmente wurden als Ausgangsbasis gewählt, da sich diese aufgrund ihres niedrigen 
Molekulargewichtes und ihrer hohen Ligandeffizienz hervorragend als Startpunkt für 
Optimierungsstrategien eignen. Für diese Zwecke wurde eine interne Fragmentbibliothek 
verwendet, die 361 Fragmente enthält und die auf der Grundlage von physikalisch-chemischen 
Eigenschaften ähnlich der Astex rule-of-three basiert. Um die interne Fragmentbibliothek zu 
durchmustern, wurden zusammen mit Kooperationspartnern aus der Industrie sechs verschiedene 
Screeningmethoden angewendet: Sättigungstransferdifferenz mit Kernspinresonanz (STD-NMR), 
Thermal Shift Assay (TSA), Reporterverdrängungsassay (RDA), Thermophorese (MST), ein 
fluoreszenzbasierter biochemischer Assay (HCS), und Massenspektrometrie (MS). Aufgrund der 
Methodenvielfalt und der individuell unterschiedlichen Sensitivität schwache Binder zu 
detektieren, wurden unterschiedliche Fragmentkonzentrationen unter möglichst ähnlich 
gehaltenen Assaybedingungen verwendet (Kapitel 2, Tabelle 2.1). Für jeden Assay wurde ein 
Schwellenwert festgesetzt, abhängig von den angewendeten Assaysystemen und der praktischen 
Erfahrung jeder der involvierten Arbeitsgruppen. Darüber hinaus wurden die relativen Hitraten,  
normiert auf die Gesamtzahl aller in dem jeweiligen Assay verwendeten Fragmente, 
berücksichtigt, da aufgrund von Löslichkeitsproblemen nicht immer die gesamte 
Fragmentbibliothek vermessen werden konnte. Im Allgemeinen haben die RDA und HCS Assays 
eine vergleichbare Anzahl an Hits gezeigt (50 (RDA) gegenüber 56 (HCS)). Jedoch ist die 
Anzahl der Hits für die TSA und MS Assays drastisch geringer (25 (TSA) gegenüber 8 (MS)), 
obwohl die Gesamtzahl der verwendeten Fragmente in allen vier Assays sehr ähnlich war (325 
(RDA), 358 (HCS), 330 (TSA), und 342 (MS)). Auffällig ist allerdings die geringe Überlappung 
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der Hits, die von jeder der sechs Methoden detektiert wurden. Während nur 41 von 361 
Fragmenten in der Bibliothekdatenbank von mindestens zwei Methoden detektiert werden 
konnten, waren es nur drei, die von fünf Methoden und kein einziges Fragment, welches von 
allen Methoden gleichzeitig detektiert wurde (Kapitel 2, Abb. 2.1). 
Aus diesem Grund wurde jedes der 361 Fragmente einzeln in apo EP-Kristalle diffundiert um mit 
den hieraus erhaltenen Daten eine Röntgenstrukturanalyse durchzuführen. Hierfür wurde eine 
sehr hohe Fragmentkonzentration von 90 mM verwendet, welche für andere Screeningmethoden 
kaum anwendbar ist. Interessanterweise konnten 71 gebundene Fragmente detektiert werden, was 
einer Hitrate von 20% entspricht. Auffallend war allerdings die Tatsache, dass nur 30% der 71 
Hits von maximal einer der sechs zuvor durchgeführten Screeningmethoden detektiert werden 
konnten. Dies stellt deutlich heraus, dass jede Screeningkaskade, bestehend aus mindestens zwei 
Methoden, nur 19 (27%) der 71 kristallographischen Hits detektiert hätte. Dies hätte zur Folge 
gehabt, dass 73% der 71 kristallographischen Hits nicht als solche erkannt worden wären. Da die 
bindenden Fragmente, abgesehen von wenigen Beispielen an der Proteinoberfläche, über die 
gesamte Bindetasche von EP verteilt waren, wurden die Hits in zwei Kategorien aufgeteilt: 
direkt- und fernbindende Fragmente. 
In Kapitel 3 wurden die Direktbinder behandelt. Dort wurde eine Vielzahl von Kopfgruppen 
beschrieben, die die katalytische Dyade entweder direkt oder über das katalytische Wasser W501 
adressieren, während sie die S1 und S1‘ Bindetaschen besetzen. Überraschenderweise konnten 
neuartige, bis jetzt noch nie zuvor als potentielle Binder für andere relevante Aspartylproteasen 
beschriebene Kopfgruppen identifiziert werden. Eine davon ist die Gruppe der Hydrazide. Vier 
davon besetzen die S1‘ Tasche, während ein Fragment (F109) sich in die entgegengesetzte 
Richtung orientiert und stattdessen die S1 Tasche besetzt. Nach anschließend durchgeführten 
Dockinganalysen, Soakingexperimenten mit einem Fragmentanalogon, und isothermaler 
Titrationskalorimetriemessungen wurde ersichtlich, dass die Verdrängung eines einzelnen 
konservierten Wassermoleküls für die getauschte Orientierung und die damit verbundene 
Affinitätserhöhung von F109 verantwortlich war. Darüber hinaus wurden Fragmente gefunden, 
die beide Bindetaschen gleichzeitig besetzen (F075, F114, F162, F255, und F260), was eine 
optimale Grundlage für Optimierungsstrategien in die benachbarten Taschen auf jeder Seite der 
katalytischen Aspartate bietet. 
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Bindestellen abseits der katalytischen Dyade wurden in Kapitel 4 beschrieben. Die so genannten 
„hot-spots“ stellen wichtige Aminosäuren dar, die in einem Optimierungsprozess adressiert 
werden sollen, um optimale Ligandbindung zu erzielen. Zum Beispiel haben viele große und 
hydrophobe Fragmente den hot-spot Rest Phe291 in der S6 Tasche adressiert. Darüber hinaus 
haben die Substituenten der Fragmente, die diesen Rest adressieren, unterschiedlichste chemische 
Beschaffenheit, was eine schlüssige Zuordnung eines größeren Teils des riesigen chemischen 
Raumes erlaubt. Dennoch kann die Position von Phe291 in anderen Proteinen aus der Familie der 
pepsinähnlichen Aspartylproteasen variieren. Zum Beispiel findet sich in Renin an dieser Stelle 
ein Aspartatrest, welches einen Lipinski Donor anstatt von einem hydrophoben Substituenten 
verlangt. Jedoch können solche Unterschiede in Bezug auf Selektivität wunderbar genutzt 
werden. Zusätzlich wurden Fragmente identifiziert, die gleichzeitig die S1 und S3 sowie die S4 
und S6 Bindetaschen besetzten. Diese deuten auf die hervorragende Optimierungsmöglichkeit 
hin, bei großen peptidomimetischen Inhibitoren eine Reduzierung der Größe zu erreichen, indem 
die jeweiligen Bindetaschen zu einer größeren verschmolzen werden könnten. 
Das Durchsatzpotenzial der Röntgenstrukturkristallographie (Kapitel 3 und 4) verglichen mit den 
anderen sechs in Kapitel 2 beschriebenen Screeningverfahren, ist noch sehr gering. Aus diesem 
Grund wurde enormer Aufwand in akademischen Kreisen und der Industrie betrieben um die 
Anwendbarkeit der Röntgenstrukturanalyse als primäre Screeningmethode zu erweitern. Wann 
immer diese als solche genutzt wurde, wurde eine Mischung aus Verbindungen in Proteinkristalle 
diffundiert um die Hitidentifizierung zu beschleunigen. Dieses Verfahren können wir jedoch 
nicht empfehlen, da wir glauben, dass Parameter wie Löslichkeit, Reaktivität zwischen den 
Verbindungen, kompetitive Bindungsposen, und Kristallschäden, die oft zu reduzierter 
Ligandbesetzung, diffuser Elektronendichte oder unterschiedlichen Fragmentbindeposen führen, 
durch die Mehrzahl an Verbindungen in einer Mischung stark beeinflusst werden. Probleme 
solcher Art sind in Kapitel 5 dokumentiert, in dem die Differenzelektronendichte zwischen 
einzeln gesoakten Fragmenten und Cocktails aus diesen direkt miteinander verglichen werden. 
Zum Beispiel konnten viele der Fragmente, die in zweier Cocktails verwendet wurden, nicht als 
Hits identifiziert werden, wohingegen in den Einzelsoaks deutliche Dichte, die das gebundene 
Fragment indiziert, beobachtet werden konnte. Darüber hinaus erfordert die klare Zuordnung 
eines Fragmentes zu diffuser Elektronendichte zusätzliche Experimente, die den Bindungsmodus 
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bestätigen. Durch die Berücksichtigung solcher aufwendigen Schritte wird die Verwendung 
dieser Methode noch zeitintensiver und verlangsamt die Hitidentifizierungsprozedur enorm.  
Der einzig plausible Grund für die Verwendung mehrerer Verbindungen in einem Cocktail ist 
eine beabsichtigte Reaktion zwischen einzelnen Komponenten. Dieses Verfahren wird 
dynamische kombinatorische Chemie (DCC) genannt und in Kapitel 6 beschrieben. Als 
Verbindungen für die Mischung wurden Hydrazide und Aldehyde gewählt, die in einer 
Kondensationsreaktion zu Acylhydrazonen reagieren. Die Bildung der stärksten Liganden, die 
Acylhydrazone (S)-H4-A4 und (R)-H3-A5, wurde durch natürliche Selektion veranlasst, da das 
Zielprotein EP solche potenten Binder aus dem Mischungsgleichgewicht zieht. In einer 
Folgestudie erfolgte basierend auf den Bindungsmodi der zwei Acylhydrazone die Kombination 
von einem bis-Aldehyd mit Hydraziden und hieraus die natürliche Selektion eines bis-
Acylhydrazones durch EP. Das auf diese Weise identifizierte bis-Acylhydrazon wies eine 240-
fach höhere Affinität im Vergleich zu den ursprünglichen Acylhydrazonen auf, resultierend in 
einem zweistellig nanomolaren Binder.   
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8. Appendix 
 
8.1 Data collection and refinement statistics of fragments 
 
Table 8.1 Data collection and refinement statistics of fragments – part 1 
Fragment number 004 005 014 017 
PDB code 4Y36 4Y3E 4Y4U 4Y3P 
Data collection and processing         
Wavelength (Å)   0.91842 0.91841 0.91841 0.91841 
Beamline BESSY BL14.1 BESSY BL14.1 BESSY BL14.1 BESSY BL14.1 
Detector MX-225 CCD MX-225 CCD MX-225 CCD MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a   
 
 
     a, b, c (Å) 45.5, 73.0, 52.6 45.3, 73.0, 52.8 45.6, 72.8, 52.7 45.4, 72.7, 52.5 
     α, β, γ (°) 90.0, 108.9, 90.0 90.0, 109.5, 90.0 90.0, 108.9, 90.0 90.0, 109.0, 90.0 
Resolution range (Å )  43.0-1.59 (1.69-1.59) 42.7-1.25 (1.33-1.25) 50.0-1.75 (1.78-1.75) 42.9-1.55 (1.64-1.55) 
Wilson B factor (Å2)   12.5 10.2 17.1 12.5 
No. of unique reflections  43597 (7012) 85993 (13556) 31788 (1542) 46729 (7195) 
Multiplicity  4.1 (4.2) 4.3 (4.2) 4.0 (4.0) 4.2 (4.1) 
Rsym (%)  7.3 (49.1) 4.4 (48.1) 6.8 (46.7) 6.3 (50.8) 
Completeness (%)  99.4 (98.9) 96.2 (94.0) 97.8 (95.9) 98.9 (94.5) 
<I/σ(I)>  14.6 (2.9) 20.3 (3.2) 17.3 (3.2) 17.1 (2.8) 
Refinement   
 
 
Resolution range  41.1 - 1.59 41.1 - 1.25 43.2 - 1.75 42.9 - 1.55 
No. of reflections used for 
refinement (work (free))  
41412 (2185) 81693 (4300) 30158 (1607) 44392 (2337) 
Rcryst (%) 17.2 11.6 15.5 11.8 
Rfree (%)  19.9 13.5 18.9 16.1 
No. of refined residues  330 330 330 330 
No. of fragment atoms 11 10 13 24 
No. of other ligand atoms 28 30 23 12 
No. of water molecules  310 342 321 317 
RMSD, bond length (Å)  0.009 0.006 0.006 0.008 
RMSD, bond angles (˚)  1.2 1.2 1.1 1.1 
Ramachandran plot (%) b   
 
 
     Most favoured  93.5 93.9 93.1 93.5 
     Additionally allowed  6.5 6.1 6.9 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c   
 
 
     All protein atoms  13.5 12.1 18.6 13.9 
     Main chain  13.3 11.2 18.2 13.0 
     Side chain  13.8 12.9 19.2 14.8 
     Fragment atoms 27.8 17.6 27.5 36.8 
     Other ligand atoms d 33.5 36.6 39.6 27.8 
     Waters  27.1 29.3 29.9 30.8 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 2 
Fragment number 031 034 035 041 
PDB code 4Y5C 5DQ1 4Y3W 4Y3Z 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.89500 
Beamline  BESSY BL14.1   BESSY BL14.1   BESSY BL14.1  BESSY BL14.3 
Detector MX-225 CCD MX-225 CCD MX-225 CCD Mar CCD 165 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.1, 52.7 45.4, 73.3, 53.0 45.1, 73.6, 52.4 45.2, 73.1, 52.7 
     α, β, γ (°) 90.0, 109.4, 90.0 90.0, 109.8, 90.0 90.0, 109.2, 90.0 90.0, 109.4, 90.0 
Resolution range (Å )  42.8-1.33 (1.41-1.33) 42.8-1.49 (1.58-1.49) 42.6-1.58 (1.67-1.58) 42.6-1.12 (1.19-1.12) 
Wilson B factor (Å2)   10.0 10.8 13.9 9.5 
No. of unique reflections  68918 (7630) 53305 (8493) 44277 (7076) 122811 (18556) 
Multiplicity  3.8 (2.5) 4.1 (3.9) 4.2 (4.1) 4.0 (3.4) 
Rsym (%)  4.5 (37.6) 7.4 (46.2) 6.2 (50.2) 5.5 (42.7) 
Completeness (%)  92.3 (63.3) 99.5 (98.5) 99.6 (98.6) 98.5 (92.3) 
<I/σ(I)>  18.9 (2.4) 14.1 (2.9) 16.2 (2.8) 14.3 (2.8) 
Refinement         
Resolution range  42.8 - 1.33 41.2 - 1.49 36.8 - 1.58 42.7 - 1.12 
No. of reflections used for 
refinement (work (free))  
65492 (3426) 50639 (2666) 42063 (2214) 116670 (6141) 
Rcryst (%) 11.9 13.4 12.3 10.9 
Rfree (%)  14.6 17.5 16.3 12.5 
No. of refined residues  330 330 330 330 
No. of fragment atoms 8 18 24 19 
No. of other ligand atoms 39 10 10 34 
No. of water molecules  301 336 302 328 
RMSD, bond length (Å)  0.007 0.008 0.005 0.007 
RMSD, bond angles (˚)  1.2 1.2 1.0 1.3 
Ramachandran plot (%) b         
     Most favoured  93.5 93.5 93.5 93.9 
     Additionally allowed  6.5 6.5 6.5 6.1 
     Generously allowed  0.0 0.0 0.0 0 
     Disallowed 0.0 0.0 0.0 0 
Mean B-values (Å2) c         
     All protein atoms  11.6 12.2 16.8 11.7 
     Main chain  10.7 11.3 15.7 10.8 
     Side chain  12.5 13.1 17.7 12.7 
     Fragment atoms 41.3 27.9 34.8 21.8 
     Other ligand atoms d 36.4 24.7 25.3 29.9 
     Waters  031 26.4 31.2 26.9 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 3  
Fragment number 042 048 051 052 
PDB code 4Y43 5DQ2 4Y4X 4Y51 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.89120 0.91841 
Beamline BESSY BL14.1 BESSY BL14.1  BESSY BL14.3  BESSY BL14.1 
Detector MX-225 CCD MX-225 CCD Mar CCD 165 MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a       
     a, b, c (Å) 45.4, 72.4, 52.5 45.6, 72.4, 52.7 45.1, 72.8, 52.5 45.1, 72.9, 52.5 
     α, β, γ (°) 90.0, 108.7, 90.0 90, 108.8, 90 90.0, 109.5, 90.0 90.0, 109.5, 90.0 
Resolution range (Å )  43.0-1.48 (1.57-1.48) 43.1-1.51 (1.61-1.51) 42.5-1.67 (1.77-1.67) 42.5-1.60 (1.70-1.60) 
Wilson B factor (Å2)   10.9 12.9 10.4 10.6 
No. of unique reflections  52124 (7097) 48966 (6641) 37024 (5927) 40865 (5688) 
Multiplicity  4.2 (4.0) 4.2 (4.1) 4.2 (4.1) 4.1 (3.4) 
Rsym (%)  4.8 (40.3) 5.6 (50.3) 9.5 (47.8) 6.7 (63.2) 
Completeness (%)  96.3 (81.2) 96.9 (82.1) 99.3 (99.0) 97.1 (84.0) 
<I/σ(I)>  21.6 (3.3) 19.0 (3.0) 15.3 (3.4) 17.3 (3.1) 
Refinement       
Resolution range  41.0 - 1.48 43.1 - 1.51 42.5-1.67 36.5 - 1.60 
No. of reflections used for 
refinement (work (free))  
49517 (2607) 46517 (2449) 35170 (1854) 38819 (2046) 
Rcryst (%) 12.6 12.1 14.9 17.0 
Rfree (%)  16.7 16.4 17.8 18.9 
No. of refined residues  330 330 330 330 
No. of fragment atoms 15 17 18 11 
No. of other ligand atoms 32 16 30 10 
No. of water molecules  339 309 292 268 
RMSD, bond length (Å)  0.005 0.008 0.006 0.006 
RMSD, bond angles (˚)  1.0 1.2 1.0 1.0 
Ramachandran plot (%) b       
     Most favoured  93.5 93.5 93.5 93.1 
     Additionally allowed  6.5 6.5 6.5 6.9 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c       
     All protein atoms  12.2 14.5 11.8 12.6 
     Main chain  11.8 13.6 11.2 12.1 
     Side chain  12.7 15.4 12.6 13.0 
     Fragment atoms 22.2 34.5 18.1 21.3 
     Other ligand atoms d 28.3 32.7 28.1 24.6 
     Waters  29.1 29.1 23.7 24.7 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 4 
Fragment number F analogue of 052 054 056 058 
PDB code 5ISK 4Y53 5DQ2 4Y56 
Data collection and processing         
Wavelength (Å)   1.00000 0.91841 0.91841 0.91841 
Beamline ELETTRA BL 5.2R BESSY BL14.1 BESSY BL14.1 BESSY BL14.1 
Detector PILATUS 2M MX-225 CCD MX-225 CCD MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a     
     a, b, c (Å) 45.1, 72.9, 52.7 45.2, 72.6, 52.7 45.6, 72.4, 52.7 45.2, 72.8, 52.5 
     α, β, γ (°) 90.0, 109.3, 90.0 90.0, 109.8, 90.0 90, 108.8, 90 90.0, 109.7, 90.0 
Resolution range (Å )  42.6-1.14 (1.21-1.14) 42.5-1.62 (1.72-1.62) 43.1-1.51 (1.61-1.51) 42.5-1.63 (1.73-1.63) 
Wilson B factor (Å2)   12.0 10.9 12.9 10.9 
No. of unique reflections  116418 (18671) 40417 (6365) 40942 (6168) 39838 (6417) 
Multiplicity  3.3 (3.1) 4.1 (3.7) 4.2 (4.1) 4.2 (4.0) 
Rsym (%)  3.3 (48.8) 7.6 (42.8) 5.6 (50.3) 5.7 (31.7) 
Completeness (%)  99.5 (99.1) 99.0 (97.3) 96.9 (82.1) 99.4 (99.2) 
<I/σ(I)>  16.8 (2.5) 14.5 (3.2) 19.0 (3.0) 20.1 (4.4) 
Refinement     
Resolution range  42.6 - 1.14 41.0 - 1.62 43.1 - 1.51 42.5 - 1.63 
No. of reflections used for 
refinement (work (free))  
110572 (5814) 38390 (2027) 38897 (2045) 37846 (1992) 
Rcryst (%) 11.9 18.5 12.1 14.3 
Rfree (%)  14.6 20.6 16.4 17.1 
No. of refined residues  330 330 330 330 
No. of fragment atoms 11 34 17 9 
No. of other ligand atoms 55 10 16 22 
No. of water molecules  344 295 309 359 
RMSD, bond length (Å)  0.007 0.007 0.008 0.01 
RMSD, bond angles (˚)  1.2 1.0 1.2 1.3 
Ramachandran plot (%) b     
     Most favoured  93.5 93.1 93.5 93.5 
     Additionally allowed  6.5 6.9 6.5 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c     
     All protein atoms  14.5 12.0 14.5 11.4 
     Main chain  13.6 11.7 13.6 11.1 
     Side chain  15.3 12.3 15.4 11.9 
     Fragment atoms 22.7 22.8 34.5 17.8 
     Other ligand atoms d 33.5 22.0 32.7 25.9 
     Waters  32.9 23.0 29.1 25.5 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 5 
Fragment number 063 066 073 075 
PDB code 4Y57 5DQ4 4Y4Z 4Y39 
Data collection and processing         
Wavelength (Å)   0.91841 0.8912 0.91841 0.8944 
Beamline BESSY BL14.1 BESSY BL14.3  BESSY BL14.1  BESSY BL14.3 
Detector MX-225 CCD Mar CCD 165 MX-225 CCD Mar CCD 165 
Space group P21 P21 P21 P21 
Unit-cell parameters a       
     a, b, c (Å) 45.6, 73.3, 53.1 45.1, 72.8, 52.6 45.3, 73.4, 52.9 45.2, 73.0, 52.6 
     α, β, γ (°) 90.0, 109.9, 90.0 90, 109.7, 90 90.0, 109.5, 90.0 90.0, 109.5, 90.0 
Resolution range (Å )  42.8-1.49 (1.58-1.49) 42.5-1.15 (1.22-1.15) 42.7-1.48 (1.57-1.48) 42.7-1.20 (1.27-1.20) 
Wilson B factor (Å2)   10.9 9.0 10.7 9.4 
No. of unique reflections  53579 (8621) 111456 (16822) 54295 (8737) 99993 (15991) 
Multiplicity  4.2 (4.2) 4.1 (3.7) 4.2 (4.1) 4.2 (4.1) 
Rsym (%)  7.5 (49.4) 3.9 (26.1) 6.6 (49.2) 4.9 (47.5) 
Completeness (%)  99.8 (99.6) 98.2 (91.8) 99.8 (99.5) 99.4 (98.7) 
<I/σ(I)>  13.5 (2.9) 21.4 (5.1) 16.6 (3.0) 17.0 (3.0) 
Refinement       
Resolution range  41.2 - 1.49 16.5 - 1.15 34.9 - 1.48 28.0 - 1.20 
No. of reflections used for 
refinement (work (free))  
50900 (2679) 105898 (5558) 51580 (2713) 94993 (5000) 
Rcryst (%) 11.7 11.1 12.3 11.7 
Rfree (%)  15.3 13.0 15.7 13.9 
No. of refined residues  330 330 330 330 
No. of fragment atoms 15 13 8 16 
No. of other ligand atoms 20 6 30 33 
No. of water molecules  326 339 261 272 
RMSD, bond length (Å)  0.008 0.008 0.005 0.008 
RMSD, bond angles (˚)  1.2 1.3 1.1 1.3 
Ramachandran plot (%) b       
     Most favoured  93.5 93.5 93.1 94.2 
     Additionally allowed  6.5 6.5 6.9 5.8 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c       
     All protein atoms  11.8 10.9 11.6 11.8 
     Main chain  10.9 10.1 10.6 10.7 
     Side chain  12.6 11.7 12.4 12.7 
     Fragment atoms 13.2 22.4 27.9 12.6 
     Other ligand atoms d 24.6 12.9 29.6 27,1 
     Waters  27.2 26.5 24.7 25.5 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 6 
Fragment number 078 081 103 109 
PDB code 4Y3F 4Y50 4Y3M 4Y3Q 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline BESSY BL14.1 BESSY BL14.1 BESSY BL14.2 BESSY BL14.2 
Detector MX-225 CCD MX-225 CCD MX-225 CCD MX-225 CCD 
Space group P21 P21 P212121 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.4, 73.0, 52.8 45.3, 73.2, 52.7 45.2, 72.5, 104.1 45.3, 72.9, 52.6 
     α, β, γ (°) 90.0, 109.8, 90.0 90.0, 109.4, 90.0 90.0, 90.0, 90.0 90.0, 109.3, 90.0 
Resolution range (Å )  42.7-1.40 (1.48-1.40) 42.7-1.32 (1.40-1.32) 45.2-1.55 (1.64-1.55) 42.7-1.17 (1.24-1.17) 
Wilson B factor (Å2)   8.2 9.7 11.1 9.1 
No. of unique reflections  63130 (9943) 75485 (12018) 50445 (8029) 108126 (17250) 
Multiplicity  4.2 (4.2) 4.2 (4.2) 8.0 (8.1) 4.1 (3.6) 
Rsym (%)  8.3 (50.0) 9.5 (47.9) 6.7 (42.0) 5.0 (48.6) 
Completeness (%)  98.9 (96.7) 99.2 (98.2) 99.9 (99.7) 99.6 (98.7) 
<I/σ(I)>  13.9 (3.4) 9.2 (2.6) 23.1 (5.1) 16.8 (2.7) 
Refinement         
Resolution range  34.9 - 1.40 29.5 - 1.32 42.3 - 1.55 36.9 - 1.17 
No. of reflections used for 
refinement (work (free))  
59973 (3157) 71710 (3775) 47922 (2523) 102719 (5407) 
Rcryst (%) 11.6 12.1 14.5 11.3 
Rfree (%)  14.6 14.5 16.6 13.4 
No. of refined residues  330 330 330 330 
No. of fragment atoms 12 13 12 15 
No. of other ligand atoms 34 52 43 51 
No. of water molecules  329 268 294 282 
RMSD, bond length (Å)  0.007 0.007 0.008 0.008 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.3 
Ramachandran plot (%) b         
     Most favoured  93.9 93.9 93.1 93.9 
     Additionally allowed  6.1 6.1 6.9 6.1 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c         
     All protein atoms  9.0 11.4 12.4 11.1 
     Main chain  8.3 10.5 11.4 10.1 
     Side chain  9.8 12.3 13.4 12.0 
     Fragment atoms 15.5 24.4 20.5 10.3 
     Other ligand atoms d 22.4 27.4 35.6 26.9 
     Waters  23.9 23.9 25.1 24.7 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 7 
Fragment number 109_analogue 112 114 125 
PDB code 5HCO 4Y41 4Y4T 4Y4W 
Data collection and processing        
Wavelength (Å)   0.91841 0.8946 0.91841 0.91841 
Beamline  BESSY BL14.1  BESSY BL14.3 BESSY BL14.2 BESSY BL14.2 
Detector PILATUS 6M Mar CCD 165 MX-225 CCD MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a        
     a, b, c (Å) 45.2, 72.9, 52.7 45.4, 72.8, 52.8 45.3, 73.1, 52.8 45.3, 72.9, 52.6 
     α, β, γ (°) 90, 109.1, 90 90.0, 109.6, 90.0 90.0, 109.3, 90.0 90.0, 109.4, 90.0 
Resolution range (Å )  42.8-1.17 (1.24-1.17) 42.7-1.40 (1.49-1.40) 42.7-1.30 (1.38-1.30) 42.7-1.45 (1.54-1.45) 
Wilson B factor (Å2)   11.4 10.7 10.4 10.5 
No. of unique reflections  108391 (17012) 62976 (10055) 78761 (12429) 56566 (9000) 
Multiplicity  3.7 (3.5) 4.2 (4.1) 4.1 (3.8) 4.2 (4.2) 
Rsym (%)  3.6 (44.2) 4.3 (39.6) 5.2 (47.7) 6.3 (48.5) 
Completeness (%)  99.3 (96.9) 99.6 (98.6) 99.0 (97.0) 99.1 (98.0) 
<I/σ(I)>  16.8 (2.6) 22.5 (3.8) 16.4 (2.9) 16.6 (3.1) 
Refinement        
Resolution range  42.8 - 1.17 29.4 - 1.40 29.5 - 1.30 28.1 - 1.45 
No. of reflections used for 
refinement (work (free))  
102971 (5420) 59827 (3149) 74823 (3938) 53737 (2829) 
Rcryst (%) 12.5 11.5 13.3 13.6 
Rfree (%)  14.3 15.1 15.6 16.0 
No. of refined residues  330 330 330 330 
No. of fragment atoms 13 30 26 19 
No. of other ligand atoms 31 28 41 54 
No. of water molecules  289 326 314 272 
RMSD, bond length (Å)  0.007 0.006 0.008 0.008 
RMSD, bond angles (˚)  1.2 1.2 1.3 1.2 
Ramachandran plot (%) b        
     Most favoured  93.9 94.2 94.2 93.5 
     Additionally allowed  6.1 5.8 5.8 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c        
     All protein atoms  14.1 11.9 12.4 12.0 
     Main chain  13.1 10.9 11.4 11.0 
     Side chain  15.0 12.8 13.3 13.0 
     Fragment atoms 15.6 19.3 16.8 22.6 
     Other ligand atoms d 38.7 26.7 30.0 31.3 
     Waters  31.4 28.1 25.6 24.3 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 8  
Fragment number 131 158 162 164 
PDB code 4Y4E 5J25 4Y47 4Y44 
Data collection and processing         
Wavelength (Å)   0.89500 0.91841 0.89440 0.91841 
Beamline BESSY BL14.3 BESSY BL14.1  BESSY BL14.3   BESSY BL14.1  
Detector Mar CCD 165 PILATUS 6M Mar CCD 165 PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.2, 52.8 45.3, 72.9, 52.6 45.3, 72.8, 52.6 45.2, 72.9, 52.6 
     α, β, γ (°) 90.0, 109.4, 90.0 90.0, 109.3, 90.0 90.0, 109.4, 90.0 90.0, 109.0, 90.0 
Resolution range (Å )  19.2-1.30 (1.38-1.30) 42.7-1.24 (1.31-1.24) 42.7-1.19 (1.26-1.19) 49.7-1.24 (1.31-1.24) 
Wilson B factor (Å2)   9.1 9.9 8.6 10.1 
No. of unique reflections  79467 (12595) 86046 (12396) 102282 (15746) 88968 (13388) 
Multiplicity  4.1 (4.0) 3.2 (3.1) 3.8 (3.3) 3.4 (3.2) 
Rsym (%)  6.1 (48.0) 3.0 (24.8) 6.5 (47.3) 3.2 (18.3) 
Completeness (%)  99.4 (97.9) 94.2 (84.2) 98.8 (94.3) 97.5 (91.0) 
<I/σ(I)>  16.1 (3.8) 21.6 (4.1) 14.5 (3.0) 20.3 (5.3) 
Refinement         
Resolution range  17.6 - 1.30 42.7 - 1.24 36.4 - 1.19 42.8 - 1.24 
No. of reflections used for 
refinement (work (free))  
75493 (3974) 81743 (4303 ) 97166 (5114) 84519 (4449) 
Rcryst (%) 11.4 11.6 13.2 11.2 
Rfree (%)  13.6 13.6 15.4 12.4 
No. of refined residues  330 330 330 330 
No. of fragment atoms 13 26 20 10 
No. of other ligand atoms 20 16 16 10 
No. of water molecules  296 300 333 282 
RMSD, bond length (Å)  0.007 0.007 0.006 0.006 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b         
     Most favoured  93.9 92.8 93.9 93.5 
     Additionally allowed  6.1 7.2 6.1 6.5 
     Generously allowed  0.0 0 0 0.0 
     Disallowed 0.0 0 0 0.0 
Mean B-values (Å2) c         
     All protein atoms  10.5 11.6 10.3 11.8 
     Main chain  9.6 10.7 9.5 10.9 
     Side chain  11.4 12.4 11.0 12.6 
     Fragment atoms 40.2 28.5 15.5 33.1 
     Other ligand atoms d 27.4 20.5 19.9 17.9 
     Waters  24.5 24.7 24.0 26.5 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 9 
Fragment number 171 181 189 203 
PDB code 4Y3X 4Y3A 4Y3H 5DR0 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.9184 0.89440 
Beamline  BESSY BL14.1   BESSY BL14.1   BESSY BL14.1  BESSY BL14.3 
Detector PILATUS 6M PILATUS 6M PILATUS 6M Mar CCD 165 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.0, 52.7 45.2, 73.0, 52.6 45.3, 72.9, 52.6 45.2, 73.0, 52.7 
     α, β, γ (°) 90.0, 109.7, 90.0 90.0, 109.1, 90.0 90.0, 109.3, 90.0 90.0, 109.2, 90.0 
Resolution range (Å )  42.7-1.25 (1.33-1.25) 42.7-1.17 (1.24-1.17) 42.7-1.23 (1.30-1.23) 42.7-1.40 (1.48-1.40) 
Wilson B factor (Å2)   8.8 9.5 9.9 9.7 
No. of unique reflections  87058 (13331) 102974 (12665) 90396 (12876) 63639 (10178) 
Multiplicity  3.8 (3.6) 3.5 (2.4) 3.7 (3.3) 3.9 (3.9) 
Rsym (%)  5.9 (40.0) 3.2 (18.8) 4.0 (24.2) 6.2 (48.2) 
Completeness (%)  97.5 (92.7) 94.9 (72.4) 96.3 (85.0) 99.5 (98.6) 
<I/σ(I)>  13.9 (3.0) 19.9 (4.3) 17.5 (4.3) 15.7 (3.1) 
Refinement         
Resolution range  42.7 - 1.25 42.7 - 1.17 42.7 - 1.23 29.4 - 1.40 
No. of reflections used for 
refinement (work (free))  
82705 (4353) 97825 (5149) 85876 (4520) 60457 (3182) 
Rcryst (%) 12.0 11.1 10.8 11.7 
Rfree (%)  14.2 12.9 12.8 14.3 
No. of refined residues  330 330 330 330 
No. of fragment atoms 26 19 9 14 
No. of other ligand atoms 32 52 50 46 
No. of water molecules  296 312 315 289 
RMSD, bond length (Å)  0.015 0.006 0.007 0.007 
RMSD, bond angles (˚)  1.6 1.3 1.2 1.2 
Ramachandran plot (%) b         
     Most favoured  93.5 93.9 93.5 93.1 
     Additionally allowed  6.5 6.1 6.5 6.9 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c         
     All protein atoms  9.9 11.2 11.7 11.5 
     Main chain  9.1 10.2 10.8 10.6 
     Side chain  10.7 12.0 12.5 12.4 
     Fragment atoms 13.0 16.3 22.6 20.9 
     Other ligand atoms d 20.7 27.6 30.8 26.6 
     Waters  24.4 28.5 28.2 26.3 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the order 
the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 10 
Fragment number 205 206 207 209 
PDB code 4Y3L 4Y5A 4Y3T 5DQ5 
Data collection and processing         
Wavelength (Å)   0.89440 0.89500 0.91841 0.91841 
Beamline  BESSY BL14.3  BESSY BL14.3  BESSY BL14.2  BESSY BL14.2 
Detector Mar CCD 165 Mar CCD 165 MX-225 CCD MX-225 CCD 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.2, 72.9, 52.6 45.4, 72.9, 52.8 45.3, 72.9, 52.6 45.3, 73.0, 53.0 
     α, β, γ (°) 90.0, 109.5, 90.0 90.0, 109.6, 90.0 90.0, 109.4, 90.0 90, 109.5, 90 
Resolution range (Å )  42.6-1.16 (1.23-1.16) 50.0-1.45 (1.48-1.45) 42.8-1.42 (1.50-1.42) 41.0-1.47 (1.56-1.47) 
Wilson B factor (Å2)   7.8 9.4 9.0 11.4 
No. of unique reflections  108943 (15845) 57009 (2868) 60833 (9430) 54315 (8604) 
Multiplicity  4.0 (3.0) 3.5 (3.4) 4.0 (3.9) 3.7 (3.4) 
Rsym (%)  6.1 (41.9) 7.8 (47.6) 6.9 (48.5) 6 (47.5) 
Completeness (%)  98.0 (88.5) 99.2 (99.9) 99.1 (95.3) 98.9 (97.5) 
<I/σ(I)>  17.7 (3.2) 16.5 (2.6) 15.7 (3.4) 16.4 (2.6) 
Refinement        
Resolution range  29.4 - 1.16 26.8 - 1.45 39.5 - 1.42 36.5 - 1.47 
No. of reflections used for 
refinement (work (free))  
103495 (5447) 54088 (2897) 57791 (3042) 51599 (2716) 
Rcryst (%) 11.6 11.9 11.7 13.0 
Rfree (%)  13.2 15.7 15.0 15.8 
No. of refined residues  330 330 330 330 
No. of fragment atoms 16 11 36 7 
No. of other ligand atoms 60 76 72 22 
No. of water molecules  298 286 289 279 
RMSD, bond length (Å)  0.006 0.007 0.007 0.008 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b        
     Most favoured  93.9 93.5 94.2 93.5 
     Additionally allowed  6.1 6.5 5.8 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c        
     All protein atoms  9.3 10.1 10.2 12.3 
     Main chain  8.5 9.2 9.3 11.5 
     Side chain  10.1 11.0 11.0 13.1 
     Fragment atoms 17.8 15.5 20.8 30.8 
     Other ligand atoms d 22.0 32.1 30.8 24.1 
     Waters  24.5 25.1 26.0 24.4 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 11 
Fragment number 211 216 218 224 
PDB code 4YCK 4YCT 4YCY 4YD3 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline BESSY BL14.1 BESSY BL14.2 BESSY BL14.2  BESSY BL14.1  
Detector PILATUS 6M MX-225 CCD MX-225 CCD PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.0, 52.8 45.2, 73.0, 52.6 45.6, 72.9, 52.7 45.3, 73.2, 52.7 
     α, β, γ (°) 90.0, 109.7, 90.0 90.0, 109.5, 90.0 90.0, 108.9, 90.0 90.0, 109.7, 90.0 
Resolution range (Å )  42.7-1.07 (1.13-1.07) 42.6-1.13 (1.20-1.13) 19.2-1.70 (1.80-1.70) 42.7-1.25 (1.32-1.25) 
Wilson B factor (Å2)   9.3 9.0 15.5 9.8 
No. of unique reflections  137772 (21639) 114817 (17169) 35814 (5648) 86779 (13216) 
Multiplicity  3.8 (3.7) 4.1 (3.8) 4.2 (4.2) 3.4 (3.3) 
Rsym (%)  4.8 (54.5) 4.8 (45.1) 5.8 (49.1) 3.9 (33.1) 
Completeness (%)  96.7 (94.0) 95.4 (88.5) 99.4 (98.5) 96.5 (91.0) 
<I/σ(I)>  14.2 (2.2) 17.4 (3.0) 19.5 (3.3) 18.9 (3.3) 
Refinement         
Resolution range  36.5 - 1.07 34.7 - 1.13 19.3 - 1.70 42.7 - 1.25 
No. of reflections used for 
refinement (work (free))  
130883 (6889) 109076 (5741) 34023 (1791) 82440 (4339) 
Rcryst (%) 11.9 13.8 16.6 11.1 
Rfree (%)  13.6 15.7 19.8 13.2 
No. of refined residues  330 328 323 330 
No. of fragment atoms 12 13 16 34 
No. of other ligand atoms 32 27 19 59 
No. of water molecules  302 267 164 293 
RMSD, bond length (Å)  0.006 0.006 0.006 0.006 
RMSD, bond angles (˚)  1.2 1.2 1.0 1.2 
Ramachandran plot (%) b         
     Most favoured  93.9 93.5 93.0 94.2 
     Additionally allowed  6.1 6.5 7.0 5.8 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c         
     All protein atoms  10.7 11.1 20.4 11.4 
     Main chain  9.8 10.3 19.7 10.4 
     Side chain  11.5 11.8 21.4 12.3 
     Fragment atoms 12.2 16.3 38.5 15.6 
     Other ligand atoms d 19.3 27.2 35.8 23.6 
     Waters  25.6 24.6 27.8 27.0 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
 
 
 
 
 
8. Appendix 
180 
 
Table 8.1 Data collection and refinement statistics of fragments – part 12   
Fragment number 227 231 236 240 
PDB code 4YD4 5DR4 4YD5 4YD6 
Data collection and processing         
Wavelength (Å)   0.89440 0.89440 0.91841 0.91841 
Beamline BESSY BL14.3 BESSY BL14.3 BESSY BL14.1 BESSY BL14.1 
Detector Mar CCD 165 Mar CCD 165 PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a       
     a, b, c (Å) 45.3, 73.2, 52.7 45.2, 73.1, 52.7 45.3, 73.0, 52.7 45.3, 73.0, 52.7 
     α, β, γ (°) 90.0, 109.7, 90.0 90.0, 109.5, 90.0 90.0, 109.3, 90.0 90.0, 109.3, 90.0 
Resolution range (Å )  42.7-1.27 (1.35-1.27) 42.6-1.50 (1.59-1.50) 42.8-1.21 (1.28-1.21) 42.6-1.30 (1.38-1.30) 
Wilson B factor (Å2)   10.1 11.9 9.8 11.0 
No. of unique reflections  84492 (13403) 51590 (8259) 96832 (14290) 76485 (11607) 
Multiplicity  4.2 (4.2) 4.2 (4.1) 3.6 (2.8) 4.2 (4.1) 
Rsym (%)  4.8 (48.3) 7.3 (48.5) 5.2 (22.4) 6.4 (47.8) 
Completeness (%)  97.8 (96.5) 99.5 (99.1) 98.1 (89.8) 96.1 (90.5) 
<I/σ(I)>  18.8 (3.2) 13.3 (3.0) 13.7 (3.6) 12.8 (2.9) 
Refinement       
Resolution range  29.6 - 1.27 28.0 - 1.50 42.8 - 1.21 28.0 - 1.30 
No. of reflections used for 
refinement (work (free))  
80267 (4225) 49010 (2580) 91990 (4842) 72660 (3825) 
Rcryst (%) 12.2 12.8 11.9 12.5 
Rfree (%)  14.7 16.0 13.6 15.1 
No. of refined residues  330 330 330 330 
No. of fragment atoms 10 11 13 9 
No. of other ligand atoms 34 35 34 41 
No. of water molecules  237 258 226 290 
RMSD, bond length (Å)  0.007 0.008 0.006 0.007 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b       
     Most favoured  94.2 93.5 94.2 93.5 
     Additionally allowed  5.8 6.5 5.8 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c       
     All protein atoms  11.9 13.7 11.6 12.9 
     Main chain  11.0 12.9 10.6 12.0 
     Side chain  12.8 14.5 12.5 13.8 
     Fragment atoms 29.0 23.1 18.6 15.4 
     Other ligand atoms d 36.7 38.2 23.6 29.3 
     Waters  27.3 24.4 25.5 27.2 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 13 
Fragment number 255 260 261 266 
PDB code 4YD7 4Y58 4Y5B 4Y3S 
Data collection and processing         
Wavelength (Å)   0.89440 0.91841 0.91841 0.91841 
Beamline BESSY BL14.3  BESSY BL14.1  BESSY BL14.1  BESSY BL14.1  
Detector Mar CCD 165 PILATUS 6M PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.1, 52.8 45.1, 72.9, 52.7 45.4, 73.1, 52.8 45.3, 73.1, 52.8 
     α, β, γ (°) 90.0, 109.6, 90.0 90.0, 109.4, 90.0 90.0, 109.5, 90.0 90.0, 109.5, 90.0 
Resolution range (Å )  19.2-1.42 (1.50-1.42) 41.1-1.17 (1.24-1.17) 42.8-1.24 (1.31-1.24) 19.8-1.10 (1.17-1.10) 
Wilson B factor (Å2)   9.9 11.0 11.1 10.4 
No. of unique reflections  61045 (9738) 106998 (16804) 91683 (14580) 127054 (19588) 
Multiplicity  4.2 (4.1) 3.6 (3.4) 3.6 (3.4) 3.6 (3.4) 
Rsym (%)  6.4 (50.2) 3.8 (48.5) 4.4 (47.3) 3.2(48.2) 
Completeness (%)  99.6 (99.0) 98.7 (96.2) 99.3 (98.1) 97.0 (93.0) 
<I/σ(I)>  17.3 (3.1) 17.6 (2.4) 16.7 (2.3) 20.5 (2.7) 
Refinement         
Resolution range  19.2 - 1.42 39.5 - 1.17 42.8 - 1.24 19.8 - 1.10 
No. of reflections used for 
refinement (work (free))  
57994 (3051) 101648 (5350) 87098 (4585) 120701 (6353) 
Rcryst (%) 11.6 12.6 12.1 12.4 
Rfree (%)  15.0 14.5 14.5 14.1 
No. of refined residues  330 330 330 330 
No. of fragment atoms 19 15 45 12 
No. of other ligand atoms 39 44 24 10 
No. of water molecules  307 313 264 273 
RMSD, bond length (Å)  0.007 0.007 0.007 0.006 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b         
     Most favoured  93.5 93.9 93.9 93.5 
     Additionally allowed  6.5 6.1 6.1 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c         
     All protein atoms  11.3 13.1 12.9 12.7 
     Main chain  10.4 12.1 11.8 11.7 
     Side chain  12.1 13.9 13.9 13.6 
     Fragment atoms 18.5 21.9 35.5 42.2 
     Other ligand atoms d 33.5 28.1 26.8 17.4 
     Waters  25.7 27.3 27.8 27.3 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 14 
Fragment number 267 268 272 273 
PDB code 4Y5C 4Y5G 4Y5G 4Y3N 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline  BESSY BL14.1   BESSY BL14.1   BESSY BL14.1   BESSY BL14.1  
Detector PILATUS 6M PILATUS 6M PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.1, 52.8 45.4, 73.1, 52.9 45.4, 73.1, 53.9 45.6, 73.0, 53.0 
     α, β, γ (°) 90.0, 109.4, 90.0 90.0, 109.5, 90.0 90.0, 109.6, 90.0 90.0, 109.4, 90.0 
Resolution range (Å )  42.7-1.19 (1.26-1.19) 41.2-1.12 (1.18-1.12) 42.8-1.47 (1.56-1.47) 43.0-1.34 (1.42-1.34) 
Wilson B factor (Å2)   11.2 10.1 11.2 12.6 
No. of unique reflections  103484 (16282) 124427 (19094) 51878 (8185) 72919 (11390) 
Multiplicity  3.5 (3.3) 3.6 (3.3) 2.3 (2.3) 3.6 (3.4) 
Rsym (%)  3.7 (49.4) 4.6 (49.0) 4.9 (27.7) 4.9 (48.8) 
Completeness (%)  99.1 (96.8) 98.7 (94.1) 93.5 (91.7) 99.0 (96.2) 
<I/σ(I)>  17.9 (2.2) 14.2 (2.3) 12.9 (3.5) 15.3 (2.3) 
Refinement         
Resolution range  39.5 - 1.19 36.5 - 1.12 42.8 - 1.47 43.0 - 1.34 
No. of reflections used for 
refinement (work (free))  
98309 (5175) 118205 (6222) 49288 (2590) 69273 (3646) 
Rcryst (%) 11.5 12.5 12.3 12.4 
Rfree (%)  14.1 14.2 15.6 15.2 
No. of refined residues  330 330 330 330 
No. of fragment atoms 16 15 18 14 
No. of other ligand atoms 22 26 14 10 
No. of water molecules  277 298 287 262 
RMSD, bond length (Å)  0.006 0.006 0.008 0.007 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b         
     Most favoured  93.5 93.1 93.5 93.9 
     Additionally allowed  6.5 6.9 6.5 6.1 
     Generously allowed  0 0.0 0 0.0 
     Disallowed 0 0.0 0 0.0 
Mean B-values (Å2) c         
     All protein atoms  13.2 12.3 11.8 14.5 
     Main chain  12.0 11.3 10.9 13.5 
     Side chain  14.4 13.3 12.7 15.4 
     Fragment atoms 34.7 24.6 17.6 24.1 
     Other ligand atoms d 26.5 25.0 19.3 24.0 
     Waters  27.6 26.4 26.0 28.6 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 15 
Fragment number 274 Br analogue of 274 Cl analogue of 274 278 
PDB code 4Y5K 5IS4 5ISJ 5DR1 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 1.00000 0.91841 
Beamline  BESSY BL14.1   BESSY BL14.1  ELETTRA BL 5.2R BESSY BL14.1 
Detector PILATUS 6M PILATUS 6M PILATUS 2M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a       
     a, b, c (Å) 45.3, 73.2, 52.8 45.2, 73.1, 52.7 45.1, 73.0, 52.7 45.3, 73.0, 53.0 
     α, β, γ (°) 90.0, 109.4, 90.0 90.0, 109.2, 90.0 90, 109.1, 90 90.0, 109.6, 90.0 
Resolution range (Å )  42.7-1.44 (1.53-1.44) 42.7-1.37 (1.45-1.37) 42.7-1.65 (1.65-1.75) 42.7-1.45 (1.54-1.45) 
Wilson B factor (Å2)   10.9 11.9 18.0 11.1 
No. of unique reflections  58762 (9404) 67872 (10813) 37526 (5699) 57303 (9151) 
Multiplicity  3.7 (3.7) 3.7 (3.7) 3.4 (3.5) 3.7 (3.8) 
Rsym (%)  5.6 (43.8) 4.4 (49.7) 3.9 (28.2) 7.1 (49.6) 
Completeness (%)  99.4 (98.8) 99.4 (98.3) 96.4 (90.7) 99.2 (98.7) 
<I/σ(I)>  16.9 (3.0) 17.8 (2.5) 19.4 (4.6) 13.2 (2.6) 
Refinement       
Resolution range  29.5 - 1.44 42.7 - 1.37 41.1 - 1.65 36.5 - 1.45 
No. of reflections used for 
refinement (work (free))  
55826 (2936) 64478 (3394) 35649 (1877) 54437 (2866) 
Rcryst (%) 12.1 12.9 14.0 15.5 
Rfree (%)  14.9 14.9 16.7 16.9 
No. of refined residues  330 330 330 330 
No. of fragment atoms 11 11 11 18 
No. of other ligand atoms 30 31 31 38 
No. of water molecules  283 283 253 236 
RMSD, bond length (Å)  0.007 0.01 0.009 0.008 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b       
     Most favoured  93.1 94.2 93.1 93.5 
     Additionally allowed  6.9 5.8 6.9 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c       
     All protein atoms  12.1 16.3 21.8 12.8 
     Main chain  11.1 15.2 20.2 11.7 
     Side chain  13.0 17.2 23.4 13.8 
     Fragment atoms 15.0 21.1 29.6 31.5 
     Other ligand atoms d 27.2 38.0 46.5 28.1 
     Waters  27.0 29.2 32.5 22.0 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 16 
Fragment number 285 286 290 291 
PDB code 4Y3G 4Y4A 4Y35 4Y45 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline  BESSY BL14.1   BESSY BL14.1   BESSY BL14.1   BESSY BL14.1  
Detector PILATUS 6M PILATUS 6M PILATUS 6M PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a         
     a, b, c (Å) 45.3, 73.1, 52.8 45.3, 73.1, 52.8 45.3, 73.2, 52.8 45.3, 73.0, 52.8 
     α, β, γ (°) 90.0, 109.5, 90.0 90.0, 109.6, 90.0 90.0, 109.5, 90.0 90.0, 109.6, 90.0 
Resolution range (Å )  19.8-1.13 (1.20-1.13) 41.2-1.28 (1.36-1.28) 41.1-1.46 (1.55-1.46) 42.7-1.06 (1.12-1.06) 
Wilson B factor (Å2)   9.8 10.7 12.2 9.7 
No. of unique reflections  117892 (18348) 83422 (13296) 56120 (8860) 144991 (22289) 
Multiplicity  3.7 (3.6) 3.7 (3.6) 3.8 (3.8) 3.6 (3.3) 
Rsym (%)  6.4 (47.5) 4.5 (42.7) 6.2 (44.2) 3.8 (46.5) 
Completeness (%)  97.5 (94.3) 99.5 (98.2) 99.3 (97.8) 98.8 (94.1) 
<I/σ(I)>  11.2 (2.5) 16.5 (2.9) 13.3 (3.4) 16.7 (2.4) 
Refinement         
Resolution range  19.8 - 1.13 36.6 - 1.28 39.6 - 1.46 42.7 - 1.06 
No. of reflections used for 
refinement (work (free))  
111997 (5895) 79251 (4171) 53313 (2807) 137741 (7250) 
Rcryst (%) 16.3 11.6 12.5 12.0 
Rfree (%)  18.4 13.9 15.9 13.6 
No. of refined residues  330 330 330 330 
No. of fragment atoms 12 11 12 31 
No. of other ligand atoms 6 16 24 18 
No. of water molecules  273 306 270 288 
RMSD, bond length (Å)  0.007 0.006 0.007 0.006 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b         
     Most favoured  93.5 93.9 93.5 92.8 
     Additionally allowed  6.5 6.1 6.5 7.2 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c         
     All protein atoms  11.3 12.7 13.8 11.5 
     Main chain  10.5 11.6 13.0 10.5 
     Side chain  12.1 13.8 14.6 12.4 
     Fragment atoms 20.1 17.4 21.6 16.1 
     Other ligand atoms d 16.4 23.2 30.3 16.2 
     Waters  24.8 27.3 27.3 24.9 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 17 
Fragment number 305 306 311 321 
PDB code 4Y37 4Y3R 5DR7 4Y3D 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.89500 0.89440 
Beamline BESSY BL14.1  BESSY BL14.1  BESSY BL14.3  BESSY BL14.3  
Detector PILATUS 6M PILATUS 6M Mar CCD 165 Mar CCD 165 
Space group P21 P21 P21 P21 
Unit-cell parameters a        
     a, b, c (Å) 45.4, 73.1, 52.9 45.2, 73.2, 52.7 45.3, 73.1, 52.8 45.2, 72.9, 52.6 
     α, β, γ (°) 90.0, 109.4, 90.0 90.0, 109.6, 90.0 90, 109.4, 90 90.0, 109.4, 90.0 
Resolution range (Å )  19.2-1.69 (1.79-1.69) 42.6-1.13 (1.20-1.13) 42.8-1.23 (1.31-1.23) 42.7-1.48 (1.57-1.48) 
Wilson B factor (Å2)   13.7 10.3 8.2 10.8 
No. of unique reflections  36243 (5481) 120427 (19326) 89949 (13347) 53444 (8611) 
Multiplicity  3.7 (3.3) 3.7 (3.5) 4.2 (4.1) 4.2 (4.1) 
Rsym (%)  9.9 (48.5) 4.1 (49.9) 9.6 (46.1) 6.9 (53.9) 
Completeness (%)  98.4 (93.4) 99.6 (99.2) 96.5 (89.1) 99.7 (99.6) 
<I/σ(I)>  12.1 (2.5) 16.7 (2.3) 11.9 (3.3) 16.2 (2.7) 
Refinement        
Resolution range  19.2 - 1.69 28.0 - 1.13 25.5 - 1.23 28.1 - 1.48 
No. of reflections used for 
refinement (work (free))  
34429 (1812) 114405 (6022) 85451 (4498) 50771 (2673) 
Rcryst (%) 18.1 12.4 12.3 11.7 
Rfree (%)  21.7 14.1 14.5 15.7 
No. of refined residues  330 330 330 330 
No. of fragment atoms 11 12 17 16 
No. of other ligand atoms 10 20 44 24 
No. of water molecules  268 290 289 320 
RMSD, bond length (Å)  0.007 0.006 0.009 0.007 
RMSD, bond angles (˚)  1.0 1.2 1.3 1.2 
Ramachandran plot (%) b        
     Most favoured  93.1 93.1 93.9 93.5 
     Additionally allowed  6.9 6.9 6.1 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c        
     All protein atoms  15.6 12.4 10.0 12.1 
     Main chain  15.0 11.4 9.1 11.2 
     Side chain  16.4 13.3 10.9 12.9 
     Fragment atoms 23.9 15.8 24.3 17.4 
     Other ligand atoms d 27.8 21.9 29.5 27.8 
     Waters  26.9 27.7 22.6 28.3 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 18 
Fragment number 323 328 330 333 
PDB code 4Y4B 4Y5M 5DR8 5DR3 
Data collection and processing         
Wavelength (Å)   0.89500 0.89500 0.895 0.89500 
Beamline BESSY BL14.3 BESSY BL14.3 BESSY BL14.3  BESSY BL14.3  
Detector Mar CCD 165 Mar CCD 165 Mar CCD 165 Mar CCD 165 
Space group P21 P21 P21 P21 
Unit-cell parameters a        
     a, b, c (Å) 45.4, 73.2, 52.9 45.3, 72.8, 52.9 45.3, 73.2, 52.9 45.3, 73.0, 52.8 
     α, β, γ (°) 90.0, 109.5, 90.0 90.0, 109.9, 90.0 90.0, 109.6, 90.0 90.0, 109.5, 90.0 
Resolution range (Å )  42.8-1.11 (1.18-1.11) 42.6-1.28 (1.36-1.28) 42.7-1.47 (1.56-1.47) 42.7-1.24 (1.31-1.24) 
Wilson B factor (Å2)   10.1 10.4 8.8 9.6 
No. of unique reflections  125728 (18023) 82855 (13281) 55239 (8809) 91107 (14458) 
Multiplicity  3.9 (3.1) 4.1 (4.1) 4.2 (4.1) 4.2 (4.1) 
Rsym (%)  4.8 (49.6) 5.0 (57.0) 7.1 (48.7) 4.4 (43.3) 
Completeness (%)  97.4 (86.7) 99.5 (99.1) 99.6 (98.8) 99.2 (97.8) 
<I/σ(I)>  14.3 (2.3) 18.5 (2.5) 19.3 (4.4) 20.3 (3.3) 
Refinement        
Resolution range  28.2 - 1.11 25.6 - 1.28 28.1 - 1.47 20.9 - 1.24 
No. of reflections used for 
refinement (work (free))  
119441 (6287) 78712 (4143) 52476 (2763) 86551 (4556) 
Rcryst (%) 12.5 11.9 12.3 11.2 
Rfree (%)  14.2 14.6 15.1 13.3 
No. of refined residues  330 330 330 330 
No. of fragment atoms 11 31 11 14 
No. of other ligand atoms 36 16 20 28 
No. of water molecules  290 366 274 341 
RMSD, bond length (Å)  0.006 0.007 0.008 0.006 
RMSD, bond angles (˚)  1.2 1.2 1.2 1.2 
Ramachandran plot (%) b        
     Most favoured  93.5 93.1 93.5 93.5 
     Additionally allowed  6.5 6.9 6.5 6.5 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c        
     All protein atoms  12.7 12.4 9.7 12.0 
     Main chain  11.8 11.5 9.0 11.0 
     Side chain  13.5 13.3 10.5 12.9 
     Fragment atoms 45.8 27.7 30.8 17.5 
     Other ligand atoms d 32.8 23.4 32.6 29.1 
     Waters  29.3 29.4 21.6 26.6 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Table 8.1 Data collection and refinement statistics of fragments – part 19 
Fragment number 337 338 
PDB code 4Y5N 4Y5P 
Data collection and processing     
Wavelength (Å)   0.89440 0.89440 
Beamline  BESSY BL14.3   BESSY BL14.3  
Detector Mar CCD 165 Mar CCD 165 
Space group P21 P21 
Unit-cell parameters a     
     a, b, c (Å) 45.3, 72.9, 52.8 45.3, 72.9, 52.7 
     α, β, γ (°) 90.0, 109.6, 90.0 90.0, 109.7, 90.0 
Resolution range (Å)  42.6-1.29 (1.37-1.29) 42.7-1.23 (1.30-1.23) 
Wilson B factor (Å2)   8.7 9.5 
No. of unique reflections  79030 (12449) 92370 (13924) 
Multiplicity  4.3 (4.3) 4.1 (3.3) 
Rsym (%)  6.3 (49.9) 5.2 (48.1) 
Completeness (%)  97.2 (95.1) 98.5 (92.2) 
<I/σ(I)>  16.6 (3.5) 16.6 (2.6) 
Refinement     
Resolution range  42.6 - 1.29 25.5 - 1.23 
No. of reflections used for 
refinement (work (free))  
75077 (3953) 87751 (4619) 
Rcryst (%) 12.1 12.2 
Rfree (%)  14.5 14.7 
No. of refined residues  330 330 
No. of fragment atoms 19 16 
No. of other ligand atoms 20 26 
No. of water molecules  307 312 
RMSD, bond length (Å)  0.007 0.007 
RMSD, bond angles (˚)  1.2 1.2 
Ramachandran plot (%) b     
     Most favoured  92.8 93.5 
     Additionally allowed  7.2 6.5 
     Generously allowed  0 0 
     Disallowed 0 0 
Mean B-values (Å2) c     
     All protein atoms  10.0 11.3 
     Main chain  9.3 10.5 
     Side chain  10.8 12.2 
     Fragment atoms 15.3 19.1 
     Other ligand atoms d 18.2 22.4 
     Waters  24.6 25.3 
a Statistic for the highest-resolution shell are shown in parenthesis; b 
Calculated by PROCHECK; c Calculated by MOLEMAN; d Other ligands are 
glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according 
to the order the fragments are mentioned in the text. 
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8.2 Data collection and refinement statistics of DCC-products 
 
Table 8.2 Data collection and refinement statistics: DCC project. 
Fragment number 
20 mM 
acylhydrazone 
100 mM 
acylhydrazone 
2 mM 
acylhydrazone 
bis-1 
PDB code 4KUP 4LBT 4LHH 5HCT 
Data collection and processing         
Wavelength (Å)   0.91841 0.91841 0.91841 0.91841 
Beamline BESSY BL14.2  BESSY BL14.2 BESSY BL14.2  BESSY BL14.1 
Detector MX-225 CCD MX-225 CCD MX-225 CCD PILATUS 6M 
Space group P21 P21 P21 P21 
Unit-cell parameters a        
     a, b, c (Å) 45.4, 72.7, 52.8 45.4, 72.9, 52.9 45.5, 73.1, 53.1 45.2, 72.8, 52.7 
     α, β, γ (°) 90.0, 109.6, 90.0 90.0, 109.6, 90.0 90.0, 109.3, 90.0 90.0, 108.9, 90.0 
Resolution range (Å )  30.0-1.31 (1.33-1.31) 30.0-1.25 (1.27-1.25) 30.0-1.73 (1.76-1.73) 42.8-1.36 (1.44-1.36) 
Wilson B factor (Å2)   10.8 9.8 13.6 12.0 
No. of unique reflections  76831 (3792) 85603 (3157) 34335 (1708) 69237 (11019) 
Multiplicity  4.1 (3.9) 4.2 (3.4) 4.1 (4.0) 3.8 (3.6) 
Rsym (%)  5.1 (40.1) 5.1 (34.5) 8.4 (48.5) 6.6 (49.1) 
Completeness (%)  99.0 (97.3) 95.4 (70.4) 99.8 (99.1) 99.6 (98.8) 
<I/σ(I)>  25.7 (3.7) 26.5 (3.3) 17.4 (2.5) 11.3 (2.4) 
Refinement        
Resolution range  26.8 - 1.31 29.5 - 1.25 26.3 - 1.73 42.8 - 1.36 
No. of reflections used for 
refinement (work (free))  
72943 (3860) 81291 (4309) 32583 (1734) 65775 (3462) 
Rcryst (%) 13.0 12.2 14.6 12.1 
Rfree (%)  14.9 13.9 17.5 15.0 
No. of refined residues  330 330 330 330 
No. of fragment atoms 38 68 26 24 
No. of other ligand atoms 48 16 44 49 
No. of water molecules  335 367 333 234 
RMSD, bond length (Å)  0.008 0.005 0.006 0.007 
RMSD, bond angles (˚)  1.2 1.1 1.0 1.2 
Ramachandran plot (%) b        
     Most favoured  94.2 93.9 94.2 93.1 
     Additionally allowed  5.8 6.1 5.8 6.9 
     Generously allowed  0 0 0 0 
     Disallowed 0 0 0 0 
Mean B-values (Å2) c        
     All protein atoms  11.6 11.0 12.7 14.4 
     Main chain  11.1 10.4 12.0 13.4 
     Side chain  12.3 11.6 13.6 15.3 
     Fragment atoms 18.6 15.1 16.5 18.5 
     Other ligand atoms d 20.8 13.3 29.4 31.5 
     Waters  26.1 26.5 27.5 29.1 
a Statistic for the highest-resolution shell are shown in parenthesis; b Calculated by PROCHECK; c Calculated by 
MOLEMAN; d Other ligands are glycerol, DMSO, EG, PEG, 1PE, and acetate. Columns are sorted according to the 
order the fragments are mentioned in the text. 
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Abbreviations List 
 
Å  Angström (1 Å = 10
-10
 m) 
ACE angiotensin converting enzyme  
ACT artemisinin-based combination therapy 
ADME parameters Adsorption, distribution, metabolism, excretion 
AIDS Acquired immunodeficiency syndrome 
Ala Alanine 
APP ß-amyloid precursor protein 
Asp Aspartate 
Aß Amyloid-ß protein  
BACE1 ß-site amyloid precursor protein cleaving enzyme 1 
BB Building block 
CCD camera Charge-coupled device camera 
clogP Calculated logarithm of the octanol-water partition coefficient 
CTL [%] Percentage control values 
Cys Cysteine 
Da Dalton (1Da = 1g/mol) 
DCC Dynamic combinatorial chemistry 
DCL Dynamic combinatorial library 
DMSO Dimethylsulfoxide 
EP Endothiapepsin 
ESI-MS  Electrospray Ionization mass spectrometry 
FBDD Fragment-based drug discovery 
FBLD Fragment-based lead discovery 
Fc  Calculated structure factor amplitudes 
FDA US Food and Drug Administration 
Fhkl Structure factor 
|Fhkl|  Structure factor amplitude 
Fhkl = F-h-k-l Friedel's law 
Fhot Fluorescence decrease 
Finitial Initial fluorescence 
Fnorm  Normalized fluorescence 
Fo  Observed structure factor amplitudes 
Gly Glycine 
GOL glycerol 
∆G0 Gibbs free energy 
HA Heavy atoms 
h, k, l Miller indices 
Abbreviations List 
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H-bond Hydrogen bond 
HIV1 protease human immunodeficiency virus type 1 protease 
HPLC–MS = LC-MS High-performance liquid chromatography-mass spectrometry 
HTS High-throughput screening 
I(hkl)  Intensity of the reflection spots 
IC50 Half maximal inhibitory concentration 
Ile Isoleucine 
IR-Laser Infrared Laser 
ITC isothermal titration calorimetry  
K Kelvin  
Kd  Dissociation constant 
LE Ligand efficiency 
Leu Leucine 
µ micro- 
m milli- 
M Molarity (mol ∙ l-1) 
MAD Multiple-wavelength anomalous dispersion 
MHz Megahertz 
MIR Multiple isomorphous replacement 
MR Molecular replacement 
MST Microscale Thermophoresis 
MW Molecular weight 
NaAc Sodium acetate 
NaCl Sodium chloride 
NaN3 Sodium azide 
NH4Ac Ammonium acetate 
NMR Nuclear magnetic resonance  
NSAID Nonsteroidal anti-inflammatory drug 
o/w Oil in water 
occ. Occupancy 
PBS Phosphate-buffered saline 
pD Negative decimal logarithm of the deuterium ion activity 
PDB Protein data bank 
PEG Polyethylene glycol 
pH Negative decimal logarithm of the hydrogen ion activity 
Phe Phenylalanine 
pI Isoelectric point 
pKa Negative decimal logarithm of the acid dissociation constant 
RDA Reporter displacement assay 
RO3 Rule of three 
RO5 Lipinski's rule of five 
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Rsym Agreement between symmetry-related reflections 
SAD Single-wavelength anomalous dispersion 
SAP Secreted aspartic proteases 
SAR by NMR Structure-activity relationship by nuclear magnetic resonance  
SBDD Structure-based drug design 
SeMet Selenomethionine 
Ser Serine 
SPR Surface Plasmon resonance  
ST Soret coefficient 
STD-NMR Saturation transfer difference nuclear magnetic resonance  
Thr Threonine 
Tm  Melting temperature 
TPSA Total polar surface area 
TSA Thermal shift assay 
Tyr Tyrosine 
u, v, w Patterson cell coordinates 
UNAIDS United Nations Programme on HIV/AIDS 
v/v Volume per volume 
w/v Weight per volume 
WHO World health organization  
x, y, z  Real cell coordinates 
φ(hkl)   Phase angle 
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